Controlled Delivery of Basal Level of Insulin by Oak, Mayura Arvind
CONTROLLED DELIVERY OF BASAL LEVEL OF INSULIN 
 
 
 
 
 A Dissertation  
Submitted to the Graduate Faculty 
of the 
North Dakota State University 
of Agriculture and Applied Science 
 
 
 
 
By 
Mayura Arvind Oak 
 
 
 
 
In Partial Fulfillment of the Requirements 
for the Degree of 
DOCTOR OF PHILOSOPHY  
 
 
 
Major Department: 
Pharmaceutical Sciences 
 
 
 
 
August 2012 
 
 
 
 
Fargo, North Dakota 
 
 
North Dakota State University 
 Graduate School 
 
 
 Title 
 
Controlled delivery of basal level of insulin 
 
 
 
 
 By 
 
 
Mayura Arvind Oak 
 
 
 
The Supervisory Committee certifies that this disquisition complies with North Dakota 
State University’s regulations and meets the accepted standards for the degree of 
                                                 
DOCTOR OF PHILOSOPHY 
 
 
 
SUPERVISORY COMMITTEE: 
 
 
Dr. Jagdish Singh 
 
Chair 
 
Dr. Sanku Mallik 
 
 
Dr. Chengwen Sun 
 
 
Dr. Rhonda Magel  
 
 
 
 
 
 
Approved by Department Chair: 
 
02/25/2013 
 
Dr. Jagdish Singh 
 
Date 
 
Signature 
 
 
iii 
 
ABSTRACT 
Present study was aimed at developing a delivery system for controlled release of insulin 
at basal level from chitosan-zinc-insulin complex incorporated into thermosensitive polymer, 
poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA). Chitosan-zinc-insulin 
complex was optimized to restrict the insulin diffusion from the delivery system by complex 
formation and thereby reducing initial burst release. Polymer concentration, insulin loading, 
chitosan and Zinc+2 addition were shown to affect the insulin release in vitro. Formulations 
containing insulin, zinc-insulin, and chitosan-insulin exhibited high initial burst (~7-14%), 
accompanied with a large secondary burst and incomplete release. Chitosan-zinc-insulin 
containing formulations showed extended release profiles of insulin for 84-90 days with a 
significant (P<0.05) reduction in initial burst release and minimal secondary burst. Increasing 
chitosan amount had no effect (P>0.05) on the initial burst, and release rate. Insulin alone and 
zinc-insulin containing formulations showed significant (p<0.05) attenuation in secondary and 
tertiary structure of insulin, as compared to chitosan-zinc-insulin. The complex formation 
conserved the physical and chemical stability of insulin and protected it from aggregation during 
release and storage. It also protected insulin from the acidic degradation product of copolymer. 
The delivery systems were investigated for continuous in vivo insulin delivery at basal 
level for prolonged period after a single subcutaneous injection. In vivo absorption and 
bioactivity of insulin released were studied in streptozotocin-induced diabetic rats. Chitosan-
zinc-insulin complex significantly (P<0.05) reduced the initial burst release of insulin in 
comparison to zinc-insulin or insulin alone. The delivery system released insulin for ~70 days in 
biologically active form with corresponding reduction in blood glucose. Blood glucose levels 
were comparable to that of control for longer duration, and were significantly (P<0.05) lower 
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than untreated diabetic animals. No significant difference (P>0.05) in blood glucose levels in two 
consecutive time points until 56-63 days indicated a pharmacodynamic manifestation of 
continuous release of insulin at steady rate. The delivery systems showed increase in 
bioavailability of insulin (1.2-2 fold increase in AUC) as compared to zinc-insulin and insulin 
alone. Insulin released from the delivery systems did not provoke any immune response. The 
delivery systems were biocompatible in vitro and in vivo and were non-toxic. 
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1. INTRODUCTION 
1.1. Controlled Release Systems 
The ‘biologics portfolio’ of biotechnology and pharmaceutical industry represents an 
important sector for sustainable advancements in a market that is estimated to be growing at a 
rate of ~13% annually (1). Protein and peptide drugs such as insulin, salmon calcitonin, growth 
hormone, and vascular endothelial growth factor (VEGF), which represent a vast majority of 
these biologics, are often constrained with issues like short half-life, delicate structure and the 
physical/chemical instabilities (2-6). These problems, combined with the delivery issues, 
necessitate the frequent injections of these biologics to obtain the desired therapeutic effect. The 
proteins and peptides usually suffer with physical and/or chemical instabilities. Physical 
instability includes the alteration of higher order protein structures without any covalent 
modification, and can lead to undesirable processes such as denaturation (protein unfolding), 
aggregation, precipitation, and adsorption to the surfaces. The chemical instability includes 
breaking or formation of covalent bonds, which may lead to formation of new chemical entities 
with altered properties. Reactions such as hydrolysis, oxidation, deamidation, racemization, and 
isomerization are reported to contribute towards the chemical instability of the biologics (7). The 
diverse nature of these physicochemical instabilities of proteins and peptides warrants 
individualized approach to the development of their formulations. Smart (stimuli-responsive, 
environmentally-sensitive) polymers offer a drug delivery platform that can be utilized to deliver 
the proteins at a controlled rate and in a stable and biologically active form (8,9). The uniqueness 
of smart polymers lies in their nonlinear response triggered by a very small stimulus which 
causes a significant macroscopic alteration in their structure and properties. They are also 
referred as ‘intelligent polymers’ since these materials are able to sense a small change in the 
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surrounding environment and respond to it in a noticeable manner, and have the ability to regain 
their original shape/state upon removal of the stimulus. The attractiveness of smart polymer-
based delivery systems is enhanced by their features such as reduced dosing frequency, improved 
safety profile, and therapeutic effectiveness. 
1.2. Smart Polymers 
Smart or the stimuli sensitive polymers are characterized by an abrupt (and hence, 
nonlinear) change in their physical properties in response to small environmental triggers. These 
transitions in smart polymers can be reversible and include changes in their solvent interactions 
(swelling/shrinking), conductivity, physical state, shape, and solubility, among others. The major 
advantages of smart polymer-based injectable delivery systems include ease of preparation and 
administration, prolonged release of incorporated drug, maintenance of desired drug-therapeutic 
levels with a single dose, site specific/localized delivery, reduced side-effects, increased stability 
of incorporated drugs during formulation, storage and release, and the most importantly, 
improved patient compliance and reduction in follow-up care (7,10).   
1.3. Classification of Smart Polymers 
The types of stimuli that elicit the responses from smart polymers can be broadly 
categorized as: a) physical, b) chemical and c) biochemical (11). The physical stimuli include 
temperature, electric/magnetic/electromagnetic fields, presence of mechanical stress or strain, 
and ultrasound waves as illustrated in figure 1. The chemical stimuli comprise of the shifts in pH, 
presence of certain chemicals or ions while the biochemical stimuli include presence of 
biological molecules such as enzymes and ligands, etc. Such triggers could be internal, external, 
single or combination of two or more stimuli (8,11,12). In the recent past, temperature and phase 
sensitive polymer-based delivery systems have been the focus of major investigations for protein 
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therapeutics. The application of smart polymers which respond to light, ultrasound, magnetic and 
electric fields is rather limited and very few studies have been reported for their use as parenteral 
protein/peptide delivery systems. Though these delivery systems are useful in controlling the 
release of incorporated proteins; their non-biodegradable nature, need of surgical procedure for 
implantation and explantation, possibility of infection, and their cost limit their application. 
 
Figure 1. Various stimuli controlling the drug release from smart polymer based delivery systems 
1.3.1. Temperature sensitive/thermosensitive polymers 
 These polymeric delivery systems exhibit sudden changes in their physical state in 
response to small changes in temperature. The aqueous thermosensitive polymer solutions which 
exhibit this temperature-dependent reversible sol/gel transitions have been studied and used 
extensively in past decade for protein delivery due to their unique and fascinating properties such 
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as ability to undergo sol-gel transitions near body temperature and controlling the release rate of 
incorporated biologics while maintaining their physicochemical stability and biological activity 
(14). Depending on their ‘critical solution temperature’, these polymers exist in two different 
phases. Jeong and co-workers (15) have defined the ‘sol phase’ as a fluid, whereas the ‘gel 
phase’ is a non-flowing state that maintains its structural integrity. These polymers are further 
subdivided into negatively (reverse), positively temperature sensitive, and thermoreversible 
according to their phase response to the temperature change (16).The aqueous polymer solutions 
are monophasic systems at certain temperatures and exhibit phase separation above a specific 
temperature known as Lower Critical Solution Temperature (LCST) (17). At this temperature, 
the interactions between polymer and water molecules become thermodynamically unfavorable 
as compared to water/water or polymer/polymer interactions, leading to phase separation due to 
the dehydration of solvated polymer chains. Some amphiphilic polymers undergo self-assembly, 
forming micelle like structures, and form gel due to energetically favorable polymer/polymer 
interactions (18). This phase separation depends on the ratio of hydrophilic to hydrophobic 
moieties in the polymer, and the polymer/solvent interactions (18,19), and is an energy driven 
phenomenon which changes depending on the entropy or enthalpy of the system (18,20). The 
major additives which can affect the phase transition behavior include salts, surfactants, and co-
solvents (19). This thermoresponsive nature of polymers offers an attractive and promising 
strategy which makes these polymers suitable for controlled drug delivery of many proteins and 
peptides. The commonly used thermosensitive polymers include poly(N-isopropylacrylamide) 
(poly(NIPAAm), Poly(N,N-diethylacrylamide (PDEAAm), Pluronics®, Tetronics®, and PLGA-
PEG-PLGA (ReGel®) (16,21). Thermosensitive polymer-based delivery systems offer 
advantages such as the avoidance of organic solvents, ease of preparation and administration, 
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site-specific delivery, ability to deliver both hydrophilic and hydrophobic drugs, reduced 
systemic toxicity, and sustained drug release (22). Though temperature is one of the easiest 
external stimuli to apply, some of the challenges associated with these delivery systems include 
low mechanical strength of the gel leading to disruption of depot with potential of dose dumping, 
gradual lowering of pH of delivery system microenvironment due to presence of acidic 
degradation products of the polymers, instability of proteins and peptides in the presence of 
acidic by-products causing formation of immunogenic moieties, and finally, the biocompatibility 
of the delivery system in some of the cases. Some analytical techniques which are routinely used 
for the characterization of thermosensitive polymers are mentioned in table 1. 
1.3.2.  Phase-sensitive polymers 
Formulations containing phase sensitive polymers have been widely studied for 
controlled delivery of proteins (36). The phase sensitive delivery system usually comprises of a 
water insoluble polymer dissolved in an organic solvent (phase), and the drug molecules are 
usually dispersed/dissolved in the organic solvent. The critical constraints for the application of 
this delivery system include the biodegradability of the polymer and toxicological properties of 
the employed organic solvent system. Since most of the organic solvents are poorly tolerated at 
the site of injection, selecting a nontoxic solvent is essential (37). After administration/injection 
of the delivery system into the body, the organic solvent dissipates into the aqueous phase and 
water penetrates into the polymer matrix leading to polymer precipitation as a consequence of 
the phase separation (9,38). Thus, a depot is formed at the site of injection from which 
incorporated drug can be released slowly for longer durations (38,39). The drug release depends 
on the rate of phase inversion, as well as the morphology of the depot (40).  
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Table 1. Polymer properties and their evaluation methods 
Polymer Property : Analytical Methods 
Structure and Molecular weight : Nuclear Magnetic Resonance (NMR) (23), Fourier 
Transform Infrared Spectroscopy (FT-IR) (14,24,25), Gel 
Permeation Chromatography (GPC) (26) 
Micelle formation, Critical 
micelle concentration (CMC), 
Critical micelle temperature 
(CMT) 
: Transmission Electron Microscopy (Cryo-TEM) (27), 
NMR (1H and 13C-NMR) (23), Dynamic Light Scattering 
(27), Dye solubilization method (23,28), Fluorescence 
Spectroscopy (Pyrene probe method) (29) 
Cloud point : Ultraviolet Spectroscopy (UV), Static Light Scattering (30) 
Sol gel transition temperature : Tube Inversion method (31) 
Rheology/ viscosity : Rheometer (32) 
Hydrogel internal/surface 
structure 
: Confocal Microscopy (30), Scanning Electron Microscopy 
(SEM) (30) 
Swelling and in vitro hydrolytic 
degradation of polymer 
hydrogels 
: GPC (33), Differential Scanning Calorimetry (DSC) (34), 
FT-IR (34) 
In vitro biocompatibility of 
polymer, and polymer extracts 
: Cell viability assay (31) 
In vivo biocompatibility : Histological analysis of tissue surface in contact (35) 
 
Various factors such as polymer molecular weight, its composition 
(hydrophobic/hydrophilic chains), depot size, drug loading affect the drug release. Poly (D, L-
lactide) (PLA), poly (D, L-lactide-co-glycolide) (PLGA), poly (ε-caprolactone) are the most 
widely studied phase-sensitive polymers, while N-methyl-2-pyrrolidone (NMP), dimethyl 
sulfoxide (DMSO), glycofurol, triacetin, ethyl acetate, benzyl benzoate (BB), benzyl alcohol 
(BA) are the commonly used solvents (7,41). These delivery systems offer many advantages 
including high protein loading, simple manufacturing procedures, and inherent extended release 
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feature. The major problems associated with phase sensitive delivery systems include burst 
release and instability of incorporated proteins due to the presence of organic solvents. It has 
been reported that the burst release can be controlled by modulating solvent composition, 
polymer concentration, whereas protein stability can be improved by adding proteins in the form 
of dry powders along with stabilizers prior to administration (7). An alternate approach of adding 
emulsifying agents along with bioactive molecules has also been investigated to improve the 
drug stability (42). 
1.3.3.  Chemosensitive polymers 
Chemosensitive polymers respond to a chemical stimulus, which includes changes in pH, 
concentration of ions, enzymes, and ligands. The pH-sensitive polymers are polyelectrolytes 
containing either acidic (e.g. carboxylic groups), or basic (ammonium groups) on their surface, 
and are capable of accepting or donating protons in response to external pH change (9,10). 
Though many pH responsive polymers are used to deliver proteins and peptides, most of these 
polymers are suitable for oral drug delivery. 
The glucose sensitive polymeric delivery system is of particular interest for controlled 
delivery of insulin. These delivery systems can be based on glucose oxidase (GOD) responsive 
polymers or simple competitive binding of glucose. In case of GOD responsive insulin delivery, 
the enzyme (GOD) is usually immobilized on the pH sensitive polymer surface/membrane with 
insulin. The mechanism of insulin release involves conversion of glucose to glucuronic acid by 
GOD causing reduction in overall pH of the system, which in turn triggers a change in polymer 
geometry/swelling leading to the release of adsorbed insulin molecules (43). In this self-
regulated insulin delivery system, polycationic, polyanionic or erodible membranes are used 
which respond differently to glucose oxidase induced change in pH (16). In case of competitive 
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binding method, glycosylated insulin moieties are adsorbed on a carbohydrate binding polymer 
such as Concanavalin A (Con A), and compete with incoming glucose molecules for binding. As 
the glucose concentration increases, it competes with and eventually displaces glycosylated 
insulin from Con A surface (44). Number of glycosylated insulin derivatives with different 
binding affinities to Con A have been studied in order to manipulate the release of immobilized 
insulin in response to different glucose levels (16). Con A cross-linked glucose sensitive sol gel 
phase reversible delivery systems have also been studied for insulin delivery. Though this type of 
delivery systems holds a great promise in self-regulating the insulin release, the slow response 
time, long restoration time after removal of the stimulus, and the immunogenic nature of con A 
warrant the application of better biocompatible glucose sensitive molecules (16). A glucose 
responsive boronic acid based system has also been evaluated for controlled release of insulin to 
overcome the limitations of enzyme based components (45). 
1.3.4.  Light-sensitive/photosensitive polymers 
These polymers display phase transition in response to exposure to light and have 
attracted great attention since the stimulus can be imposed with extreme accuracy and precision 
and is easy to manipulate. Light sensitive smart polymers are partly water soluble, 
biodegradable, and biocompatible (7). These polymers can be sub-classified on the basis of the 
wavelength of the light that can trigger the phase transition response (16). The hydrogels of the 
polymers sensitive to light in UV region undergo swelling due to increased osmotic pressure in 
response to ionization induced by UV radiation, while in absence of this stimulus the gel 
collapses. Visible light sensitive gels are usually prepared by incorporating photosensitive 
molecules/chromophores. Therefore, the phase transition behavior of polymer depends on 
absorbance of light energy by chromophores, which is then dissipated as heat in the 
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surroundings, which in turn leads to heating/swelling on polymer chains. The process is 
considered fast as compared to UV sensitive polymer gels (46). Additionally, visible light 
sensitive polymers are comparatively easy to manipulate, safe and inexpensive as compared to 
their UV light sensing counterparts (16). Some photo-responsive polymers have been studied for 
in vitro release of bovine serum albumin (BSA) and lysozyme (7). The limitations of light 
sensitive polymers include slow response of hydrogels to stimulus (light), and an inconsistent 
response due to leaching out of non-covalently bound chromophores during swelling or 
deswelling (16).  
1.3.5.  Ultrasound sensitive polymers 
Considerable research has been done to exploit the use of ultrasound waves for controlled 
delivery of proteins using both bio-erodible and non-erodible polymer depots. Lavon and Kost 
(47) have investigated a non-erodible ethylenevinylacetate (EVAc) copolymer matrix to regulate 
the protein release in response to ultrasound radiation. The mechanism of enhanced protein 
release includes convection generated by cavitation without alteration in the polymer structure 
and morphology, and is a useful stimulus for enhancing the drug delivery from diffusion 
dependent non-bioerodable systems. The precise physical characteristics of polymers that 
respond to ultrasound is difficult to determine, but the factors that influence the drug release 
involve ultrasound frequency, structure and size of pores of polymer matrix, polymer 
degradation rate, and the properties of drug incorporated. While these systems have potential of 
offering highly tunable protein release, the lack of biocompatible and biodegradable ultrasound 
sensitive polymers can potentially hamper their widespread applications. 
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1.3.6.  Magnetic field sensitive polymers 
This type of delivery system usually consists of a polymer matrix embedding small 
magnetic beads and the biotherapeutic protein/peptide of interest. Under the influence of external 
magnetic field, the small magnetic beads oscillate within the matrix, leading to drug release from 
the matrix. Such release of the incorporated drugs depends on number of factors including 
magnetic strength, orientation and position of magnetic beads, the amplitude and frequency of 
external magnetic field, as well as the mechanical properties of the polymer matrix (48). Hsieh et 
al., (49) reported the protein release from the polymeric delivery system modulated and 
controlled by application of external oscillating magnetic field. Multiple studies have been 
reported the use of polymer implants/matrices embedded with magnetic beads to achieve 
optimum controlled insulin release both in vitro and in vivo (10). Alginate spheres embedded 
with magnetic beads, and alginate/chitosan microcapsules containing magnetic nanoparticles 
have been evaluated for controlled delivery of insulin (50,51). While affording a better control 
over the drug release profile, these delivery systems are often plagued with issues of 
biocompatibility, need of surgical implantation/explantation, and subsequent potential patient 
compliance issues. 
1.3.7.  Electric field sensitive polymers 
Electric field responsive/electroresponsive polymers change their physical state in 
response to small change in electric current. Usually, these polymers contain ionisable groups 
which are sensitive to pH. The electric current causes increase/decrease in the local pH which 
leads to disruption of hydrogen bonding between polymer chains, causing polymer 
swelling/deswelling or degradation and finally drug release. Various cationic, anionic or neutral 
molecules can be delivered using different amplitudes of current. An electroresponsive polymer 
11 
 
matrix prepared using poly(ethyloxazoline)-poly(methacrylic acid) has been reported for protein 
delivery (52). In this approach, a pulsatile release of incorporated protein was seen due to the 
erosion of polymer matrix/hydrogel using a well-regulated electric stimulus. Drug can be 
incorporated into the electroresponsive polymer and injected subcutaneously to form a depot, 
followed by application of a low electric current (well-tolerated by human) to release the drug in 
pulsatile manner. The mechanism of release is reported to be due to the transportation of counter 
ions and water molecules in the polyelectrolyte gel matrix. These gels of 
poly(dimethylaminopropylacrylamide) (PDMAPAA) have been evaluated for pulsatile insulin 
delivery in vivo (53). Another important mechanism of drug release from electro-responsive 
polymers involves forced convection of drug upon polymer swelling/deswelling (54). The drug 
release from these types of gels can be changed by modulating the electric current. Responsive 
hydrogels made up of chondroitin sulfate have been explored for the delivery of various proteins 
and peptides, where the macromolecules get released upon application of electric field (55). 
Another type of electric field responsive hydrogel made up of hyaluronic acid shown the release 
of glutamic acid and tyrosine when the electric current is “switched off.” In this type of delivery 
system, small amino acids can diffuse easily through the pores of the swollen hydrogels in 
absence of electric current via diffusion, but cannot diffuse out when the gel shrinks under the 
influence of electric current (55). The major advantage of this type of delivery system is a simple 
control of drug release in a constant/pulsatile manner by modulating the external electric field. 
Though it seems to be a promising approach, its in vivo application should be assessed with 
extreme care. The important constraint that has to be considered while designing this type of 
delivery system includes the critical selection of electric current which will be sufficient to 
trigger the drug release without stimulating the nerve endings in the surrounding tissue. 
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1.3.8.  Mechanical stress/strain sensitive polymers 
The delivery systems formulated from mechanical stress/strain sensitive polymers 
respond to the external stress/compressive force and release the incorporated drug from the 
polymer matrix. After removal of the external force/stress the matrix regains its original 
shape/volume reducing the release. Though this type of delivery system has a potential to be 
used for controlled delivery of various small and large molecules, very few finding have been 
reported regarding the use of mechanical stimuli-sensitive delivery systems. Alginate hydrogel 
implants were tested for their ability to deliver vascular endothelial growth factor (VEGF) in a 
pulsatile manner upon mechanical stimulation both in vitro and in vivo (56).  
1.3.9.  Antigen-responsive polymers 
This type of delivery system is fabricated by grafting specific antigen and corresponding 
antibody to the polymer chains. The antibody-antigen binding leads to the crosslinking between 
the polymer chains forming a three dimensional gel network. The release of incorporated protein 
is based on the competitive binding between the polymer-bound and free antigen present in the 
release medium, causing changes in the hydrogel shape, size, or crosslinking. The 
polyacrylamide based semi interpenetrating network (IPN) hydrogels have been studied for the 
pulsatile delivery of a model protein, hemoglobin (57). The most important property of this IPN 
is that the hydrogel shows a shape-memory behavior, which is solely dependent on the 
concentration of free antigen, and consequently the hydrogel swelling and protein release. 
Therefore, the protein release can be controlled by a change in antigen concentration (57). 
1.3.10.  Multiple-stimuli responsive polymers 
While a single stimulus would restrict the practical application of smart polymers, multi-
stimuli responsive polymer-based drug delivery platforms are receiving heightened interest as 
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controlled delivery systems (58), since these multiple responsive polymers establish a better 
control over the drug release profile and duration. Al-Tahami and Singh (7) have summarized 
some recent patents describing the use of multiple-stimuli sensitive polymers for the delivery of 
proteins for prolonged period. A pH/temperature-sensitive injectable pentablock copolymer 
hydrogel has already been used for insulin delivery in vitro and in vivo (59). This dual 
responsive pH/ temperature sensitive copolymers overcome the limitations of both temperature 
and pH sensitive polymers, like clogging of needle during injection, reduction in the 
development of acidic conditions due to degradation of polymer chains etc. Additionally, 
cationic polymer chains can form reversible complex with anionic proteins/peptide at 
physiological pH by ionic interactions leading to sustained release, and also help in reducing 
initial burst release (60). Even though these multiple stimuli sensitive systems have certain 
advantages over single stimulus, there complicated structure, and different degradation rates 
make the formulation optimization difficult. The number of factors to be fine-tuned while 
developing such delivery systems include injectability, gel/depot strength after incorporation of 
drugs, interaction with incorporated proteins/peptides, interaction with surrounding tissues, and  
finally not the least, biodegradability, and biocompatibility. 
1.4. Biocompatibility of the Delivery Systems 
In the development of increasing number of new polymers for controlled delivery 
systems, ‘biocompatibility’ is the key prerequisite they have to fulfill for their safe use. Local 
skin/tissue compatibility is an essential parameter in their in vivo application. Non-biodegradable 
implantable polymeric materials need surgical procedures for their implantation and 
explantation, and extended exposure to these polymers may cause chronic inflammation of the 
surrounding tissue, as well as tissue damage. The foreign body reaction caused by implants 
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presents a great risk and inconvenience to the patients and is one of the most important reasons 
for their low patient acceptance. Onuki et al., (61) has described various types of foreign body 
reactions towards the implants and ways to overcome them. Since biocompatibility of a delivery 
system is an essential feature to be considered during formulation, the correct choice of a 
biocompatible material can minimize the untoward body reactions, thereby improving the 
durability of the formulation. International Standard ISO-10993 has prepared a guideline for 
testing the biocompatible nature of materials for medical applications using both direct and 
indirect contact approaches (62).  
Biodegradable polylactic acid (PLA), and PEG based polymers and copolymers are of 
great technological interest, and are commonly used in many biomedical devices due to their 
biocompatible nature. PLA degrades by non-enzymatic hydrolysis of ester bonds, and the 
degradation products are further transformed into non-toxic moieties which are easily eliminated 
by the body. Though the polymer is biodegradable, it does not mean that it is non-toxic and 
biocompatible. There are number of in vitro and in vivo tests used to determine the 
biocompatibility of these polymers. The commonly used methods for determination of in vitro 
biocompatibility include, a cell viability assay, while for in vivo biocompatibility evaluation, 
tissue inflammatory reaction upon administration of the polymeric material is visualized 
(14,31,35,63,64). The in vitro cytotoxicity tests such as agar diffusion test, filter test, and MTT 
assay are very effective methods for biocompatibility evaluation; however, an MTT assay is 
much more sensitive than other tests. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) cell viability assay is the most popular and widely used assay for 
in vitro biocompatibility testing for many years. Ignatius and Claes (65) have explained a 
procedure to determine the in vitro cytotoxicity of polymers and their extracts or degradation 
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products. For this, the polymers are extracted in PBS by incubating at 37 and 70°C. Since 
degradation rate of polymers is greater at higher temperatures, the extracts prepared at 70°C 
mimics the long-term effects of the delivery system. To exclude the effect of pH on the cell 
viability, pH neutralized extracts are usually prepared and are incubated with cells for a specific 
duration. After incubation, the cell viability is assessed by mitochondrial succinate 
dehydrogenase activity using MTT. Since only live cells can metabolize MTT into purple 
formazan crystals, the results are indirectly correlated with the number of viable cells after 
polymer treatment. Though this is widely accepted method for cytotoxicity evaluation, it does 
not reflect the actual effect of reduced pH due to polymer degradation. The reduced pH may 
cause several acute or chronic inflammatory reactions in the surround tissue after implantation, 
and hence, it is very essential to evaluate the biocompatibility of the delivery system in vivo. 
A series of inflammatory events that occur after implantation of PLA and PLGA poly 
(DL, lactide-co-glycolide) polymeric delivery systems in vivo have been described by Shive and 
Anderson (66). Though degradation rate varies according to the nature of the polymeric delivery 
system, the presence of depot initiates a series of inflammatory events in the surrounding tissue 
after injection, and the severity of the foreign body reaction determines the biocompatibility of 
the polymer. For an ideal delivery system, the polymer should cause minimal inflammation for 
short duration, and tissue damage should be reversible without formation of any scar tissue or 
necrosis.  
1.5. Various Stages of Drug Release from Controlled Delivery System 
An important factor that has to be studied during development of a controlled delivery 
system is the different stages of drug release. Most of the polymeric controlled delivery systems 
usually follow a triphasic or sigmoidal release pattern (67-73), which can be divided into 
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following stages: a) fast initial burst release as a result of quick diffusion of drug molecules 
located at the surface, b) slow release for days/weeks where drug is released in controlled 
fashion, c) rapid release/secondary burst release due to polymer degradation, and sometimes a 
fourth phase which is characterized by a slow release observed after secondary burst, usually as a 
result of depletion of drug content. This sigmoidal release pattern is not desirable in most of the 
situations except in case of vaccine immunizations (74), where the triphasic release pattern 
mimics the traditional boosting regimes. 
The release pattern of controlled delivery system usually comprises of a characteristic 
phenomenon, called as “initial burst release,” which usually reduces the effective lifetime of the 
delivery system. It has been reported that, in case of many controlled release formulations, 
immediately upon placement in the release medium, an initial large bolus of drug is released 
before the actual release starts (75,76). This is a short-term phenomenon compared to the entire 
release process, but affects the overall release duration, therapeutic efficacy and safety profile of 
the incorporated drug molecules. Since the burst occurs in a very short period as compared to the 
entire release process, it was not explored in detail earlier, and never considered as an essential 
part during mathematical modeling of the release. But, recently this phenomenon has been 
noticed and widely explored. Researchers are trying to understand the mechanisms of burst 
release and ways to prevent it using various approaches (75). There are number of publications in 
which this key issue is addressed (69,77-80). Though the burst release is favorable in some cases 
(81), it is considered as an undesirable effect, and has to be taken into consideration while 
designing a controlled delivery system.  
Studies reported that the initial burst release occurs due to the presence of drug molecules 
located close to the surface of the delivery system. For example, in case of insulin-loaded 
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microspheres, initial burst release was noticed due to the presence of insulin molecules in 
vicinity of microsphere surface (3,82), and it eventually reduced the overall release duration 
from microspheres. Strategies tried to lower the initial burst release include, non-uniform drug 
loading in the polymer matrices (83), changing the hydrophilic or hydrophobic content of the 
polymeric delivery system (35,84), increasing the size, or reducing the solubility of the drug 
molecule (2) to name a few. However, sometimes these additional steps involved in the 
formulation process could potentially result into reduction in drug loading and might increase the 
overall cost of the formulation.  
1.6. Delivery of Proteins and Peptides 
Most of the protein/peptide drugs are administered via invasive routes and need multiple 
injections. Though the conventional routes have been tried for the delivery of proteins and 
peptides their delivery is still difficult and challenging. Various strategies have been developed 
to overcome the barriers for protein delivery via oral route, but their fragile nature, delicate 
structure and degradation by various enzymes in the gastrointestinal tract limits the application 
of oral route. Other routes such as buccal, nasal, rectal, vaginal, ocular, and transdermal have 
also been tried for delivery of proteins with limited success (85). The primary reason is their low 
bioavailability, mostly due to the poor permeability through the mucosa and skin tissue (36). 
Therefore, parenteral route is the most preferred route for delivery of proteins and peptides.  
Thus, before even it can be considered as a candidate for treatment, its complex 
biochemical and biological properties should be taken into consideration. Proteins usually 
comprise of higher order of structures to elicit their biological response, and any alteration in 
their primary/secondary/tertiary or quaternary structure greatly influences their activity. The 
structure of protein is divided into primary (amino acids sequence), secondary (α-helix, β-sheets, 
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β-turns, random coils), tertiary (folding into three dimensional structure), and quaternary (spatial 
arrangement of its subunits) structure (86). Due to the relatively poor stability, the formulation 
and storage conditions greatly hamper their higher order structures. Disruption of these structures 
leads to the loss of their biological activity, and sometimes increases immunogenic potential. 
Thus, is very crucial to maintain the highly organized structure of protein for proper activity and 
functionality (87). The partially unfolded protein undergoes precipitation/aggregation reactions 
and is able to provoke immune response. It also increases its rate of clearance from the body 
leading to reduced efficacy, and subsequently repeated administration becomes inevitable (88). 
These problems related to protein instabilities can be divided into two major categories 
namely; a) instabilities during formulation, and b) during storage and administration (89). It has 
been reported that the harsh manufacturing conditions, use of organic solvents, high 
temperatures, agitation, presence of detergents, and hydrophobic surfaces could risk the chemical 
and structural integrity of proteins (44). Even after administration, proteins get hydrated, remain 
hydrated, and get exposed to various physiological conditions (pH, temperature, enzymes) for 
long duration. This type of prolonged exposure to various stress conditions can adversely affect 
their effective half-life in body. Some of the degradation reactions proteins can undergo include 
deamidation (asparagine and glutamine residues), peptide bond hydrolysis (aspartic residues), β-
elimination and disulphide bond reshuffling (cysteine residues), and oxidation (cysteine and 
methionine residues) (90). Protein aggregation is an important issue usually encountered during 
almost all stages during formulation and development of proteins and peptides. It is reported that 
there are more than 20 diseases caused as a result of partial/abnormal protein aggregation (91). 
The key factors contributing towards protein aggregation include, moisture (92-94), temperature 
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(95,96), pH (96), shaking (97), presence of hydrophobic surfaces (98), organic solvents (99), and 
free-drying/ freeze-thawing procedures (100,101).  
Therefore, to get a clinically viable formulation, researchers have tried to overcome the 
difficulties with protein degradation and aggregation in the delivery systems, which would 
finally result into a product having an intact structural integrity and biological activity of the 
incorporated protein (90). The primary focus of protein formulation development should be not 
only minimizing the degradation reactions, but also avoiding the causes of these reactions. One 
way to overcome these difficulties associated with protein stability is to add stabilizers (102), 
polyethylene glycol (103,104), non-ionic surfactants (105), inorganic bases (magnesium 
hydroxide) (106,107), or divalent ions (zinc) (108). Another way is to decrease the formation of 
harmful degradation products of controlled release polymeric delivery systems which is one of 
the crucial factors affecting protein degradation/aggregation (90). The third approach would be 
‘PEGylation’, i.e. modifying the protein by covalently conjugating with nontoxic and non-
immunogenic polyethylene glycol (PEG), which would help to improve the protein stability and 
retention time in blood as well as reduces the proteolytic degradation (109,110). 
1.7. Techniques of Protein Stability Evaluation 
Some of techniques used to monitor protein/peptide stability include calorimetry 
(Differential Scanning Calorimetry), chromatography (High Performance Liquid 
Chromatography, Size Exclusion Chromatography), gel electrophoresis (Native/SDS-
Polyacrylamide Gel Electrophoresis), mass spectroscopy (Matrix Assisted Laser 
Ionization/Desorption-Time of Flight), rheology and microscopy (111). These methods mainly 
focus on physicochemical characterization, such as presence of secondary structural components 
of protein (α helix, β sheets, and random coils), association state, folding/unfolding, molecular 
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weight and structural integrity. Additionally, the biological activity of a protein can be evaluated 
directly using various protein-specific bioassay procedures or indirectly by determining its 
pharmacodynamic activity (2-4,31,35,64). Some of the commonly used techniques are discussed 
below. 
1.7.1.  Circular dichroism spectroscopy (CD) 
Circular dichroism spectroscopy is one of the most widely used techniques for structural 
determination of protein. ‘Circular dichroism’ is defined as “the unequal absorption of left-
handed and right-handed circularly polarized light” (112). The clockwise/counter-clockwise 
rotation of the wave helps in determining the structure of a molecule (112). This effect usually 
takes place when a chromophore itself is optically active (chiral), covalently linked to a chiral 
molecule, or is placed in an asymmetric environment (113). The far UV region in CD spectra 
gives an idea about the structure of the backbone of the protein, and can be directly correlated to 
the relative composition, and changes in secondary structure of protein (2-4,31,35,64). At the 
same time, the near UV CD spectra can be used to estimate the presence of aromatic residues 
present on the surface of a protein and further can help in identifying its association state. A 
characteristic CD spectrum is usually observed depending on the alignment of the chromophores 
in the polypeptide backbone. The negative bands at 208 and 222 nm, and a positive band at 193 
nm arise specifically due to the presence of α-helical structure of protein, while anti-parallel β-
sheets show a negative band at 218 nm and a positive band at 195 nm (114). The presence of 
random coils shows a positive band at 212 nm, and a negative band around 195 nm (115). Thus, 
every protein has specific percentage of α-helix, β-sheet, or random coils content, and therefore it 
is a widely accepted method for determination of any change in the secondary structure of 
protein under various stress conditions during formulation or storage. For tertiary structure 
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analysis, near-UV CD spectra provide the useful information, and arise from the presence of 
aromatic residues like tryptophan, tyrosine and phenylalanine on protein surface (116). Thus, 
even if the protein has well defined secondary structure but showing inadequate near-UV CD 
signal indicates that it is not folded correctly. Thus, a well-defined band in near UV region is 
also considered as a good indication that the protein in folded in a well-defined structure (115). 
1.7.2.  Differential scanning calorimetry (DSC) 
DSC has a long history in understanding protein energetics, and is one of the important 
techniques in evaluation of folded/unfolded state of proteins with respect to change in 
temperature. The primary sequence of amino acids is a driving force for interactions between 
amino acids, between protein and solvent, and is mainly governed by thermodynamics, and there 
is a delicate balance between the thermodynamic parameters and protein folding. The protein 
structure in folded state is usually stabilized by ~80-120 kJ/mol (20-30 kcal/mol) (117), and DSC 
aids to determine the heat capacity of protein solution (Cp) as a function of temperature. The 
melting temperature (Tm), also known as midpoint temperature, is also a good indicator of 
folding/unfolding state of protein. Assuming a two-state transition, Tm is defined as a 
temperature at which the half of the protein molecule is in unfolded state (118). Thus, during 
denaturation of protein in response to temperature, the transition shows a sharp endothermic peak 
with Tm at the center and maximum in Cp. The area under the transition peak gives the 
information about the transition enthalpy (∆H), and is correlated with the content of secondary 
structure of a protein. Thus, Tm indicates the thermostability of a protein and it is observed that, 
higher is the Tm; more thermodynamically stable is the protein. Therefore, proteins with higher 
Tm are less prone to unfolding/denaturation (118). 
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1.7.3.  High performance liquid chromatography (HPLC) 
Reversed-phase high performance liquid chromatography (RP-HPLC) is a well-
established tool used in the analysis of proteins and peptides and their degradation/aggregation 
products. It separates proteins/peptides depending on their affinities towards the stationary phase 
and mobile phase. The RP-HPLC experimental system for proteins/peptides usually consists of 
an n-alkylsilica-based sorbent and an organic solvent such as acetonitrile containing an ionic 
modifier (e.g. trifluoroacetic acid, TFA) (119). This is a widely used technique for protein and 
peptide separation since it separates the complex mixtures easily at picomolar/femtomolar 
concentrations and can be collected for further characterization. It is a versatile and reliable 
technique used for detection of both covalent and non-covalent aggregates as opposed to Size 
Exclusion Chromatography (SEC-HPLC) which detects the presence of aggregates based on size 
(111). 
1.7.4.  Polyacrylamide gel electrophoresis (PAGE) and sodium dodecyl sulfate-PAGE 
(SDS-PAGE) 
One dimensional polyacrylamide gel electrophoresis (PAGE) is another simple method 
which provides information about the molecular size, purity, and presence of protein aggregates. 
In native PAGE, the rate of protein migration depends on the size, charge, shape of the molecule, 
and pore size of the gel matrix, under the influence of an external electrical field. Gel 
electrophoresis under denaturing conditions (in the presence of SDS, without a reducing agent 
such as 2-mercaptoethanol), separates the protein only depending on its size (120), and does not 
dissociate the covalent disulfide bonds, and therefore can be used to distinguish between the 
covalent/non-covalent protein aggregates (121).   
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1.7.5.  Matrix assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) 
MALDI-TOF MS, an analytical method, has been first described in 1988 (122), which 
essentially estimates the molecular weight of proteins accurately up to 100 kDa from picomolar 
amount of sample (123). This technique can be used to identify proteins and their degradation 
products without prior chromatographic separation, helps to determine higher orders protein 
structures, is highly sensitive, and requires minimal sample for analysis (124,125). The important 
constituent of this analysis is matrix molecules of organic nature. The role of matrix material is 
crucial and aids in co-crystallization of the analyte, absorbs energy from the strong laser pulse 
thereby protecting analyte, and expels analyte into gas phase, and helps in ionization of the 
analyte. The matrices are usually aromatic compounds containing carboxylic acid functional 
groups such as several cinnamic acid derivatives, sinapinic acids and 2,5-dihydroxybenzoic acid 
(122). 
1.8.  Diabetes Mellitus and Insulin 
Diabetes mellitus is cited as one of the most challenging health problems in the 21st 
century. More than four million patients in the United States use insulin for the treatment of 
diabetes mellitus (126). World Health Organization defines diabetes mellitus as “A metabolic 
disorder of multiple etiologies characterized by chronic hyperglycemia with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin 
action or both” (127). It is a growing health concern around the globe in spite of the employment 
of newer treatment regimes. It is characterized by absolute or relative (type 1 or 2) deficiency in 
insulin secretion/response resulting in hyperglycemia. Insulin, a polypeptide hormone, decreases 
the level of glucose in blood and regulates the metabolism of glucose, fat and proteins, thus 
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helping to achieve proper glycemic control. Despite the fact that insulin is discovered almost 90 
years ago, clinicians have been still challenged to achieve euglycemia in their patients using 
injectable insulin formulations.  
Human insulin (~6000 Da) consists of 51 amino acid residues divided into two chains; 
chain A contains 21 amino acids, while chain B has 30 amino acids (128). Though there is 
species variation in the primary structure of insulin, the folding of two chains and its three-
dimensional conformation is reported to be same. The A chain forms two anti-parallel α helixes, 
and an additional α-helix, a turn and a β-sheet is formed by B chain (128). The isoelectric point 
(pI) of insulin is ~5.4 (129), and therefore it carries a positive charge below pI, while, above the 
pI it carries net negative charge (130). The chemical stability of insulin is a function of pH, and 
around pH 4 it forms covalent dimers, while undergoes minimum hydrolytic degradation near pH 
6.5 (131). Depending on the concentration and pH, insulin forms dimers and in presence of 
divalent cations it self-associates to form hexamers. The self-association is an important 
phenomenon since the hexameric state provides insulin stability. It is known that the metal 
bound insulin hexamers usually exist in three different states, namely T6, T3R3, and R6 
conformations. In solution state these states are in equilibrium and can be shifted from one 
another in the presence of some additives such are phenols, inorganic anions etc. (132). It has 
been reported that insulin monomers associate with zinc by co-ordinate bonds, and this 
association is very important for storage, and secretion of insulin (133). The zinc coordinated 
hexamer is a physiological form of insulin, and is stored in the body in this form in storage 
granules (134). Increasing the number of zinc ions (more than 4/hexamer) adversely affects 
insulin stability by causing peptide link cleavage (131), and therefore, the zinc/insulin hexamer 
ratio during formulation should be closely monitored. The availability of insulin molecules in the 
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body depends on the dissociation of its hexameric state, and its rate of diffusion from the site of 
administration into the blood. Thus, its availability can be varied by changing its solubility and in 
turn association state.  
In healthy individuals, physiological insulin secretion has two phases; basal secretion, 
wherein the pancreas secrete a constant low level of insulin into the circulation throughout the 
day, and stimulated secretion, where the pancreas respond to food intake by secreting large bolus 
of insulin to maintain normoglycemia (135). The basal insulin which is secreted at a rate of 0.5-
1U/h throughout the day and between meals, accounts for ~50% of the total daily output, and 
plays a major role in preventing long-term diabetic complications (136,137). Basal insulin 
secretion does not shut-off hepatic glucose production and provides adequate substrate for 
cerebral glucose metabolism (138). In a normal non-diabetic individual the stimulated insulin 
levels up to 60-80 µU/ml can be observed within few minutes after ingestion of a meal. This 
increased insulin secretion leads to disposition of glucose and various nutrients mainly into 
muscle and to a slight extent into liver. Therefore, type 1 diabetic patients with absolute 
deficiency of insulin completely rely on basal-bolus insulin regimen for maintaining their blood 
glucose levels. This regimen attempts to replicate the normal insulin secretion profile and 
comprises of multiple injections of rapid acting insulin before each meal to mimic prandial 
insulin secretion, and an additional injection of intermediate/long acting insulin before bedtime 
to mimic basal insulin secretion. This repeated insulin administration gives rise to numerous 
complications and the pain from multiple daily injections adversely affects the quality of life of 
patients. Therefore, from a patient compliance perspective, to avoid the discomfort and 
inconvenience associated with multiple daily injections, alternate administration routes have 
been explored.  
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Various inhalation insulin preparations (Exubera®, AERx® insulin) (139,140), nasal 
sprays (Nasulin™) (141), and oral insulin spray (Oralin™) (142) have been used to relieve pain 
and discomfort experienced by patients due to repeated injections. However, due to the absence 
of the controlled delivery feature, these systems do not offer a prolonged insulin release. Insulin 
pumps are extensively tried due to their ability to offer improved glycemic control as compared 
to daily injections (143). Almost every feasible route for insulin administration has been tested 
with limited success and the subcutaneous route still remains the principal route of 
administration. The two long acting basal insulin analogues, Lantus® (Insulin Glargine), and 
Levemir® (Insulin detemir) have become available in recent years to achieve adequate glycemic 
control (144-146). Though these analogues are known to achieve good glycemic control, and 
lower the incidence of fasting hypoglycemia efficiently (147); they do not completely eliminate 
the risk of nocturnal/fasting hypoglycemia (148). In view of these shortcomings, attempt have 
been made to fabricate an ideal basal insulin therapy, which will essentially provide a constant, 
peak-free, prolonged and continuous insulin supply after subcutaneous administration, 
eliminating the risk of fasting hypoglycemia.  
1.9.  Controlled Delivery of Insulin 
Controlled delivery of insulin using in situ gel forming delivery systems can be an 
effective strategy which could provide continuous low basal insulin level, and partly alleviate the 
pain felt by multiple injections (35). Such insulin delivery is also critical in reducing the 
long-term micro and macro vascular complications of diabetes (3). Several researchers have 
focused on the development of injectable thermosensitive copolymeric delivery systems for the 
delivery of insulin at a controlled rate and in response to the physiological need (35,59,149). 
These delivery systems with varying hydrophilic/hydrophobic content can alter the rate of insulin 
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release. The major advantage of these delivery systems is absence of organic phase which 
hampers the delicate protein structure (4,149-151). Additionally, the biodegradable and 
biocompatible nature of the copolymers, as well as simplicity of administration of the delivery 
system makes them attractive candidates for sustained drug delivery. Some of the biodegradable 
thermosensitive copolymers investigated include, poly(D,L-lactide-co-glycolide)-poly(ethylene 
glycol)- poly(D,L-lactide-co-glycolide) PLGA-PEG-PLGA (149), a mixture of pH/temperature-
sensitive poly(β-amino ester)-poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone)-
poly(β-amino ester), PAE-PCL-PEG-PCL-PAE pentablock copolymer (150), 
chitosan/glycerophosphate complex (151). Even though these polymeric systems have many 
advantages, the issues such as high initial burst release, relatively short release duration of the 
incorporated drug, and incomplete release make their development difficult. The high initial 
burst release of insulin often leads to hypoglycemia and is considered as the major barrier in 
achieving good glycemic control. Hence the delivery system which shows a relatively flat/peak-
less time action profile could limit the peak induced hypoglycemia. Some of the approaches that 
have been tried in order to reduce the initial burst of insulin, to control the release duration, and 
stabilization of insulin are PEGylation of insulin, addition of zinc salts, ethanol and/or glycerol, 
hydroxypropyl-β-cyclodextrins (HP-β-CD), sugars, salts, cationic polyelectrolyte and nonionic 
and ionic surfactants to insulin (3,152-159). A combination approach of two or more delivery 
systems such as nanoparticle/microsphere or microsphere/hydrogel has also been tried to control 
and prolong the release behavior of various proteins (160-163). 
1.10. Chitosan as Protein Stabilizer 
Chitosan is a linear polysaccharide, made up of randomly distributed α-(1-4)-linked D-
glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit) (164). The 
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structure of chitosan is presented in figure 2. Chitosan is obtained by partial deacetylation of 
chitin under alkaline conditions (164,165). It is reported as a biocompatible and biodegradable 
positively charged polymer with minimum immunogenic potential and also possesses low 
cytotoxicity (166). 
 
Figure 2. Chemical structure of chitosan 
 
It is a well-known gene delivery vector and has been reported as a safe and promising 
material for controlled drug delivery (164,166,167). It has been widely used for encapsulating 
number of drugs and biological substances by simple and nontoxic procedures (168-171). It has 
been reported that chitosan interacts with peptides/proteins and imparts a stabilizing effect on the 
proteins (168,172-174). The pH and temperature of both chitosan and peptide are important 
factors need to be considered while preparing the chitosan-protein drug delivery systems (175). 
1.10.1.  Chitosan based polyelectrolyte complexes for drug delivery 
When the oppositely charged polymers/polyelectrolytes are mixed together in solution, 
they self-assemble due to the presence of electrostatic interactions to form a ‘polyelectrolyte 
complex.’ According to the IUPAC Compendium of Chemical Terminology 2007, the 
polyelectrolyte complex is “Neutral polymer-polymer complex composed of macromolecules 
carrying charges of opposite sign causing the macromolecules to be bound together by 
electrostatic interactions.” Polyelectrolyte complexes have been used as non-viral gene carriers 
(176-181), drug carriers (182-184), bioseparation (185), and multilayer/films (186-189). 
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Chitosan has an ability to form specific complexes with polyanions of various types which 
involve electrostatic and dipole-dipole interactions, hydrogen and hydrophobic bonds (190). The 
positively charged amino groups on chitosan (C2 position in glucopyranose unit) can interact 
with negatively charged groups (carboxylic acids) on polyanions electrostatically, to form 
polyelectrolyte complexes (191). The pka value of chitosan is reported to be ~6.3-6.5, thus, in 
acidic pH most of the amino groups on chitosan are in protonated form and hence can form 
complexes with various polyanions near this pH range (192,193). It has been reported that the 
polyelectrolyte complex formation depends on number of factors such as the degree of ionization 
of cationic and anionic polymers, in turn, pH and ionic strength of the solutions, the 
concentration of the polyelectrolytes, their mixing ratio, nature of ionic groups and their charge 
density, temperature, as well as polymer chain flexibility (191). 
1.10.2.  Chitosan for insulin delivery 
Chitosan and its derivatives have been widely used for delivery of insulin via various 
routes including oral (194-199), nasal (200-203), and buccal (204). Chitosan based injectable 
microparticles have also been investigated for the delivery of insulin (3,172,205,206). In case of 
chitosan-insulin nanoparticles, the formulation pH and insulin loading played important role 
(207), and it has been reported that, pH had the major impact on the conformational as well as 
chemical stability of incorporated insulin (131).  
1.11.  Statement of Problem 
The objective of the proposed research was to develop a controlled release polymeric 
formulation based on chitosan-zinc-insulin complex incorporated into thermosensitive polymer, 
which can deliver insulin continuously over three months to meet basal insulin requirement after 
a single subcutaneous injection. The delivery system is also expected to eliminate the initial burst 
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release of insulin, and preserve its stability during release and storage. Additionally, the delivery 
system should be biodegradable and biocompatible in vitro and in vivo. 
To achieve this goal we took a dual approach: 
• We utilized the self-association property of insulin to form hexamers in the presence of Zn+2. 
Hexameric insulin is less soluble and highly stable. 
• The second approach is to restrict diffusion of a large chitosan-zinc-insulin complex through 
the inner gel passage/pathway of the polymer gel matrix. 
Chitosan has abundant positive charge due to the presence of primary amine groups on its 
surface, and insulin carries negative charge at pH > pI (5.4). Therefore, complexes can be formed 
under optimized conditions by electrostatic interactions between positively charged chitosan and 
negatively charged insulin. By incorporating the chitosan-zinc-insulin complex in the 
thermosensitive polymeric delivery system, the rate of insulin release can be controlled. We 
hypothesize that the novel approach of utilizing the combination of distinctive properties of 
insulin such as self-association in presence of zinc, their ability to interact electrostatically with 
chitosan and subsequent addition of the chitosan-zinc-insulin complex into thermosensitive 
polymer solution would circumvent the problems associated with insulin burst release and 
stability, while providing controlled release of insulin at basal level over long duration. The 
chitosan-zinc-insulin complexes were designed characterized by ionic interactions between 
chitosan and insulin, and the schematic is presented in figure 3. 
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Figure 3. Schematic representation comparing the release behavior of (A) insulin loaded, and (B) 
chitosan-zinc-insulin complex loaded thermosensitive polymeric delivery system 
We propose the following specific aims to test our hypothesis and to accomplish the 
above stated goals: 
• Synthesis and characterization of triblock thermosensitive copolymer, and study of 
hydrolytic degradation of polymer in presence of various molecules 
♦ To synthesize thermosensitive Polylactic acid-Polyethylene glycol-Polylactic acid 
(PLA-PEG-PLA) triblock copolymer with 1500-1500-1500, and 1600-1500-1600 chain 
lengths (4500, and 4700 Da, respectively). 
♦ To characterize the synthesized copolymers for structure, molecular weight and 
polydispersity using Nuclear Magnetic Resonance (NMR), and Gel Permeation 
Chromatography (GPC), and tube inversion method. 
♦ To study the hydrolytic degradation of copolymer A and B using Nuclear Magnetic 
Resonance (NMR), and Gel Permeation Chromatography (GPC), and Scanning 
Electron Microscopy (SEM). 
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♦ To study the effect of various model molecules on hydrolytic degradation of copolymer 
A, and to study in vitro release of incorporated molecules from the delivery systems. 
• Study the effect of various formulation parameters on release profile of insulin 
♦ To study the effect of polymer concentration, insulin loading, and zinc addition on in 
vitro release of insulin from the thermosensitive polymeric delivery system. 
♦ To determine the stability of insulin released in vitro. 
• Study the effect of addition of chitosan on insulin release and stability 
♦ To evaluate the effect of addition of chitosan on stability of insulin by UV, fluorescence 
and CD spectroscopy, and to prepare the delivery system and investigate the effect of 
chitosan on the in vitro release of insulin from the thermosensitive polymeric delivery 
systems. 
♦ To optimize the delivery system to achieve a controlled, and predictable release of 
insulin for approximately three months at basal level. 
♦ To investigate the stability of insulin released from the delivery systems in vitro. 
♦ To investigate the stability of insulin during storage at 37°C and 4°C, as well as to 
investigate the stability of insulin in the polymeric delivery systems during in vitro 
release. 
The instrumental techniques used for stability analysis include: 
♦ Circular Dichroism (CD), Differential Scanning Calorimetry (DSC), Native 
Polyacrylamide Gel Electrophoresis (PAGE)/ Sodium Dodecyl Sulfate-PAGE (SDS-
PAGE), Matrix Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) 
Mass Spectroscopy, and High Performance Liquid Chromatography (HPLC). 
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•  Study in vivo release, and bioactivity of insulin released from the delivery   systems, 
and the biocompatibility of the delivery systems in vitro and in vivo 
♦ To study the in vivo absorption, release profile and bioactivity of insulin released from 
thermosensitive gel depots in streptozotocin induced diabetic rat model. 
♦ To study the in vitro biocompatibility by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide) cell viability assay. 
♦ To study the in vivo biocompatibility by histological analysis of tissue-delivery system 
interface using light microscopy. 
♦ To study the immunogenic potential of insulin released in vivo using an indirect 
ELISA. 
Accomplishing the above specific aims will result in a biodegradable polymeric delivery 
system which can deliver adequate basal insulin continuously over three months after a single 
subcutaneous injection with minimal initial burst release, and could partially relieve patients 
from multiple daily injections, thus improving patient compliance. Figure 4 is a pictorial 
representation depicting the events following subcutaneous administration of chitosan-zinc-
insulin complex loaded thermosensitive delivery system in vivo. It included the formation of 
depot at the site of injection, polymer degradation and dissociation of the chitosan-zinc-insulin 
complex into insulin monomers, and finally absorption of insulin monomers into systemic 
circulation to elicit the pharmacological response. 
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Figure 4. The events following subcutaneous administration of chitosan-zinc-insulin complex 
loaded thermosensitive delivery system in vivo 
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2. MATERIALS AND METHODS 
2.1.  Materials 
The list of materials used in this study is presented in table 2. 
Table 2. Materials used and their source 
Materials : Source and location 
Human recombinant insulin 
(Incelligent SG) 
: Millipore Corporation, (GA, USA) 
Polyelthylene glycol (1500 Da) : Sigma Aldrich Co., (MO, USA) 
D,L-lactide : Alfa Aesar, (MA, USA) 
Stannous octoate : Pfaltz and Bauer Inc., (CT, USA) 
MicroBCA protein assay kit : Pierce Biotechnology Inc., (IL, USA) 
MTT : Sigma Aldrich Co., (MO, USA) 
Dimethyl sufoxide : Calbiochem, (USA) 
Nembutal (Pentobarbital 
Sodium) 
: Lundbeck, (IL, USA) 
10% Neutral buffered formalin : Richard-Allan Scientific, (MI, USA) 
Glucometer  : Bayer Contour® Glucometer, (IN, USA) 
Streptozotocin  : Enzo Life Sciences, (NY, USA) 
OmniPur®Acrylamide:Bis-
acrylamide 
: EMD Chemicals, (NJ, USA) 
OmniPur Ammonium 
persulphate (APS) 
: EMD Chemicals, (NJ, USA) 
Tetramethylethylenediamine 
(TEMED) 
: Promega Corporation, (WI, USA) 
  (Continued) 
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Table 2. Materials used and their source (Continued) 
Materials : Source and location 
Sodium dodecyl sulphate (SDS) : Promega Corporation, (WI, USA) 
PlusOne Tris : Amersham Biosciences, (Uppasala, Sweden) 
Seeblue® plus protein marker : Invitrogen Corp., (CA, USA) 
Chitosan  : Sigma Aldrich Co., (MO, USA) 
Acetonitrile : Sigma Aldrich Co., (MO, USA) 
Triacetin  : Sigma Aldrich Co., (MO, USA) 
Human Embryonic Kidney 
(HEK293) cell line 
: American Type Culture Collection (ATCC), 
(MD, USA) 
α-cyano-4-hydroxycinnamic acid : Sigma Chemical Co., (MO, USA) 
Ketoprofen  : Medisca, (NY, USA) 
Rat immunoglobulin (IgG) : Santa Cruz Biotechnology, (CA, USA) 
2.2.  Animals 
Male Sprague-Dawley rats weighing 180-200 g were obtained from Harlan Laboratories 
Inc., USA. Rats were housed in a temperature controlled facility maintained at 12 hour light-dark 
cycle in North Dakota State University Department of Pharmaceutical Sciences animal care 
facility. All animal experiments were performed according to the guidelines by NDSU 
Institutional Animal Care and Use Committee (IACUC). The experimental protocol was 
approved by IACUC (Protocol #A10054). 
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2.3.  Methods 
2.3.1.  Synthesis and characterization of thermosensitive polymers 
The synthesis and characterization of copolymer poly(lactic acid)-poly(ethylene glycol)-
poly(lactic acid) (PLA-PEG-PLA) triblock copolymer used in this study has been reported by 
Al-Tahami K (84). The two copolymers with 1500-1500-1500 (4500 Da, copolymer A), and 
1600-1500-1600 (4700 Da, copolymer B) chain lengths were synthesized by the ring opening 
polymerization of D, L lactide, catalyzed by stannous octoate, using polyethylene glycol (PEG 
1500 Da) as an initiator. The scheme of synthesis is described in figure 5. Briefly, D, L lactide 
was charged into the three-necked flask containing pre-dried PEG (MW 1500 Da). To the molten 
reactants, stannous octoate (0.03% w/w) was added, and the reaction was carried out under 
nitrogen atmosphere at 120°C for 12 h to prepare the copolymer. The crude product obtained 
after polymerization was dissolved in ice cold water at 5-8°C, and reheated to 80°C for 
purification. To remove the unreacted monomers, impurities and to improve the purity of the 
synthesized copolymer the dissolution and reheating steps were repeated. The purified aqueous 
copolymeric solution was freeze-dried to remove the residual water content.  
The synthesized copolymer was characterized by 1H and 13C NMR spectrometry and Gel 
Permeation Chromatography (GPC) in order to determine the structure, number average 
molecular weight, and molecular weight distribution (Polydispersity Index, PDI). 
2.3.1.1. Proton and 13C nuclear magnetic resonance (NMR) 
The chemical structure of the synthesized polymer was determined by proton and carbon 
NMR using deuterated chloroform (CDCl3) as a solvent. Tetramethylsilane (TMS) signal was 
used for calibration and its signal was taken as the zero chemical shift. Varian spectrometer 
operated at 400 MHz and 25°C was used for the measurements. The signals corresponding to 
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chemical groups such as -CH and -CH3 of LA and -CH2 of ethylene glycol in 1H-NMR were 
integrated and used to calculate the number average molecular weight (Mn) of the polymer. The 
presence of PLA and PEG blocks were confirmed by the 13C NMR spectra. 
 
Figure 5. Scheme of synthesis of PLA-PEG-PLA triblock copolymer by ring opening 
polymerization reaction (84) 
2.3.1.2.  Gel permeation chromatography (GPC) 
The number average molecular weight (Mn) and weight average molecular weight (Mw), 
as well as molecular weight distribution (polydispersity index, PDI) of the synthesized 
copolymers were determined using Gel Permeation Chromatography (GPC) (Waters 515, 
Milford, MA). Waters 2410 refractive index detector, and two Styragel® HR4E and HR5E 
columns (Milford, MA) were used. The analysis was based on the calibration using polystyrene 
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standards and tetrahydrofuran (THF) as a carrier solvent at 30°C with a flow rate of 1 mL/min 
and sample volume 100 µl. 
2.3.1.3.  Phase inversion of aqueous copolymer solutions 
Aqueous solutions of triblock copolymers A and B at various concentrations were 
prepared (10, 15, 20, 25, 30, 35, 40% w/w) at 4°C. The vials containing aqueous copolymer 
solutions were equilibrated at 10°C by immersing in a temperature controlled water bath before 
the start of the experiment. The temperature of the water bath was raised at 2°C/step, and the 
phase transition temperatures of the sol (flow) to gel (no flow) of these solutions were noted by 
inverting the vials horizontally after keeping the sample at constant temperature for 10 min 
(208). 
2.3.1.4. Morphology of polymeric delivery systems determined by scanning electron 
microscopy (Cryo-SEM) 
Thermosensitive nature of the delivery system was studied by visualizing the surface 
morphologies. To visualize the surface morphology of copolymer solution maintained at room 
temperature (25°C), small amount of copolymer solution was mounted on a brass mount with an 
excess amount on the surface, and the mount was immersed into liquid nitrogen immediately to 
flash freeze the solution. The frozen sample was cut with a sharp, cold scalpel to obtain a clean 
surface, and visualized immediately (0 min), and at 5 min after sublimation using JEOL JSM-
6490LV High-performance variable pressure SEM with a laser beam (15kV acceleration 
voltage) under low vacuum, and at 1500x magnification. Sublimation under low vacuum (35Pa) 
helped to remove the frozen layer of water from surface. To determine the thermosensitive 
behavior of the delivery system, aqueous copolymer solution (30%w/w) was injected into a tube, 
and incubated at body temperature (37°C) allowing it to form gel. The entire tube was immersed 
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into liquid nitrogen to flash freeze the hydrogel, and to avoid the ice crystal formation during 
freezing, as well as to minimize the alteration in gel structure. The delivery system surface was 
cut with the cold scalpel, and visualized under SEM. 
2.3.2.  Hydrolytic degradation and drug release behaviors of the delivery systems 
The delivery systems were investigated for mass loss to study the time dependent 
hydrolytic degradation of the PLA-PEG-PLA copolymers. Proton NMR and GPC were used to 
determine the reduction in molecular weight during hydrolytic degradation.  
2.3.2.1. Mass loss of polymer hydrogels during hydrolytic degradation 
PLA-PEG-PLA copolymer based delivery systems (30 and 40 %w/w) were injected into 
the polypropylene tubes using 25G needle, incubated at body temperature and allowed to form 
gels. A pre-warmed phosphate buffered saline (PBS, pH 7.4, 10 ml) was added to each tube as 
release medium. At predetermined time intervals, the release medium was decanted, the 
hydrogels were freeze-dried, weighed and the % mass loss was calculated. The effect of PLA 
chain length, and polymer concentration on the mass loss was studied. 
2.3.2.2. Hydrolytic degradation of copolymer determined by proton NMR 
The freeze dried copolymer residues obtained at particular time points were dissolved in 
deuterated chloroform (CDCl3), and proton NMR spectra was recorded on Varian Spectrometer 
(400 MHz), as per the procedure described earlier. The proton NMR signals were integrated and 
the ratio of lactic acid (LA) to ethylene glycol (EG) moieties was used to determine the 
degradation behavior. 
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2.3.2.3. Hydrolytic degradation of copolymer determined by GPC 
GPC was used to evaluate the change in molecular weight, and molecular weight 
distribution of copolymers during hydrolytic degradation. The freeze dried copolymer residues 
obtained at 0, 30, 60, and 90 min were dissolved in tetrahydrofuran (THF), and analyzed using 
GPC (Waters 515, Milford, MA). The GPC experiment was carried out as per the procedure 
described previously. 
2.3.2.4. In vitro release of incorporated molecules from the delivery systems 
The in vitro release and degradation behavior of the delivery systems in presence of three 
different molecules was studied in detail. Aqueous solutions of thermosensitive copolymer A 
were prepared at a concentration of 30% w/w by stirring at 4°C. The copolymer solutions were 
examined for injectability by passing through 25 G needle. The model molecule (i.e. BSA, 
risperidone, or insulin) was dispersed into the aqueous copolymer solutions at room temperature, 
and homogenized at 8000 rpm for 30 seconds. The formulations (1ml) were injected in a tube 
and were allowed to form gels by incubating at 37°C. PBS (pH 7.4, 10 ml) was added slowly 
over the gel depot as release medium, and the entire assembly was incubated at 37°C in a water 
bath. The release medium was replaced periodically for the entire study period, and the amount 
of protein released was quantified by Pierce Micro BCA™ protein assay kit, according to the 
manufacturer’s instructions (209). Agilent 1120 compact LC system was used to determine the 
amount of risperidone released (210). An Agilent Eclipse Plus C18 column (4.6 x 150 mm, 5 
µm, Agilent, Santa Clara, California) was used, and risperidone analysis was performed using 
isocratic elution. The mobile phase consisted of methanol and ammonium acetate buffer (10 
mM, pH 5.5) in the ratio of 85:15 at a flow rate of 1mL/min. Run time was 5 min and absorbance 
was monitored continuously at 280 nm. EZChrom Elite™ 3.3.2 software (Agilent, Santa Clara, 
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CA, USA) was used for data acquisition and analysis. The concentration correction was 
performed according to the method described by Hayton and Chen (211). 
2.3.2.5. Mass loss of polymer hydrogels during in vitro release 
The delivery systems prepared for in vitro release studies were also evaluated for percent 
mass loss. At predetermined time intervals, the release medium was removed, and the delivery 
systems were freeze-dried, weighed and the mass loss was calculated. 
2.3.2.6. Hydrolytic degradation determined by proton NMR 
The freeze dried formulation residues obtained at particular time points were mixed with 
CDCl3, and proton NMR spectra was recorded. 
2.3.2.7. Hydrolytic degradation determined by GPC 
The change in molecular weight and its distribution of copolymer during in vitro release 
was determined using GPC. The freeze dried residues obtained at 0, 30, 60, and 90 min, were 
dissolved in THF, and were analyzed using GPC as per the procedure described earlier. 
2.3.2.8. Morphology of polymer hydrogels visualized using SEM 
The morphology and pore size of the drug loaded delivery systems were visualized using 
cryo-SEM. The delivery system containing insulin, risperidone or BSA were prepared, injected 
into polypropylene tubes, and incubated at 37°C to form gel. The in vitro release study was 
carried out as per the procedure described earlier. At 30 and 60 days, the release medium was 
decanted, and the delivery system was flash frozen by immersing in liquid nitrogen. The surface 
of the delivery system was cut with the cold scalpel, and was visualized under low vacuum 
(35Pa), 15kV acceleration voltage, and 1500x magnification. Approximately 200 pores were 
measured for their size. 
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2.3.2.9. Effect of molecular modification of insulin by chitosan, and zinc on in vitro release 
The formulations were prepared by dispersing insulin, zinc-insulin, chitosan-zinc-insulin 
complexes in aqueous copolymer A (30% w/w) solutions at room temperature. In vitro release 
study was performed as described earlier, and the effect of molecular size and solubility on the in 
vitro release profile insulin was investigated. 
2.3.2.10. Effect of chitosan on pH of release medium during hydrolytic degradation 
The effect of addition of a cationic copolymer on pH of the release medium was 
investigated. Chitosan solution (0.2% w/v, pH 6.8) was mixed with the aqueous solution of 
copolymer A (30% w/w) at room temperature. One ml of the delivery system was injected in a 
tube and allowed to form gel at 37°C. Pre-warmed PBS (10 ml) was added as a release medium, 
and the pH of release medium was monitored during hydrolytic degradation for ~70 days. 
2.4.  Formulation of Delivery Systems for Insulin and In Vitro Release 
The in vitro release profile of insulin was governed by various factors including 
concentration of the copolymer, addition of zinc, and insulin loading in the delivery systems. It 
has also reported that the polymeric delivery system at 40% w/w copolymer concentration 
reduced the initial burst release of insulin, and exhibited best fit for zero order release (84). Zinc 
addition (5:1 zinc ions: insulin hexamer) further helped to reduce the initial burst release and the 
release was prolonged for two months. For this reason, these previously studied delivery systems 
(copolymer concentrations: 30, and 40% w/w, and zinc: insulin hexamer ratio: 5:1) were utilized 
in preliminary studies.  Formulations were prepared by dispersing insulin alone or zinc-insulin in 
aqueous copolymer solutions. The injectability of formulations was tested by passing through 
25 G needle. The effect of zinc and polymer concentration (30 % w/w and 40 %w/w) on in vitro 
release profile of insulin at 60 mg insulin loading from the thermosensitive delivery system was 
44 
 
studied. To study the effect of insulin loading on in vitro release, copolymer concentration was 
fixed at 30% w/w, since it was difficult to inject the formulations at increased insulin loading and 
higher polymer concentration (40% w/w) from 25 G needle. Therefore, insulin was incorporated 
at different doses (60, 80 and 100 mg zinc-insulin) into the thermosensitive delivery system 
(30% w/w), and in vitro release study was performed. The delivery system compositions are 
listed in table 3. 
Table 3. Delivery system compositions for in vitro release 
Formulations Zinc:Insulin hexamer Insulin loading PLA-PEG-PLA 
I ----- 60 mg 30% (w/w) 
II 5:1 60 mg 30% (w/w) 
III ----- 60 mg 40% (w/w) 
IV 5:1 60 mg 40% (w/w) 
V ----- 60 mg 30% (w/w) 
VI 5:1 60 mg 30% (w/w) 
VII 5:1 80 mg 30% (w/w) 
VIII 5:1 100 mg 30% (w/w) 
(Mean ± SD, n=4) 
For in vitro release study, an aliquot of 1 ml of the formulation was injected into the 
polypropylene tube and transferred to 37°C water bath for 2 minutes to form a gel. Twenty 
milliliters of pre-warmed PBS (pH 7.4) was added to the tube as release medium, and the tube 
was incubated in shaking water bath maintained at 37°C and 35 rpm for the entire study duration. 
Five milliliters of the release medium was withdrawn periodically and replaced with the same 
amount of fresh PBS. The amount of insulin released was determined by MicroBCA protein 
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assay kit. To ensure that the entrapped insulin is released in its native form, CD, native PAGE, 
SDS-PAGE and MALDI-TOF MS were performed. 
2.4.1.  Circular dichroism spectroscopy (CD) 
J-815 CD Spectrometer (Jasco, Tokyo, Japan) was used to record the CD spectra. The 
released samples of insulin were filtered, and scanned in near-UV region (250-300 nm) in order 
to determine the tertiary structure, while far-UV CD (200-250 nm) spectra were used to 
investigate the changes in the secondary structure of released insulin during in vitro release. Five 
scans at a scan rate of 5 nm per min were recorded at 25°C using a quartz cuvette (0.1 cm path 
length). To remove the background interference, fresh PBS (pH 7.4) was scanned in the same 
range, and freshly prepared insulin solution was used as standard. Spectra manager®2 software 
(Jasco, Tokyo, Japan) was used for spectrum analysis. The molar ellipticity was calculated using 
the following equation: 
Molar	Ellipticity	Θ = ΘC x	l 
[θ: Ellipticity in mdeg; C: Concentration of insulin in mmol/L; l: Path length of the cell (0.1 cm)] 
2.4.2.  Polyacrylamide gel electrophoresis (Native and SDS-PAGE) 
Native polyacrylamide gel electrophoresis (Native PAGE) was performed on Bio-Rad 
Mini-Protean tetra-cell electrophoresis (Hercules, CA) system. Native PAGE was performed to 
determine the presence of aggregates of insulin during in vitro release. The in vitro released 
samples of insulin were mixed with loading buffer (62.5 mM Tris-HCl, pH 6.8, 40% glycerol, 
0.01% w/v bromophenol blue) before loading onto the polyacrylamide gel consisting of 
separating (12.5%) and stacking gel (5%). Fresh insulin solution was used as a standard, and the 
gels were ran at 100 V in tris-glycine buffer, then stained with Coomassie blue, and then 
46 
 
destained. Pre-stained protein marker (SeeBlue plus 2 Prestained Standard) was used to analyze 
the insulin band. In case of higher molecular weight bands, the covalent or non-covalent nature 
of insulin aggregates was assessed using non reducing SDS-PAGE. SDS-PAGE under non-
reducing conditions helps to dissociate non-covalent aggregates. In SDS-PAGE analysis, 
samples collected during in vitro release studies at various time points were incubated with equal 
volume of SDS-PAGE sample loading buffer, and then resolved through the polyacrylamide gel 
at constant voltage (100V) for ~90 min. The molecular weights of the detected bands were 
compared with fresh insulin as well as with the pre-stained protein marker. 
2.4.3.  MALDI-TOF mass spectroscopy 
Primary structural integrity of the insulin released from polymeric delivery system was 
evaluated using MALDI-TOF Mass Spectrometry. MALDI-TOF experiments were carried out 
using a Bruker MALDI TOF II-MS (Bruker Daltonics Inc., Billerica, MA) combined with a solid 
state smart-beam laser operated at a frequency of 200 Hz. A standard protein/peptide mixture kit 
(Bruker Daltonics) was used for the external calibration of the instrument before use. The sample 
was prepared as follows; The matrix solution was prepared by dissolving 10 mg of α-Cyano-4-
hydroxycinnamic acid in 1 ml mixture of acetonitrile/1% TFA water (v/v = l:l). Twenty 
microliters of released insulin sample was mixed with 90 µl of matrix solution, and 2 µl of the 
final solution was placed on the MALDI-sample plate, air dried at room temperature, and 
analyzed in the Positive Reflectron mode. FlexAnalysis® software was used for data analysis. 
2.5. Chitosan-Zinc-Insulin Complex Formation, Dissociation, and Effect of Chitosan on 
Insulin Stability 
Since pH is one of the important factors in determining the complex formation between 
zinc-insulin and chitosan, the relationship between pH of the overall system and transmittance 
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was studied in our preliminary studies. Zinc-insulin-chitosan complexes were prepared at 
increasing chitosan to zinc-insulin weight ratio (1:1, 2:1, 4:1, 8:1) at different pH conditions, and 
the % transmittance of the overall system was recorded as a function of change in pH using 
UV/Vis spectrophotometer (UV-1601, Shimadzu, Japan). The complexes were centrifuged and 
the amount of insulin entrapped was determined. The amount of insulin entrapped was calculated 
by measuring the difference between the total amount of insulin added and the amount of non-
associated insulin in the aqueous supernatant after complex formation. For this purpose, the 
formed chitosan-insulin complex was centrifuged at 10000 rpm for 30 min at room temperature, 
and the amount of unassociated insulin in the supernatant was measured using Pierce Micro 
BCA™ protein assay reagent kit (209). 
The formation of complex between insulin and chitosan was visualized using gel 
retardation assay (native PAGE) and the dissociation of complex was characterized using SDS 
PAGE. Chitosan-zinc-insulin complexes were prepared at various ratios by mixing zinc-insulin 
with chitosan solutions (1:1, 1:2, 1:4, 1:8, 1:16 and 1:32 weight ratio), and incubated for 20 
minutes at room temperature. The complexes were mixed with a loading dye before loading and 
native gel electrophoresis was performed as described earlier. 
The structural changes in the insulin during complex formation with chitosan were 
assessed by Fluorescence and Circular Dichroism (CD) Spectroscopy, and Differential Scanning 
Calorimetry (DSC). 
2.5.1.  Fluorescence spectroscopy 
Chitosan solution (0.0666 mg/ml, pH 6.8) was added to insulin solution (1 mg/ml, pH 
6.8), at increasing amount (1:1, 1:2, 1:4 v/v) and the effect of chitosan on the fluorescence 
property of insulin (tyrosine/phenylalanine fluorescence) was recorded using Fluoromax-4 
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Spectrofluorometer (Horiba Scientific, New Jersey, NJ), with a 200 µl capacity quartz cell. The 
excitation/emission slit width was set at 5 nm, and the excitation wavelength was fixed at 280 
nm to excite tyrosine and phenylalanine residues, and the emission spectra were collected in the 
range of 295-400 nm.  
2.5.2.  Circular dichroism spectroscopy (CD) 
Chitosan solution (pH 6.8) was mixed with to zinc-insulin solution at increasing weight 
ratios (1:1, 1:2, 1:4, 1:8, 1:16 v/v) and the changes in the secondary structure (200-250 nm) of 
insulin upon addition of chitosan were determined using CD spectroscopy. The scan rate of 
5nm/min was used, and all spectra were recorded at 25°C with a quartz cuvette (0.1 cm path 
length). To remove the background interference, fresh PBS (pH 7.4) was scanned in the same 
range, while freshly prepared insulin solution was used as standard. Spectra manager 2 software 
(Jasco, Tokyo, Japan) was used for spectrum analysis, and molar ellipticity was calculated as 
described earlier. 
2.5.3.  Differential scanning calorimetry (DSC) 
The change in association state of zinc-insulin and its thermostability of insulin after 
addition of chitosan was investigated using DSC. The change in the unfolding temperature of 
insulin and zinc insulin after the addition of chitosan was recorded using Nano-DSC (TA 
Instruments, DE, USA). Before loading into the cells, samples and reference buffer (PBS, 10 
mM, pH 7.4) were degassed under vacuum. Data was collected by scanning the samples from 10 
to 110°C at a scan rate of 1°C/min. The reference scan (buffer scan) was subtracted from sample 
scan during the data analysis. All data analysis was performed using Nanoanalyze® software 
provided with the instrument. The transition curve was fitted using two-state scaled model 
following the “pseudo” V’ant Hoff method. 
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2.6. Stability of Insulin, Zinc-Insulin, and Chitosan-Zinc-Insulin Complex in Presence of 
Lactic Acid 
Insulin alone, zinc-insulin, and chitosan-zinc-insulin complexes were incubated with the 
lactic acid which is the major end product of copolymer degradation, and the stability of insulin 
was investigated using titrimetric analysis, and DSC. Chitosan-zinc-insulin complexes were 
prepared by mixing 200 mg of chitosan with 1 ml of 60 mg/ml zinc-insulin hexamer solution in 
water at pH 7.4. A 1 ml aliquot of the solution containing this complex was titrated against 5 ml 
of 40 mg/ml of lactic acid (total theoretical lactic acid content in 1 ml of final formulation). The 
zinc-insulin complex without addition of chitosan was used as a control and the change in pH of 
final solution was measured using a calibrated pH meter. The zinc-insulin complex without 
addition of chitosan was used as a control and the change in pH of final solution was measured 
using a calibrated pH meter. To confirm the stability of insulin after addition of lactic acid, 
diluted titrates from the above experiment was subjected to analysis by DSC.  
2.7. Formulation of Chitosan-Zinc-Insulin Complex Loaded Thermosensitive Copolymer 
Delivery System, and In Vitro Release  
The formation of chitosan-zinc-insulin loaded thermosensitive polymeric formulations is 
presented in figure 6. The details about the composition of the delivery systems prepared are in 
table 4. The formulations were tested for their injectability, and thermosensitivity, and in vitro 
release study was performed as per the procedure described earlier. Briefly, 1 ml formulation 
was injected into a polypropylene tube and allowed to form gel by incubating in a water bath at 
37°C. Upon gel formation, pre-warmed PBS was added slowly to the tubes as release medium, 
and the entire assembly was kept in a reciprocating water bath maintained at 37°C and 35 rpm. 
The released medium was removed and replaced periodically, and the amount of insulin released 
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was quantified by Pierce Micro BCA™ protein assay reagent kit. The concentration correction 
was performed according to the method described by Hayton and Chen (211). 
 
Figure 6. Scheme of formulation of chitosan-zinc-insulin complex loaded thermosensitive 
delivery system 
 
Table 4. Polymeric formulations of insulin 
Formulation PLA-PEG-PLA Insulin Zinc:Insulin Hexamer Chitosan (w/v) 
A 30% (w/w) 5 mg ---- ---- 
B 30% (w/w) 5 mg 4:1 ---- 
C 30% (w/w) 5 mg ---- 0.2% 
D (Blank) 30% (w/w) 5 mg 4:1 0.2% 
(N=4, mean ± SD) 
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2.7.1. Optimization of the delivery systems at higher insulin loading, in vitro release, and 
stability of insulin released in vitro 
The delivery systems were optimized for higher insulin loading (30, 45, and 60 mg), and 
the effect of increasing amount of chitosan was also studied. Chitosan (50 kDa) solution in 1% 
acetic acid (0.2 and 0.4 % w/v of the total delivery system) was mixed with zinc-insulin (4:1 zinc 
to insulin hexamer) at an optimized pH (~6.8), and incubated at room temperature for 15 min. 
Zinc acetate was used as a source of zinc. Table 5 describes the formulation parameters for 
various insulin preparations studied. Insulin, zinc-insulin or chitosan-zinc-insulin complexes 
were incorporated into the thermosensitive polymeric delivery system (30% w/w), and 1 ml 
formulation was injected into a 50 ml tube using a 25 G needle. The delivery system was 
incubated in a reciprocating bath maintained at 37°C. After the solutions were transformed into 
gels, 30 ml of pre-warmed phosphate buffered saline (pH 7.4) was added as a release medium. 
During the release study, the tubes were incubated in a reciprocating water bath maintained at 
37°C with mild shaking (35 rpm). Ten milliliter samples were removed from the media at 
specific time points, and replaced periodically with fresh buffer to maintain the sink condition. 
The released samples were then centrifuged and the amount of insulin released was determined 
using micro BCA protein assay. Delivery system without insulin was used as a blank control for 
absorbance correction. The amount of insulin released was obtained from the standard curve and 
corrected for sample removal as described earlier. The effect of chitosan and insulin amount on 
in vitro release of insulin was also studied.  
The stability of in vitro released insulin was determined by the aforementioned analytical 
techniques. 
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Table 5. Polymeric formulations of insulin 
Formulation PLA-PEG-PLA Insulin Zinc: Insulin Hexamer 
Chitosan 
(w/v) 
A 30% (w/w) 30 mg ---- ---- 
B 30% (w/w) 30 mg 4:1 ---- 
C 30% (w/w) 30 mg ---- 0.2% 
D 30% (w/w) 30 mg 4:1 0.2% 
E 30% (w/w) 30 mg 4:1 0.4% 
F 30% (w/w) 45 mg 4:1 0.2% 
G 30% (w/w) 45 mg ---- ---- 
H 30% (w/w) 45 mg 4:1 ---- 
I (Blank) 30% (w/w) ---- ---- ---- 
J 30% (w/w) 60 mg 4:1 0.2% 
K 30% (w/w) 60 mg ---- ---- 
L 30% (w/w) 60 mg 4:1 ---- 
M (Blank) 30% (w/w) ---- ---- ---- 
(Mean ± SD, n=4) 
2.7.1.1. Circular dichroism spectroscopy (CD) 
The released samples of insulin were filtered, and scanned in near, and far UV regions in 
order to determine the 2° and 3° structures to investigate the changes in the secondary structure 
of insulin after incubation at 37°C for ~3 months. The detailed procedure can be found in section 
2.3.2.1. The secondary structure analysis was performed using Spectra Manager 2 software and 
the percentages of α helix, β sheets, and random ordered structures were determined. 
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2.7.1.2. Differential scanning calorimetry (DSC) 
Insulin released from the delivery systems containing insulin alone, zinc-insulin, and 
chitosan-zinc-insulin complex at day 7, 30, and 60 were analyzed for their thermostability using 
DSC. The released samples were filtered, degassed, and DSC analysis was performed to 
determine the calorimetric measurements including midpoint transition temperature (Tm) and the 
calorimetric enthalpy (∆H). All data was analyzed using Nanoanalyze software, and fitted with 
two-state scaled model. 
2.7.1.3. Polyacrylamide gel electrophoresis (Native and SDS-PAGE) 
The released samples of insulin from formulations D and H, at day 15, 30, 45, and 60, 
were analyzed using PAGE and SDS-PAGE to determine the presence and nature of insulin 
aggregates during release. 
2.7.1.4. High performance liquid chromatography (HPLC) 
The chemical stability of in vitro released insulin was assessed by RP-HPLC (3,212), and 
the chromatographic conditions used are presented in table 6. 
2.7.1.5. MALDI-TOF mass spectroscopy 
Primary structural integrity of the insulin released from various polymeric formulations 
was evaluated using MALDI-TOF MS. Freshly prepared insulin solution was used as control, 
and the details about the procedure are in section 2.4.3. 
2.7.2. Stability of insulin in delivery system during release 
In this study, polymeric formulations containing chitosan-zinc-insulin complex were 
injected into a tube using 25 G needle at room temperature and incubated in a water bath at 37°C 
in order to transform the solutions into hydrogels. Pre-warmed PBS (pH 7.4) was added as 
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dissolution medium and replaced periodically similar to release study for the entire release 
duration (~60 days). At predetermined time points, the gel depot was collected after decanting 
the supernatant. Insulin remaining inside the gel depot was extracted using 1:1 (v/v) mixture of 
acetonitrile and PBS with a mild shaking for ~15 min. the samples were then centrifuged at 5000 
rpm for 20 min. The stability of insulin was determined using MALDI-TOF MS and HPLC. 
Table 6. Chromatographic conditions for insulin analysis 
Chromatographic 
conditions 
: Details  
System : Agilent 1120 compact LC system 
Column : Zorbax-SB reversed-phase C18 column (4.6x150 mm, 5µm) 
Elution : Gradient 
Mobile phase A : 0.1% v/v TFA in water 
Mobile phase B : 0.1% v/v TFA in acetonitrile 
Mobile phase composition : 75:25 (A:B) to 50:50 (A:B) 
Flow rate : 1 ml/min 
Injection volume : 25 µl 
Run time : 20 min 
Detector  : UV 
Detection wavelength  280 nm 
Retention time : 9.8 min  
Data acquisition and 
analysis 
 EZChrom Elite 3.3.2 software (Agilent, Santa Clara, CA) 
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2.7.3. Stability of insulin in delivery system during storage 
The effect of zinc and chitosan on the stability of insulin in the polymeric delivery 
systems during storage at 4°C and 37°C was also investigated. The polymeric delivery systems 
containing chitosan-zinc-insulin complex were stored at 4°C and 37°C for 60 days. Insulin was 
extracted from the polymeric gel using acetonitrile-PBS (1:1) at predetermined time points, and 
the stability of insulin inside the polymeric formulations was determined using HPLC and 
MALDI-TOF MS. The stability of insulin in the presence of zinc and chitosan was compared 
with that of fresh insulin and insulin control (insulin incubated in PBS at similar conditions). 
2.7.4.  In vivo absorption and bioactivity of insulin 
The North Dakota State University Institutional Animal Care and Use Committee 
(IACUC) approved the animal study protocol and experiments. Eight weeks old male Sprague-
Dawley rats weighing 180-200 g were used to study the in vivo absorption and bioactivity of the 
recombinant human insulin (rH) released from the delivery systems. Rats were housed in a 
temperature controlled facility maintained at 12 h light-dark cycle, and allowed free access to 
food and water. The rats were acclimatized to the housing conditions one week before the study 
initiation. A single dose of freshly prepared streptozotocin (STZ, 55 mg/kg body weight) 
dissolved in ice cold citrate buffer (pH 4.5) was injected intraperitoneally to the rats to induce 
diabetes. Post-injection, rats were provided with 5% sucrose solution to counteract the potential 
risk of hypoglycemia caused by massive insulin release under the influence of STZ. Rats were 
monitored daily, and one week after STZ injection, blood glucose levels were measured. The rats 
with fasting blood glucose levels >200 mg/dl were considered diabetic and retained in the study. 
The diabetic rats were divided into 8 different groups (6 animals/group), and assigned to the 
treatments randomly. An additional group of non-diabetic rats was used as control. The 
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formulations were injected as a single subcutaneous dose at the back neck region of rats using 25 
G needle. The treatment groups were injected with the polymeric delivery systems (500µl) 
containing either insulin alone, zinc-insulin or and chitosan-zinc-insulin complexes at two 
different doses. Assuming the daily basal insulin requirement of ~18-24 IU (~0.4-0.5 IU/kg/day; 
total dose: ~30 and 45 IU/kg for 90 days), two doses were selected to provide a continuous basal 
level of insulin. Groups I and II were injected with the thermosensitive delivery system 
containing insulin alone at a dose of 30 and 45 IU/kg, groups III and IV with zinc-insulin (30 and 
45 IU/kg), and group V and VI with chitosan-zinc-insulin complex at a dose of 30 and 45 IU/kg. 
Group VII was treated with single dose of insulin (2 IU/kg) dissolved in PBS (pH 7.4) 
subcutaneously; while STZ treated animals without treatment (group VIII) were used as a 
negative control. After the initial week, blood sampling was performed on a weekly basis until 
three months using tail vein puncture. At the end of the study period, an intravenous injection of 
pentobarbital (150 mg/kg) was used to euthanize the rats. 
2.7.4.1. Quantification of serum insulin levels using enzyme linked immunosorbent assay 
(ELISA) 
Insulin levels were measured by sampling blood from the tail vein of rats at pre-
determined time points after overnight fasting. Serum was collected after centrifuging the blood 
samples at 4°C at 3000 rpm for 15 min, and stored at -20°C. Mercodia Human Insulin ELISA kit 
was utilized to determine the of serum insulin (rH) levels (213). 
2.7.4.2. Determination of blood glucose levels 
The pharmacodynamic activity of insulin released from the delivery systems was 
estimated from blood glucose levels. After overnight fasting, blood was withdrawn from tail vein 
of rats, and the fasting blood glucose levels were measured by the glucose oxidase method using 
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a glucometer (Bayer CONTOUR blood glucose monitoring system, IN), and expressed in 
milligrams per deciliter (mg/dl).  
2.7.4.3. Body weight determination 
The change in the body weight of rats before and after induction of diabetes, as well as 
after insulin treatment was noted daily for the first week, and further monitored on weekly basis 
during entire study duration. 
2.7.4.4. Detection of anti-insulin (rH) antibodies 
The rat serum samples were collected after 1, 2 and 3 months of treatment and were 
subjected to ELISA. For detection of anti-human insulin antibodies in rat serum an indirect 
ELISA was performed (214). Briefly, ELISA plate was coated with 800 ng/ml insulin in coating 
buffer (carbonate buffer, 50 mM, pH 9.6, 100 µl/well), and kept overnight at 4°C. Plates were 
incubated with a blocking agent [3% bovine serum albumin (BSA)], at 37°C for 1 h. The plates 
were washed with PBS containing 0.02% tween 20 (PBST) followed by addition of diluted rat 
serum and again incubated at 37°C for 1 h. The plates were washed again with PBST, and 
1:5000 diluted goat anti-rat-IgG-Horseradish Peroxidase conjugated secondary antibody was 
added, followed by incubation at 37°C for 2 h. Substrate solution (tetramethylbenzidine, TMB) 
was added at the end of incubation, and the plates were further incubated for 20 min at 37°C. 
Sulfuric acid (0.5 M) was used to stop the reaction, and the optical density was recorded at 450 
nm using a microplate reader. Rat IgG were used as a control. 
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2.7.5.  Biocompatibility of the delivery systems 
The in vitro biocompatibility of the delivery systems was determined by a cell viability 
assay, while for determination of in vivo biocompatibility, histology of implanted skin tissue was 
studied after injection of the delivery system. 
2.7.5.1.  In vitro biocompatibility of the delivery systems 
In vitro biocompatibility of the thermosensitive polymeric delivery system with and 
without chitosan was quantitatively assessed using a standard MTT cell viability assay. This 
assay was aimed to evaluate the effect of polymer extracts, and their degradation products on the 
cell viability in vitro. The detailed procedure is described previously (64). Briefly, the aqueous 
solutions of thermosensitive polymer (30% w/w, 500µl) with/without chitosan were prepared, 
injected in a tube, and allowed to form gels by incubating at 37°C in water bath. The polymeric 
hydrogels were extracted into PBS (10 ml, pH 7.4) at 37 and 70°C by incubating for 10 days. 
The extracts were diluted with growth medium, added to the Human Embryonic Kidney 
(HEK293) cells and incubated for 24, 48 and 72 hours. Percent cell viability was calculated 
considering the cell viability of untreated cells (growth medium only) as 100%. For comparison 
purposes cells treated with PBS (without polymer), 2% DMSO, and chitosan were used. 
2.7.5.2. In vivo biocompatibility of the delivery systems 
The in vivo biodegradability and biocompatibility of the delivery system with and 
without chitosan was evaluated after injecting 500 µl of the delivery system subcutaneously into 
the upper neck area of rats. The appearance of gel lump was monitored regularly by visual 
examination. At 1, 7, 30 and 90 days post-injection, rats were euthanized, and the subcutaneous 
tissue surrounding the injection site was excised and examined visually for the presence of any 
delivery system residue. For assessing the biocompatibility of the delivery system, the excised 
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hydrogel-contacting subcutaneous tissue was fixed in 10% neutrally buffered formalin at room 
temperature, sectioned (5 µm thickness), and processed for histological analysis. The skin 
sections were stained with hematoxylin eosin (H&E) and examined under the light microscope 
for any inflammatory reactions.  
The collagen deposition near the injection site was visualized by staining the skin 
sections with Gomori’s trichrome stain, and the collagen density and its appearance at the 
injection site were compared to that of normal skin tissue using ImageJ 1.45 software (NIH, 
MD). 
2.7.6.  Statistical analysis 
For statistical analysis, a single factor ANOVA was performed using Minitab 16 
statistical software (Minitab Inc., PA). A p-value of less than 0.05 was considered to be 
significant. Serum insulin levels were plotted against time and the bioavaialability of insulin was 
determined based on the area under the curve (AUC) data calculated by linear trapezoidal rule 
(215). The concentration versus time profile was used to determine maximum serum 
concentration (Cmax) and corresponding time at which maximum concentration is reached (Tmax) 
for the solution group (Insulin in PBS: 2 IU/kg SC).  
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3.  RESULTS 
A series of PLA-PEG-PLA copolymers of different molecular weights, and PEG/PLA 
block ratios were synthesized and studied for insulin delivery by Al-Tahami (84). The most 
promising copolymers in terms of release duration and rate among them were PLA-PEG-PLA 
with chain lengths 1500-1500-1500, and 1600-1500-1600 (molecular weights 4500, and 4700 
Da), and hence were used in our further studies. 
3.1.  Synthesis and Characterization of Thermosensitive Copolymer 
PLA-PEG-PLA triblock copolymers A and B, with molecular weights of 4500, and 4700 
Da, respectively, were synthesized by ring opening polymerization reaction using PEG (an 
initiator), and D, L lactide. The synthesis and characterization of PLA-PEG-PLA triblock 
copolymer used in this study has been reported by Al-Tahami (84) however, some essential 
properties were re-determined for reproducibility. The structure of the copolymer is presented in 
figure 7. 
 
Figure 7. Structure of polylactic acid-polyethylene glycol-polylactic acid (PLA-PEG-PLA) 
triblock copolymer 
3.1.1.  Proton and 13C nuclear magnetic resonance (NMR) 
The proton and 13C NMR spectra of the synthesized copolymer are presented in figures 8 
and 9. The proton NMR spectrum was similar to the reported spectrum of PLA-PEG-PLA (84). 
The signals corresponding to -CH (methine) of LA at 5.20, -CH3 (methyl) of LA at 1.55, -CH2 
(methene) of PEG at 3.65, and -OH of LA at 2.35 ppm were observed and shown in figure 8. To 
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determine the number average molecular weight, the peaks corresponding to -CH of LA, -CH2 of 
PEG and -CH3 of LA at 5.2, 3.65 and 1.55 ppm, respectively, were used and the calculation 
details can be found in the work of Jeong et al (23). The 13C NMR spectrum (figure 9) showed 
the presence of the groups, -C=O, -CH and -CH3 in the PLA block at 170, 69.4 and 17 ppm, 
respectively, while -CH2 group in PEG block was found at 71 ppm. The NMR spectra confirmed 
the structure of the synthesized copolymer. 
 
Figure 8. Proton NMR spectrum of triblock copolymer PLA-PEG-PLA 
 
 
Figure 9. 13C NMR spectrum of triblock copolymer PLA-PEG-PLA 
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3.1.2. Gel permeation chromatography (GPC) 
The number average molecular weight (Mn), weight average molecular weight (Mw) and 
molecular weight distribution of the synthesized copolymers determined by GPC is presented in 
table 7. A representative chromatogram from GPC analysis is shown in figure 10. The retention 
times for triblock copolymer A and B were found to be ~17.3, and 18 min, respectively, with a 
unimodal GPC trace, and the PDI was found to be 1.11. The characteristics of the copolymer 
determined by GPC and NMR are summarized in table 7. 
 
Figure 10. GPC chromatogram for triblock copolymer PLA-PEG-PLA (1500-1500-1500) 
 
 
Table 7. Characteristics of copolymer PLA-PEG-PLA 
NMR GPC 
Copolymer Mna Retention Time Mnb Mwc Polydispersityd (Mwc/Mnb) 
PLA-PEG-PLA 4480 17.957 4344 4865 1.119 
PLA-PEG-PLA 4720 17.353 4917 5408 1.1 
Mna : Number average molecular weight determined by NMR 
Mnb : Number average molecular weight determined by GPC 
Mnc : Weight average molecular weight determined by GPC 
d
 Polydispersity index determined by GPC 
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3.1.3.  Phase inversion of aqueous copolymer solutions 
The phase behavior of aqueous copolymer solutions is an essential property involved in 
the design of thermosensitive polymer based drug delivery systems. The sol-gel transition of the 
triblock copolymer was determined by tube inversion method and the phase diagram is presented 
in figure 11. At lower concentration (10 % w/w), copolymer solutions did not turned into gel 
form but, when the concentration of the copolymer was increased to 15-40% w/w, the aqueous 
copolymer solutions existed in three distinct phases namely sol, gel and precipitate in the 
temperature range of 15-65°C. It existed in ‘sol phase’ below the lower critical solution 
temperature (LCST), and above LCST, it existed in the ‘gel form’. When the copolymer 
concentration was increased from 15 to 30% w/w and higher, sol-gel transition temperature 
reduced by ~8-10°C, and gel-sol transition temperature increased by ~14-16°C. As the 
temperature increased above the upper critical transition temperature (UCST), the polymer 
precipitated. The thermosensitive nature of the polymeric delivery system is presented in figure 
12. 
 
Figure 11. Sol-gel transition of triblock copolymer PLA-PEG-PLA aqueous solutions  
(1500-1500-1500 (●), and 1600-1500-1600 (■) copolymers) 
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Figure 12. Thermosensitive nature of the delivery system at room temperature (A) and body 
temperature (B) 
3.2. Morphology of Polymeric Delivery System Determined by Cryo-SEM 
Freshly cut surface morphologies of the delivery systems maintained at room temperature 
(25°C) and body temperature (37°C) visualized using cryo-SEM are presented in figure 13. The 
delivery systems showed a marked difference in their appearance. The freshly cut surface of 
copolymer solution maintained at 25°C did not show any particular three dimensional surface 
characteristics (figure 13 A and B). According to the approach orientation of the scalpel blade, 
the delivery surface showed striations oriented along the cut surface. On the other hand, freshly 
cut surface of the delivery system maintained at body temperature showed presence of three 
dimensional structures consisting of two distinct domains. The polymer rich portion was 
observed as dense white area, while the water filled pores were observed as dark empty spaces 
(figure 13C). 
3.3. Hydrolytic Degradation of the Copolymers 
3.3.1. Mass loss of polymer hydrogels during hydrolytic degradation 
The total mass loss in the delivery systems containing copolymer A (1500-1500-1500), 
and copolymer B (1600-1500-1600) at specific time points during hydrolytic degradation is 
presented in figure 14. It was observed that the copolymer with higher PLA chain length (1600-
1500-1600) degraded slower, and a significant (P<0.05) difference in the percent mass loss was 
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observed until 30 days as compared to the copolymer with smaller PLA chains. The effect of 
polymer concentration on the mass loss was studied and the data is presented in figure 15. The 
delivery system showed significant difference (P<0.05) in mass loss for ~45-50 days, however, 
after that both the hydrogels degraded at similar rate. 
      
 
Figure 13. Cryo-SEM images visualizing the morphologies of freshly cut surfaces of the 
polymeric delivery systems maintained at 25°C at 0 min (A) and 5 min (B) after sublimation, and 
at 37°C (C), 5 min after sublimation 
 
 
Figure 14. Effect of PLA chain length on in vitro hydrolytic degradation of 30% w/w delivery 
system (●) copolymer A (1500-1500-1500) and (♦) copolymer B (1600-1500-1600) 
(n=4, mean ± SD, *: significant at p<0.05) 
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Figure 15. Effect of polymer concentration on in vitro hydrolytic degradation 
(●) 30% w/w, and (■) 40% w/w copolymer A containing delivery systems  
(n=4, mean ± SD, *: significant at p<0.05) 
3.3.2.  Hydrolytic degradation determined by proton NMR 
Figure 16 summarizes the changes in the relative amount of LA and EG content of the 
copolymers (A and B) after degradation in PBS (pH 7.4) at 37°C. The change in the peak height 
of -CH3 of PLA (1.55 ppm) and -CH2 of PEG (3.65 ppm) in proton NMR spectra was used to 
evaluate the content of lactide (LA) and ethylene glycol (EG), respectively. No significant 
difference in the content of residual polymers was noticed until ~45 days of degradation. 
However, a significant increase (P<0.05) in the peak height of -CH3 of LA and corresponding 
reduction in the EG signal at 3.65 ppm was observed in case of both the delivery systems at days 
60 and 90. The effect of concentration of copolymers on degradation profile was also evaluated 
by studying the change in LA/EG ratio, and is presented in figure 17. The results indicated that 
there was gradual increase in LA content, but the copolymer concentration did not significantly 
(p>0.05) affect the LA/EG ratio during entire degradation period. 
67 
 
 
Figure 16. Effect of PLA chain length on hydrolytic degradation 
A) Copolymer A (1500-1500-1500), and B) Copolymer B (1600-1500-1600)  
(n=4, mean ± SD, *: significant at p<0.05) 
 
 
Figure 17. The change in LA/EG ratio of copolymer A (1500-1500-1500), during hydrolytic 
degradation at 30% and 40% w/w concentration 
(n=4, mean ± SD) 
3.3.3. Hydrolytic degradation determined by GPC 
The results of GPC for hydrolytic degradation of copolymer A are summarized in table 8. 
The GPC trace of copolymer A was unimodal initially, with a bell-shaped peak near 17.9 min 
(RT), which was attributed to the similar molecular weight (Mw) of the copolymer. During 
hydrolytic degradation, a slight increase in RT (18.05 min) was observed after 30 days, with a 
bimodal GPC chromatogram. The delivery systems showed a noticeable degradation after 30 
days of incubation at 37°C in PBS (pH 7.4), and at the end of 60 days copolymer was completely 
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degraded into smaller segments (RT1: 18.19 and RT2: 20.83). At the end of 90 days no peak 
corresponding to original polymer was detected. 
Table 8. Molecular weight of the polymer PLA-PEG-PLA (4500 Da) remaining after hydrolytic 
degradation in PBS, pH 7.4 at 37ºC 
Sample Time Mn (1) RT PDI Mn (2) RT PDI 
Copolymer A 
(1500-1500-1500) 
0 days 4344 17.957 1.119 ---- ---- ---- 
30 days 3177 18.054 1.283 335 20.812 1.214 
60 days 2673 18.190 1.152 200 20.836 1.160 
90 days ---- ---- ---- 188 20.92 1.163 
3.4.  Effect of Various Molecules on In Vitro Release Behavior of Delivery Systems 
In vitro release behaviors of small protein insulin, large hydrophilic protein BSA, and a 
small hydrophobic molecule, risperidone from the polymeric delivery system containing 30% 
w/w PLA-PEG-PLA is presented in figure 18. The polymer degradation pattern of hydrogels in 
presence of these different molecules was studied using NMR, and GPC, while the gel 
morphology was visualized using Cryo-SEM.  
 
Figure 18. In vitro release profiles of (●) risperidone, (▲) BSA, and (■) insulin released from 
30% w/w copolymer A containing delivery systems (n=4, mean ± SD, drug loading: 0.3% w/v) 
69 
 
The HPLC chromatogram of freshly prepared risperidone solution showed retention time 
(RT) at 2.16 min. The release profile of risperidone showed that only 2.13±0.047% of the total 
risperidone incorporated into the delivery system was released in day 1. It was observed that only 
10% of the total risperidone was released in 15 days, and the overall release period lasted for 
approximately 77 days. While BSA showed high initial burst release (13.54±0.89%), followed 
by insulin (7.32±3.1%). BSA was released rapidly and completely in ~42 days including a fast 
release phase observed up to 7 days, followed by a slow release phase for 42 days. Insulin was 
released over 70 days in a controlled manner after an initial burst release. The correlation 
coefficients for BSA, insulin, and risperidone were 0.76, 0.86, and 0.98, respectively, for zero 
order release kinetics. 
3.4.1.  Mass loss of polymer hydrogels during in vitro release 
It was observed that the hydrophobicity of the incorporated molecule affected the mass 
loss in hydrogels. Figure 19 shows the degradation of copolymer A in presence of various 
molecules. The delivery system containing BSA degraded faster as compared to risperidone, and 
insulin containing delivery systems, and the mass loss was significantly higher (p<0.05) until 45 
days of release. 
3.4.2.  Hydrolytic degradation of polymer hydrogels determined by proton NMR  
Figure 20 shows the change in the relative amount of LA and EG content of the 
copolymer after degradation in PBS (pH 7.4) at 37°C in presence of risperidone, BSA and 
insulin. In case of BSA containing delivery system the ratio of LA and EG increased to 1.4 after 
30 days of degradation, indicating preferential loss of hydrophilic PEG segments. The delivery 
systems containing insulin and risperidone showed gradual increase in LA/EG ratio. The residual 
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polymer appearance was visually compared and it was noted that the BSA loaded delivery 
systems appeared more porous. 
 
Figure 19. Weight loss of the delivery system during in vitro release of (●) BSA, (▲) 
risperidone, and (■) insulin, from 30% w/w copolymer A containing delivery systems 
(n=4, mean ± SD, *: significant at p<0.05) 
 
Figure 20. The change in LA/EG ratio of the polymer containing (A) zinc-insulin + polymer, (B) 
BSA + polymer, and (C) risperidone + polymer, during in vitro release 
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3.4.3.  Hydrolytic degradation determined by GPC 
GPC helped to determine the change in molecular weight of copolymer during hydrolytic 
degradation. GPC results of polymer alone, and loaded with BSA, insulin, and risperidone 
analyzed over the release duration are summarized in table 9. The drug loaded delivery systems 
showed noticeable degradation after 30 days of in vitro release. As the degradation proceeded, 
the chromatogram showed a bimodal distribution, and a reduction in molecular weight (Mn) of 
polymer illustrated by an increase in retention time (RT) was observed. Increase in the 
polydispersity index (PDI) observed indicated that the rate of degradation was faster in case of 
polymeric delivery system containing BSA as compared to that of insulin or risperidone. The 
reduction in molecular weight was rapid after 30 days of incubation, and at the end of 60 days, 
most of the polymer was hydrolyzed into smaller segments indicated by corresponding increase 
in RT. At the end of 90 days, no peak corresponding to original polymer was detected, while 
increase in polymer degradation products with RT near 20 min was noticed. 
3.4.4.  Morphology of the delivery system determined using Cryo-SEM 
Figure 21 (A-F) shows the morphology of the delivery systems after incorporation of 
insulin, BSA, and risperidone. It was observed that the size of pores formed in the delivery 
system was dependent on the type of drug incorporated. Table 10 shows the average size of 
pores formed in the delivery systems at various drug loading. By the end of day 30, the hydrogel 
containing BSA showed significantly larger (p<0.05) pores (3.95±1.45 µm) than insulin 
(2.53±0.93 µm), or risperidone (0.96±0.26 µm) loaded hydrogels as shown in figure 21 (C, E and 
G). At the end of 60 days, pore size increased irrespective of drug loading and no significant 
difference was observed in the mean pore size (figure 21 D, F, and H). 
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Table 9. Molecular weight of the polymer PLA-PEG-PLA (4500 Da) remaining after hydrolytic 
degradation in PBS, pH 7.4 at 37ºC 
Sample Time Mn (1) RT PDI Mn (2) RT PDI 
Polymer + Insulin 0 days 344 17.957 1.119 ---- ---- ---- 
 30 days 3157 18.047 1.285 317 20.649 1.150 
 60 days 2073 18.086 1.291 258 20.751 1.351 
 90 days ---- ---- ---- 200 20.84 1.161 
Polymer + Risperidone 0 days 4344 17.957 1.119 ---- ---- ---- 
 30 days 2567 18.095 1.164 ---- ---- ---- 
 60 days 1902 18.175 1.32 200 20.839 1.159 
 90 days ---- ---- ---- 208 20.81 1.158 
Polymer + BSA 0 days 4344 17.957 1.119 ---- ---- ---- 
 30 days 2431 18.030 1.288 225 20.653 1.168 
 60 days ---- ---- ---- 307 20.715 1.230 
 90 days ---- ---- ---- ---- ---- ---- 
 
Table 10. Average size of pores formed in the delivery systems loaded with different molecules 
Incorporated molecules Day 30                      (average pore size, n=200) 
Day 60                      
(average pore size, n=20) 
Blank (Polymer only) 2.17 ± 0.41 µm 10.84 ± 1.68 µm 
Risperidone 0.96 ± 0.26 µm 9.67 ± 2.81 µm 
Zinc-Insulin 2.53 ± 0.93 µm 12.58 ± 2.55 µm 
BSA 3.95 ±1.45 µm 15.31 ± 3.66 µm 
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Figure 21. Cryo-SEM images of porous morphology of freshly cut surfaces of the polymeric 
delivery systems loaded with risperidone (30 and 60 days) (C-D), insulin (30 and 60 days) (E-F), 
and BSA (30 and 60 days) (G-H) maintained at body temperature (5 min sublimation) 
3.5. Effect of Increasing Molecular Size on In Vitro Release Behavior of Thermosensitive 
Polymeric Delivery Systems 
The effect of molecular size and solubility on the in vitro release profile of delivery 
system was studied using insulin, zinc-insulin and chitosan-zinc-insulin complexes. The in vitro 
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release profile is presented in figure 22. It was observed that the rate of release of insulin 
monomers was faster as compared to zinc-insulin hexamers or chitosan-zinc-insulin complexes. 
Insulin containing formulations showed highest initial burst release (14.21±0.51%), followed by 
zinc-insulin (9.23±1.25%), and chitosan-zinc-insulin complexes (8.87±1.5%). The delivery 
system containing chitosan-zinc-insulin complex showed higher correlation coefficient 
(r2=0.983), followed by zinc-insulin (r2=0.95), and insulin alone (r2=0.884), respectively, for 
zero order release kinetics. 
 
Figure 22. In vitro release profiles of (♦) insulin, (●) zinc-insulin, and (■) chitosan-zinc-insulin 
complex released from 30% w/w copolymer A containing delivery systems 
(n=4, mean ± SD, drug loading: 0.3% w/v) 
3.6. Effect of Chitosan (Cationic Polymer) on pH of Release Medium During Hydrolytic 
Degradation 
The change in pH of the delivery system during hydrolytic degradation in presence and 
absence of a cationic polymer, chitosan is presented in figure 23. It was observed that the 
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delivery system containing copolymer A alone showed gradual reduction in pH, and the pH 
dropped rapidly after ~40 days of incubation, and at the end of 70 days, it reached to ~4.5. In 
contrast, the delivery system containing chitosan resisted the change in pH for ~45-50 days, and 
then pH reduced gradually over the period of 70 days. However, the pH of the release medium 
still remained higher as compared to the delivery system without chitosan. 
 
Figure 23. Change in the pH of the release medium during hydrolytic degradation of 
copolymer A (♦) copolymer alone, and (●) copolymer A + Chitosan 
(n=4, mean ±SD) 
3.7.  Preparation of Polymer Formulations for Insulin, In Vitro Release, and Stability 
The polymeric formulations containing insulin, or zinc-insulin were easily injectable 
through 25 G needle at room temperature and formed gel in ~30 sec upon incubation at body 
temperature.  
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3.7.1. Effect of polymer concentration, zinc addition and insulin loading on in vitro release 
of insulin released in vitro 
Figures 24 and 25 show the release profiles of insulin alone and in presence of zinc at 60 
mg loading. We found 11.45±2.3%, and 10.28±1% initial burst release of insulin from 
formulations containing insulin alone in 30% and 40% w/w polymeric systems. While, 
7.64±0.96%, 5.41±3.3% burst release of insulin was observed from formulations containing 
zinc-insulin, in 30% and 40% w/w polymeric delivery systems, respectively. In addition to 
reduced initial burst release, zinc also helped control the release of insulin from the delivery 
system for ~84 days. The delivery system containing insulin alone showed poorly controlled 
release and only 70-75% of the total insulin loading released from delivery system at the end of 
three months. It was observed that increasing polymer concentration from 30 to 40 % w/w 
(formulations I-III, and II-IV) improved the correlation coefficients for zero order for insulin, 
and zinc-insulin.  
The release kinetics is listed in table 11. The insulin loading in the delivery system was 
selected to meet the basal insulin requirement (0.5-1 IU/h corresponding to 0.5-1mg/day) for two 
to three months. We used the release kinetics equations as follows: zero order (Mt /M∞ = k t), 
First order ln[(Mt /M∞)] = kt, and Higuchi (Mt /M∞) = kt0.5,  where (Mt /M∞) is the fractional 
release of the loaded protein, k is a kinetic constant, and t is the release time. 
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Figure 24. In vitro release of insulin from 30% w/w thermosensitive polymeric delivery system 
(A), (●) 60 mg insulin alone and (▲) 60 mg zinc-insulin, and initial burst release (B) of insulin 
from the formulations 
(n=4, mean ± SD, *: significantly lower at p<0.05) 
 
 
Figure 25. In vitro release of insulin from 40% w/w thermosensitive polymeric delivery system 
(A), (♦) 60 mg insulin alone and (■) 60 mg zinc-insulin, and initial burst release (B) of insulin 
from the formulations 
(n=4, mean ± SD, *: significantly lower at p<0.05) 
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Table 11. Release kinetics of insulin from formulations 
Formulations Insulin loading Zero order (r2) Higuchi (r2) 
I 60 mg 0.88 0.94 
II 60 mg 0.91 0.82 
III 60 mg 0.90 0.91 
IV 60 mg 0.93 0.87 
V 60 mg 0.86 0.92 
VI 60 mg 0.90 0.89 
VII 80 mg 0.88 0.80 
VIII 100 mg 0.83 0.77 
 
Since zinc addition significantly reduced the initial burst release of insulin at 60 mg drug 
loading, the effect of zinc addition (1:5 insulin hexamer: zinc ions) on insulin release from the 
thermosensitive delivery systems was determined at higher insulin loading (80 and 100 mg 
insulin). The release profile of insulin from all formulations is presented in figure 26. The in 
vitro release study showed that the addition of zinc to insulin lowered the initial burst release in 
comparison to formulation without zinc, even at higher protein loading. The results indicate that 
the protein loading played a major role in controlling the release. There was no significant 
difference in initial burst release (7.00±0.41, 7.91±0.15, and 8.33±0.12 %) from formulations 
containing 60 mg insulin alone, and 60, 80 and 100 mg zinc-insulin, respectively. Compared to 
the large burst release (~10.4%) from formulation containing insulin alone, addition of zinc 
significantly (p<0.05) reduced the initial burst release to a relatively low level. After the initial 
burst an extended lag period was observed where a negligible amount of insulin was released 
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from the delivery system. In case of all formulations a sudden increase in the release rate 
(secondary burst release) was observed after ~25-35 days. A consistent and complete release of 
insulin was expected due to the progressive degradation of the delivery system, but it was 
observed that as the insulin loading was increased from 60 to 100 mg, only 68-70% of the total 
insulin loading was released. As the amount of insulin was increased in the delivery system from 
60 to 80 and 100 mg, it reduced the correlation coefficient for zero order release (R2: 0.90, 0.88, 
0.83). 
3.7.2.  Stability studies of insulin released in vitro 
The stability of in vitro released insulin was determined by CD, PAGE/SDS-PAGE, and 
MALDI-TOF MS. 
 
Figure 26. Effect of insulin loading on in vitro release profile of insulin from 30% w/w 
polymeric delivery system (▲) 60 mg insulin alone, (●) 60 mg zinc-insulin, (■) 80 mg zinc-
insulin, and (♦) 100 mg zinc-insulin (n=4, mean ± SD) 
3.7.2.1. Circular dichroism spectroscopy (CD) 
The representative far UV-CD spectra of insulin released at various time points from 
delivery systems containing zinc-insulin are presented in figure 27A. The CD spectra in far UV 
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region showed presence of two characteristic minima at 208 and 222 nm indicating the 
secondary structure of insulin was preserved up to 42 days. An increase in random coils and 
reduction in α-helix and β-sheets (reduction in the minima at 208 and 222 nm) in secondary 
structure of released insulin was observed after ~56 days from all formulations as compared to 
fresh insulin. The secondary structure analysis of released samples of insulin is presented in table 
12. During tertiary structure analysis it was observed that the tyrosyl signal at 278 nm in near 
UV-CD spectra was increased in the initially released samples of insulin. The results indicated 
that the increased in the intensity is noticed when insulin is in the form of hexamers, but 
eventually the signal intensity reduced and was comparable to that of fresh insulin (figure 27B). 
Thus insulin was released in the form of hexamers initially, and as the release duration 
proceeded, they dissociated into dimers and hexamers. 
 
 
Figure 27. Far UV-CD (A) and near UV-CD (B) spectra of insulin released from formulation 
containing 60 mg zinc-insulin in 30% w/w polymeric delivery system 
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Table 12. Secondary structure analysis of insulin released from formulations 
Formulations Insulin loading Days α Helix β Sheets β turns 
Random 
Coils 
Fresh Insulin in PBS --- --- 39±1 16±2 21±2 24±4 
A (Insulin alone) 60 mg 
30 18±2 6±1 47±3 29±3 
60 9±2 8±1 44±1 39±2 
B (Zinc-insulin) 60 mg 
30 35±2 20±4 22±1 23±2 
60 20±3 9±1 41±2 30±2 
C (Zinc-insulin) 80 mg 
30 25±3 15±3 40±4 20±3 
60 12±3 6±2 47±6 35±2 
D (Zinc-insulin) 100 mg 
30 38±1 10±3 22±3 30±2 
60 10±2 12±2 46±5 32±3 
(n=4, mean ± SD) 
3.7.2.2. Polyacrylamide gel electrophoresis (Native and SDS-PAGE) 
Freshly prepared sample of insulin showed a band at 6 kDa in native PAGE. 
Representative gel images for native PAGE and SDS-PAGE for released samples of insulin from 
formulation containing zinc-insulin are presented in figure 28A and B. We found higher 
molecular weight bands at 12 and 36 kDa, initially (released samples of 7 days) in native PAGE 
experiments along with a strong presence of insulin monomers at 6 kDa. These higher molecular 
weight bands indicated the presence of insulin dimer aggregates (~ 12 kDa) or hexameric insulin 
(36 kDa). Though monomeric insulin band was found during native PAGE analysis, the insulin 
released from formulations was in the form of mixture containing dimers/hexamers. The 
covalent or non-covalent nature of aggregates can be determined using SDS-PAGE under non-
reducing conditions, since it dissociates non-covalent aggregates. A single band corresponding to 
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6 kDa was observed in SDS-PAGE experiments under non-reducing conditions. The formulation 
without zinc also showed a single band around 6 kDa indicating that no dimerization occurred 
during formulation of the delivery system. No additional bands were observed below 6 kDa in 
both SDS-PAGE and native PAGE experiments. 
    
Figure 28. Native PAGE (A) and SDS-PAGE (B) analysis of insulin released 
(lane 1: molecular marker, lane 2: fresh insulin and lanes 3-10: insulin released at day 1, 3, 7, 14, 
28, 42, 56, and 77 days from zinc-insulin containing polymeric delivery system) 
3.7.2.3. MALDI-TOF mass spectroscopy 
The MALDI-TOF MS helped to detect the chemical stability of released insulin from the 
delivery systems containing zinc-insulin and the results are presented in figure 29. Fresh insulin 
shows peak at ~5808 Da. A single peak corresponding to native insulin was observed 
corresponding to a molecular mass of (M+H)+ 5808.477 Da. No major degradation products 
were detected in MALDI-TOF analysis till one month in vitro release. Some degradation 
products were observed in the released samples after two months. The released sample of insulin 
showed the presence of a peak corresponding to native insulin along with a small peak at 
2907.95 Da along with some unidentified peaks.  
3.8. Chitosan-Zinc-Insulin Complex Formation, Dissociation, and Effect of Chitosan 
Addition on Insulin Stability 
To reduce the initial burst release from the delivery system, and to reduce the diffusion of 
insulin monomers from the polymeric delivery system, chitosan-zinc-insulin complexes were 
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prepared. The complexes were incorporated into the thermosensitive polymeric delivery system 
and the effect of chitosan and zinc addition on initial burst release, in vitro release profile of 
insulin as well as stability was observed. Since insulin is stable in the pH range of 5-8, complex 
formation between insulin and chitosan was characterized using turbidimetry (preliminary 
studies) at a pH range of 5 to 8. After addition of chitosan to insulin, a gradual increase in the 
transmittance was observed, and plateau appeared at pH ~6.5-6.8. Above pH 6.8, since both 
insulin (isoelectric point 5.4) and chitosan bear opposite charges, large insoluble complexes were 
observed indicated by increased turbidity and subsequent precipitation. It was also noted that the 
insulin/chitosan complex formation took place in the pH range of 6.5-6.8 irrespective of the 
chitosan concentration. The entrapment efficiency was found to be ~70-76%.  
The results of gel retardation assay and SDS-PAGE are depicted in figure 30. It was 
observed that when the chitosan: insulin weight ratio was increased to 4:1; most of the protein 
was retained in the gel wells indicated by the disappearance of band at 6 kDa (figure 30A). After 
incubation of chitosan-insulin complex with an anionic surfactant SDS it was noted that insulin 
was released from the complex and a band corresponding to fresh insulin was observed at (6 
kDa) (figure 30B). 
3.8.1.  Fluorescence spectroscopy 
The fluorescence property of insulin (tyrosine/phenylalanine fluorescence) was studied 
after addition of insulin to chitosan solutions at increasing weight ratios and the spectra is 
presented in figure 31. The fluorescence spectra of insulin in presence of increasing amount of 
chitosan indicated no shift in the λemission for tyrosine/phenylalanine of insulin. It was observed 
that chitosan does not show any fluoresce when excited at 280 nm. But insulin molecules excited 
at 280 nm showed the fluorescence spectra collected at wavelength between 295-395nm (λem). It 
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was noted that even after addition of increasing amount of chitosan to insulin there was no shift 
in the λem appeared due to tyrosine/phenylalanine residues. These results suggested that there is 
no change in the tertiary structure of insulin in presence of chitosan at the concentrations tested. 
This further substantiates that the 3-D structure of insulin is conserved during complex formation 
with chitosan. 
 
 
Figure 29. MALDI-TOF mass spectra of fresh insulin (A), insulin released from the polymeric 
delivery system containing zinc-insulin at 1 and 2 months (B and C) 
 
 
Figure 30. Gel retardation assay (native PAGE) (A), and SDS-PAGE (B) for insulin-chitosan 
complexes (lane 1: molecular marker, lane 2: fresh insulin, lanes 3-9: insulin: chitosan 1:0.5, 1:1, 
1:2, 1:4, 1:8, 1:16 and 1:32 w/w) 
 
B C 
A 
85 
 
 
Figure 31. Fluorescence spectra of insulin after addition of chitosan  
(insulin: 1 mg/ml, pH 6.8, chitosan: 0.0666 mg/ml, pH 6.8) 
3.8.2.  Circular dichroism spectroscopy (CD) 
The change in the secondary structure of insulin in the presence of chitosan was 
determined by CD spectroscopy and the results are presented in figure 32. Fresh insulin shows 
the presence of 2 distinct minima at 208 and 222 nm in far UV-CD region. This is due to the 
presence of α helix in the structure of insulin. After addition of chitosan to insulin at increasing 
weight ratios and incubating for 20 min, it was observed that there was no shift in the minima 
observed at 208 and 222 nm, but, a very small reduction in the CD signal intensity was observed 
with increased chitosan concentration. 
3.8.3.  Differential scanning calorimetry (DSC) 
DSC also helped to study the structural changes in insulin after addition of chitosan. DSC 
spectra of insulin in presence of zinc, and chitosan are presented in figure 33. Fresh insulin 
showed two distinct transitions at 68.0±2.1°C (Tm1) and 82.4±1.41°C (Tm2). This biphasic 
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denaturation was observed due to the presence of dimers and hexamers present. Further increase 
in Tm and ∆H (90.3±0.79°C, and ~11.6 KCal/mol) was observed after addition of chitosan to 
zinc-insulin compared to zinc-insulin (84.5±1.2°C, and ~9.89 KCal/mol). At increasing the 
chitosan amount in the complex analyzed with DSC showed that the Tm reached to a maximum 
value of 90±0.8°C. Since addition of chitosan solution (0.066 mg/ml) to insulin solution (1 
mg/ml) at a ratio of 1:2 v/v (1:15 w/w) showed stabilizing effect on zinc-insulin indicated by 
increased Tm which reached to a maximum value of 90.3°C, this or higher weight ratio was used 
during formulating the delivery system containing chitosan-zinc-insulin complex. 
 
Figure 32. Far UV-CD spectra of insulin after addition of chitosan 
(insulin: 1 mg/ml, pH 6.8, chitosan: 0.0666 mg/ml, pH 6.8) 
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Figure 33. DSC thermograms of zinc-insulin after addition of chitosan  
(insulin: 1 mg/ml, pH 6.8, chitosan: 0.0666 mg/ml, pH 6.8) 
3.8.4.  Stability of insulin, zinc-insulin and chitosan-zinc-insulin complex in presence of 
lactic acid 
Figure 34 represents the thermostability of insulin, zinc-insulin, and chitosan-zinc-insulin 
complexes in presence of lactic acid. It was noticed that presence of lactic acid completely 
destroyed the insulin structure, and reduced the thermostability of zinc-insulin indicated by shift 
in Tm to 60 and 79°C, respectively for insulin monomers and hexamers (figure 34A). But, it did 
not significantly affect insulin in the form of chitosan-zinc-insulin complex (figure 34B). These 
results indicate the additional stabilizing effect of chitosan on protein structure. Chitosan also 
possesses good buffering ability which might have resisted the major pH change in the 
microenvironment of the delivery system (figure 35). 
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Figure 34. DSC thermograms of zinc-insulin (A) and chitosan-zinc-insulin (B) complex 
incubated with lactic acid 
 
 
Figure 35. Buffering ability of chitosan-zinc-insulin complex 
It was observed that the chitosan could effectively resist the change in the pH by lactic 
acid, which is generated by degradation of the thermosensitive polymer, even in the highly 
unlikely scenario of complete, instantaneous degradation of polymer in the delivery system.  
3.9.  Formulation of the Delivery System Containing Chitosan-Zinc-Insulin Complex and 
In Vitro Release 
The amount of free insulin present in the supernatant was ~18-20% of the total loading. 
The formulations were injectable through 25 G needle at room temperature without clogging the 
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needle, and showed rapid conversion from sol to gel within ~ 50 sec near body temperature. The 
effect of addition of chitosan on in vitro release of insulin at low protein loading (5 mg) was 
evaluated in our initial studies. Figure 36A represents the release profile of insulin alone, zinc-
insulin, chitosan-insulin and chitosan-zinc-insulin complex from thermosensitive polymeric 
delivery systems (30% w/w). The formulation containing chitosan-insulin and zinc-insulin 
showed reduction in the initial burst release as compared to formulation containing insulin alone. 
It was observed that chitosan-zinc-insulin complex helped to reduce the initial burst release, with 
minimal secondary burst and controlled the release up to ~91 days with the cumulative release of 
96%. Significantly low (p<0.05) initial burst was observed as compared to insulin alone, zinc-
insulin or chitosan-insulin containing formulations (figure 36B). The release constants (zero 
order) were 0.84, 0.93, 0.93, and 0.99 for formulations containing insulin alone, zinc-insulin, 
chitosan-insulin and chitosan-zinc-insulin complex, respectively. 
  
Figure 36. Effect of chitosan on in vitro release of insulin from 30% w/w copolymeric delivery 
system (A) at insulin loading 5 mg and initial burst release from the formulations (B) 
(♦) insulin alone, (■) chitosan-insulin, (▲) zinc-insulin, (●) chitosan-zinc-insulin complex; (n=4, 
mean ± SD, P <0.05, *: significant compared to insulin alone, #: significant compared to zinc-
insulin, and ‡: significant compared to chitosan-insulin loaded delivery system) 
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3.9.1. Optimization of the delivery system for higher drug loading and in vitro release 
From the results of the preliminary in vitro release experiments as well as stability studies 
the polymeric delivery systems were optimized. The delivery systems were formulated to deliver 
30, 45, and 60 mg insulin in the form of chitosan-zinc-insulin complex. The amounts of insulin 
correspond to the basal level requirement for three months. The concentration of the 
thermosensitive polymer, amount of chitosan, zinc ions to insulin ratio were fixed to get the 
desired release profile. Initially in our preliminary studies it was noted that, at zinc: insulin 
hexamer ratio more than 4:1, some degradation products were observed might be due to the 
presence of higher amount of zinc in the delivery system. At the same time it was observed that 
at higher protein loading use of polymer concentration more than 30% w/w lead to highly 
viscous formulation which was difficult to inject from 25 G needle at room temperature. Hence 
zinc: insulin hexamer ratio was optimized to 4:1 and the concentration of the thermosensitive 
polymer was fixed at 30% w/w. During optimization studies, the amount of chitosan in the 
delivery system was varied keeping all other formulation parameters constant, to determine the 
effect of increasing chitosan concentration on initial burst release as well as the entire release 
profile of insulin. The in vitro release profile of insulin at higher loading (30, 45 and 60 mg) is 
displayed in figures 37-40. Figure 37 displayed the release profile of insulin in vitro from 
formulations containing 30 mg insulin alone, zinc-insulin, chitosan-insulin or chitosan-zinc-
insulin in thermosensitive polymeric delivery system (formulations A-D). Addition of zinc to 
insulin (Formulation B) showed significant reduction (P<0.05) in the initial burst (7.64±0.91%), 
compared to the formulations containing insulin alone (10.28±1.2%) and chitosan-insulin 
(13.24±2.07%). The formulation containing chitosan-insulin showed high initial burst and the 
overall release period up to 45 days. Along with the initial burst, only 65% of the total protein 
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was released from the delivery system. Even though zinc helped to prolong the overall release 
period (~63 days) as compared to insulin alone or chitosan-insulin, a high secondary burst 
release was also observed after ~35 days. The correlation coefficients (r2) for the insulin release 
profile from various formulations are presented in table 13. All delivery systems indicated best 
fit for Higuchi model, while chitosan-zinc-insulin containing delivery system showed best fit for 
zero order release model. This high zero order correlation is highly desirable to ensure a constant 
release from the delivery systems. The amount of insulin remained in the delivery systems (A, B 
and C) after three months of release was approximately 15-20%. On the other hand, continuous 
release of insulin was observed over 84 days from the delivery system containing chitosan-zinc-
insulin complex (formulation D). A significant decrease (p<0.05) in initial burst (3.85±0.64) was 
observed compared to all other formulations. Additionally, the release of insulin was complete 
from formulation D compared to formulations A, B and C. 
 
Figure 37. In vitro release of insulin from 30% w/w copolymeric delivery system (A) at insulin 
loading 30 mg, and initial burst release of insulin from formulations (B)  
((♦) chitosan-zinc-insulin complex, (■) zinc-insulin, (▲) insulin alone, and (●) chitosan-insulin; 
(n=4, mean ± SD)) 
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The influence of increasing amount of chitosan (0.4% w/v) on insulin release was also 
investigated. Increasing the amount of chitosan from 0.2% to 0.4% w/v in the delivery system 
(Formulation E) did not significantly affect the initial burst, as well as the release rate of insulin 
as shown in figure 38. When the chitosan amount in the delivery system was increased further, it 
was observed that it affects the injectability of the formulation. The insulin loading was 
increased further to 45 mg and the in vitro release of insulin was evaluated. With increase in 
insulin loading from 30 mg to 45 mg in polymeric formulation H (chitosan-zinc-insulin 
complex), increase in the initial burst was observed, and the release was controlled for ~91 days 
(figure 39).  
Table 13. Release kinetics of insulin from formulations 
Formulations Insulin loading 
PLA-PEG-PLA 
Copolymer (w/w) 
Zero 
order r2 
Higuchi 
r2 
First 
order r2 
A (Insulin alone) 30 mg 30% 0.90 0.95 0.67 
B (Zinc-insulin) 30 mg 30% 0.97 0.93 0.77 
C (Chitosan-insulin) 30 mg 30% 0.89 0.97 0.64 
D (Chitosan-zinc-insulin) 30 mg 30% 0.98 0.96 0.76 
F (Insulin alone) 45 mg 30% 0.89 0.96 0.66 
G (Zinc-insulin) 45 mg 30% 0.95 0.93 0.74 
H (Chitosan-zinc-insulin) 45 mg 30% 0.98 0.94 0.78 
I (Insulin alone) 60 mg 30% 0.87 0.89 0.80 
J (Zinc-insulin) 60 mg 30% 0.90 0.807 0.58 
K (Chitosan-zinc-insulin) 60 mg 30% 0.96 0.91 0.70 
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Even though the release was controlled in a better way compared to insulin alone 
(formulation F) and zinc-insulin (Formulation G), only 89% of the total drug was release at the 
end of three months. A small decrease in the secondary burst was observed compared to the 
formulations F and G. The in vitro release profile of insulin from the delivery system containing 
60 mg insulin in the form of insulin alone, zinc-insulin or chitosan-zinc-insulin complex is 
depicted in figure 40. Formulation containing insulin alone (formulation I) showed high initial 
burst (11.45±1.9%) followed by a typical triphasic release pattern. 
 
Figure 38. Effect of chitosan amount on in vitro release of zinc-insulin from triblock copolymer 
at insulin loading 30 mg 
(chitosan amount (■) 0.2% w/v, and (●) 0.4% w/v of the delivery system, (n=4, mean ± SD)) 
Zinc-insulin containing delivery system (formulation J) showed reduction in initial burst 
release (6.83±0.59%), followed by a constant release rate that was observed up to ~56-63 days. 
Addition of zinc to insulin reduced the initial burst and prolonged the overall release period. As 
observed in our earlier studies, a high secondary burst after ~35 days was observed from zinc-
insulin containing formulation and almost 55% of the total insulin loading was released in 20 
days. 
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Figure 39. In vitro release of insulin from 30% (w/w) copolymer based delivery system at insulin 
loading 45 mg (A), and initial burst release of insulin from formulations (B) 
((●) chitosan-zinc-insulin, (■) zinc-insulin, and (▲) insulin alone, (n=4, mean ± SD, *: 
significant compared to insulin alone, #: significant compared to zinc-insulin at P <0.05)) 
 
 
 
Figure 40. In vitro release of insulin from 30% (w/w) copolymer based delivery system at insulin 
loading 60 mg 
((●) chitosan-zinc-insulin, (■) zinc-insulin, (▲) insulin alone (n = 4, mean ± SD)) 
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Chitosan-zinc-insulin complex (formulation K) showed significant reduction (P<0.05) in 
the initial burst release of insulin (7.54±0.67%), as compared to the formulations containing 
insulin alone with the cumulative release of 91% of the total insulin loading in 98 days. Similar 
to our earlier studies, an incomplete release (~70%) was observed from insulin/zinc-insulin 
containing delivery systems. 
3.10.  Stability of Insulin Released In Vitro 
The stability of released insulin was investigated using series of studies using CD, DSC, 
PAGE/ SDS-PAGE, HPLC and MALDI-TOF Mass Spectroscopy techniques. 
3.10.1.  Circular dichroism spectroscopy (CD) 
Results depicted in figures 41 (A-D) showed the far UV-CD spectra of fresh and in vitro 
released insulin from formulations A-H. Native insulin showed well-defined negative bands in 
CD spectrum with two minima at ~208 and 222 nm, indicating the presence of major alpha helix 
structure (38%) with a small part of beta-sheets (~17%). Significant attenuation was observed in 
the percent of α helix (~18%) and β sheets (~4%) for formulation containing insulin alone after 
~30 days of release in comparison to the formulations containing zinc-insulin and chitosan-
insulin. Even though the released insulin CD spectra from formulation containing zinc closely 
resembles the native insulin spectrum up to 30 days, demonstrating the structural stabilizing 
effect of zinc, marked reduction in α helix (19%) and β sheets (8%) was observed in released 
samples after 45 days. Similarly, addition of chitosan to insulin (formulation C) did not improve 
its stability and increase in random ordered structures (>65%) was observed after ~30 days. 
Addition of chitosan to zinc-insulin (formulation D and H) showed additional stabilizing effect, 
indicated by preservation of secondary structure of released insulin up to 56 days. Reduction in α 
helix (17%) and β sheets (4%) with corresponding increase (~76%) in unordered structures was 
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observed in all released samples of insulin after ~60 days of release. The detailed secondary 
structure analysis of insulin released from formulations A-K is summarized in tables 14 and 15. 
At 60 mg insulin loading major loss of secondary structure was observed after 35 days of release 
in case of delivery systems containing insulin alone and zinc-insulin (formulations I and J, 
respectively). The signal intensity was further reduced after 56 days and the released insulin 
showed increase in random ordered structures (table 15). Chitosan-zinc-insulin complex helped 
preserve the secondary structure for ~63 days (formulation K). 
The possible changes in the tertiary structure of released insulin were also investigated 
using near UV-CD spectrum (figures 42 A-D). Fresh insulin showed a negative signal at 278 nm. 
Increased intensity of near UV-CD signal at 278 nm was observed in released samples of insulin 
initially, indicating the presence of insulin dimers and hexamers in the released samples. No 
perturbation in the near UV-CD spectra of insulin confirmed that the tertiary structure of insulin 
was not affected during release from formulations containing chitosan-zinc-insulin up to 45 days 
in comparison to formulations containing zinc-insulin, chitosan-insulin and insulin alone. A 
slight reduction in the signal intensity was observed after 45 days, but it reduced substantially 
after 56 days. The results suggest that there was partial loss of tertiary structure of released 
insulin after 56 days. 
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Figure 41. Far UV CD spectra of released insulin from the delivery system at 30 mg insulin 
loading at 15 (A), and 45 days (C), and released insulin from the delivery system containing 45 
mg/ml of insulin at 30 (B), and 60 days (D) 
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Figure 42. Near UV-CD spectra of released insulin from the delivery system containing 30 
mg/ml of insulin, at 15 (A), and 45 days (C), and released insulin from the delivery system at 45 
mg insulin loading, at 30 (B), and 60 days (D) 
 
Table 14. Secondary structure analysis of insulin released from formulations (30 and 45 mg 
insulin loading) 
Formulations Days α Helix β Sheets β turns Random Coils 
Fresh Insulin in PBS --- 38±1 17±2 23±2 22±4 
A (Insulin alone) 
30 18±4 4±2 49±4 29±4 
60 8±1 5±1 49±2 38±2 
90 7±3 6±2 46±3 41±3 
B (Zinc-insulin) 
30 37±2 18±1 26±2 19±4 
60 20±3 7±1 43±2 30±2 
90 12±3 7±4 45±3 36±5 
     (Continued) 
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Table 14. Secondary structure analysis of insulin released from formulations (30 and 45 
mg insulin loading) (Continued) 
Formulations Days α Helix β Sheets β turns Random Coils 
C (Chitosan-insulin) 
30 20±2 12±5 45±1 23±2 
60 12±3 8±2 46±6 34±3 
90 6±2 6±2 44±5 44±2 
D (Chitosan-zinc-insulin) 
30 31±1 10±3 28±1 31±2 
60 19±2 4±1 41±3 36±1 
90 13±3 6±3 40±2 41±2 
F (Insulin alone) 
30 17±1 5±3 44±1 34±2 
60 10±3 5±1 51±3 34±4 
90 6±2 7±4 48±2 39±3 
G (Zinc-insulin) 
30 28±1 12±1 28±1 32±2 
60 17±3 9±3 44±3 30±1 
90 10±2 8±2 44±1 38±3 
H (Chitosan-zinc-insulin) 
30 29±4 10±2 29±1 32±4 
60 16±3 4±2 39±4 41±2 
90 13±3 7±3 46±5 34±3 
(n=4, mean ± SD) 
3.10.2. Differential scanning calorimetry (DSC) 
DSC measurements were used for the assessment of conformational stability of various 
association states of insulin during release. Heat capacity scans originated from fresh insulin, and 
released samples of insulin, are presented here in figure 43. Fresh insulin showed two distinct 
transitions at 68.0±2.1°C (Tm1) and 82.4±1.41°C (Tm2). This biphasic denaturation was observed 
due to the presence of dimers and hexamers in the sample. Insulin released from the delivery 
system containing zinc-insulin (formulation B) showed the presence of insulin hexamers, 
indicated by a single peak observed at 83.3±1.2°C (Tm2) at day 7. Insulin released from 
(chitosan-insulin) formulation C showed presence of mixture of dimers and hexamers. Insulin 
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released initially from formulation D showed the presence of chitosan-zinc-insulin complex 
indicated by increased thermal transition observed at 90±0.8°C (Tm2) at day 7.  
 
Table 15. Secondary structure analysis of released insulin (60 mg insulin loading) 
Formulations Days α Helix β Sheets β turns Random Coils 
Fresh Insulin in PBS --- 36±3 17±1 25±4 22±3 
I (Insulin alone) 
30 18±2 6±4 44±3 32±3 
60 8±3 5±3 43±2 44±4 
90 7±3 6±2 45±2 42±3 
J (Zinc-insulin) 
30 34±4 20±2 23±3 23±2 
60 14±3 12±1 38±4 36±3 
90 10±4 13±5 44±3 33±3 
K (Chitosan-zinc-insulin) 
30 38±3 15±4 29±3 18±4 
60 28±3 16±2 26±6 30±3 
90 13±5 10±6 41±3 36±2 
(n=4, mean ± SD) 
 
 
 
Figure 43. DSC fitted thermograms of released insulin after 7 days from polymeric delivery 
systems 
101 
 
 
Figure 44. DSC fitted thermograms of released insulin after 30 and 60 days from polymeric 
delivery systems 
 
The released insulin from formulations containing chitosan-zinc-insulin examined at 30 
and 60 days showed the presence of peaks corresponding to unfolding of hexamers, and dimers 
indicating dissociation of chitosan-zinc-insulin complex over the period of time (figure 44). The 
thermal stability of insulin released at various time points from formulation K was determined by 
DSC and is presented in figure 45A. In accordance with our previous studies, it was noted that 
insulin was released only in the form of chitosan-zinc-insulin complex till day 15 indicated by 
higher Tm (~90°C). The released samples of insulin at 60 and 90 days showed the presence of 
monomers with very small amount of hexamers. Upon dilution, the initially released samples of 
insulin (day 7 and 15) were easily dissociated and showed the presence of monomers/dimers 
(Tm: ~68°C) and hexamers (Tm: ~84°C) (figure 45B). 
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Figure 45. DSC thermograms of insulin released from formulation containing chitosan-zinc-
insulin complex loaded thermosensitive polymer (formulation K, at 60 mg insulin loading) (A); 
and DSC thermograms of diluted samples of insulin released (B) 
3.10.3.  Polyacrylamide gel electrophoresis (Native and SDS PAGE) 
The PAGE, and SDS-PAGE analysis results of insulin released from chitosan-zinc-
insulin complex containing delivery systems is presented in figures 46-48. Fresh insulin analyzed 
using native PAGE showed a band at 6 kDa, while a band near 12 kDa was observed due to the 
presence of mixture of insulin monomers and dimers. Similar Molecular weight bands at 6, and 
12 kDa were observed initially released samples (15 days) of insulin in native PAGE 
experiments implying the presence of dimers and monomers in the released insulin (figures 46A 
and 47). SDS-PAGE performed under non-reducing conditions showed the presence of single 
band corresponding to 6 kDa similar to fresh insulin (figures 46B and 48). Thus higher molecular 
weight products were dissociated in presence of SDS under non-reducing conditions. 
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Figure 46. Native PAGE (A) and SDS-PAGE (B) of insulin released during in vitro release 
(lane 1: fresh insulin, lane 2-5: insulin released from the polymeric formulation D, and lane 6-9 
insulin released from formulation H, at day 15, 30, 45 and 60, respectively) 
 
 
 
Figure 47. Native PAGE of insulin released from formulation K during in vitro release study 
(lane 1: molecular marker, lane 2: zinc-insulin, and lane 3-6: insulin released at day 1, 3, 7, and 
15, respectively) 
 
 
Figure 48. SDS-PAGE of insulin released from formulation K during in vitro release study 
(lane 1: molecular marker, lane 2: fresh insulin, lane 3: zinc-insulin, and lane 4-10: insulin 
released at day 1, 3, 7, 15, 30, 60 and 90, respectively) 
3.10.4.  High performance liquid chromatography (HPLC) 
The HPLC analysis results of fresh and released samples of insulin from polymeric 
formulations D and H are presented in figure 49. Freshly prepared insulin showed a single peak 
at retention time around 9.8 min. The insulin released from all formulations showed a major 
absorption peak at 9.8 min, without any major sign of degradation till 30 days. Some degradation 
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products were observed in the released samples indicated by the presence of absorption peak at 
4.8 min along with intact insulin after 45 days of incubation. The control insulin solution 
maintained at similar conditions showed a major peak of insulin at 9.8 min at day 7. A 
significant reduction in the peak height was observed after 15 days and no peak of intact insulin 
was detected after 30 days of incubation, indicating complete degradation of insulin.  
The HPLC analysis was also performed to determine the presence of any degradation 
products of insulin released from formulation K (60 mg insulin loading in the form of chitosan-
zinc-insulin complex). For fresh insulin the peak appeared at 9.8 min (retention time), and the 
released samples of insulin also showed similar peaks at 9.8 min without any degradation till 45 
days. Though very small peaks appeared near 5.2, and 5.6 min indicating some insulin might 
have degraded during release, a distinct peak at retention time 9.8 min showed that the most of 
the protein was in native form during release (figure 50).  
3.10.5.  MALDI-TOF mass spectroscopy 
MALDI-TOF mass spectrum of intact recombinant human insulin showed peaks at 5808 
m/z corresponding to single (+1) protonated insulin molecule (figure 51a). The control insulin 
solution withdrawn at day 15 exhibited a major peak at of 5808.480 m/z ratio along with some 
degradation products (figure 51b). No peak analogous to intact insulin was observed in 30 days 
sample suggesting that all protein was degraded (figure 51c). A small signal corresponding to 
cyclic imide product at ~5789 m/z was observed in one and two month’s released samples from 
formulations containing zinc-insulin (figures 51d and e). But the intensity of cyclic imide signal 
was increased in two month’s released sample of insulin as compared to formulation containing 
chitosan-zinc-insulin complex. A peak at 2905.828 m/z was observed in two months released 
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sample from formulation containing chitosan-zinc-insulin complex which might be due to the 
double (+2) protonated insulin molecules (figure 51g).  
 
 
Figure 49. Chemical stability of insulin by HPLC: chromatogram of fresh insulin (I), insulin 
control (insulin solution in PBS incubated at 37°C) (II), and insulin released from the polymeric 
formulations at 30 and 45 mg insulin loading (III) 
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Figure 50. HPLC chromatograms of fresh insulin (A), and insulin released from delivery system 
containing chitosan-zinc-insulin complex at 15, 30, 60 and 90 days (B-E) 
A peak at ~11685 m/z was also observed in the released sample of insulin from 
formulation A at day 30 (figure 51h). This could be due to the presence of a dimer of covalent 
[covalent insulin dimer (CID)] or non-covalent nature. Signal corresponding to dimer was found 
only at trace level in the released samples from formulation B moreover the data obtained 
confirmed that the monomeric form was predominant. 
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Figure 51. MALDI-TOF mass spectroscopy of fresh insulin (a), and insulin control at15 days (b), 
and 1 month (insulin solution maintained at 37°C) (c); insulin released from formulation 
containing zinc-insulin at 1 month (d) and 2 months (e); insulin released from formulation 
containing chitosan-zinc- insulin complex 1 month (f) and 2 months (g), and insulin released 
from polymeric formulation A at 1 month (30 and 45 mg insulin loading) (h) 
3.11.  Stability of Insulin in the Gel Depot During Release 
Insulin remaining in the gel depot during release was extracted using 1:1 (v/v) mixture of 
acetonitrile and PBS with a mild shaking and was analyzed for its stability. Figures 52 and 53 
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show respectively, the MALDI-TOF and HPLC analysis of insulin samples extracted from 
polymeric delivery system during release.  
 
Figure 52. MALDI-TOF mass spectroscopy of insulin extracted from polymeric formulations 
during release, 1 month (a) and 2 months (b) from formulation containing insulin alone; 1 month 
(c) and 2 months (d) from formulation containing zinc-insulin; and 1month (e) and 2 months (f) 
from formulation containing chitosan-zinc-insulin (30 and 45 mg insulin loading) 
 
Signals corresponding to some degradation products were observed in the extracted 
sample at 30 days from the formulation containing insulin alone during release (figure 52a). A 
signal corresponding to intact insulin at ~5808 m/z was observed from all samples, without the 
sign of degradation indicted the protecting effect of zinc as well as chitosan on insulin in the gel 
depot (figures 52b-f). HPLC results were in agreement with MALDI-TOF analysis (figure 53). 
Similarly the native PAGE experiments also showed a single band near 6 kDa for the insulin 
extracted from the gel depot (figure 54). 
109 
 
 
Figure 53. Chemical stability of insulin extracted from polymeric gel during release at 37°C 
determined by HPLC at 30 and 45 mg insulin loading 
 
 
Figure 54. Native PAGE (A) and SDS-PAGE (B) of insulin extracted from depot during release  
(lane 1: fresh insulin, lane 2-5: insulin extracted from polymeric formulation D, and lane 6-9 
insulin extracted from formulation H, at day 15, 30, 45 and 60) 
3.12.  Stability of Insulin in the Delivery System During Storage 
The effect of zinc and chitosan on the stability of insulin inside the polymeric delivery 
systems during storage at 4°C and 37°C was determined using MALDI-TOF and HPLC, and the 
results are presented in figures 55 and 56. The stability of insulin in presence of zinc and 
chitosan was compared with fresh insulin. Figure 55 (a-d) shows the MALDI-TOF and HPLC 
(figures 56 IV-V) results of insulin extracted from the polymer hydrogel at predetermined time 
points. A major peak corresponding to intact insulin was observed in all extracted samples. A 
single peak at 9.8 min in HPLC also confirmed the presence of intact insulin in the stored 
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samples. A single band at 6 kDa was observed in native PAGE experiments, also confirmed the 
structural preservation of insulin during storage at 4 and 37°C (figure 57 C-D). 
 
Figure 55. MALDI-TOF mass spectroscopy of insulin extracted from polymeric gel during 
storage, 1 month (a), and 2 months (b) at 37°C; and 1 month (c) and 2 months (d) stored at 4°C 
 
 
 
Figure 56. Chemical stability of insulin extracted from polymeric gel during storage determined 
by HPLC, insulin extracted from polymeric formulations stored at 4°C (I), and insulin extracted 
from polymeric formulations stored at 37°C (II) 
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Figure 57. Native (A) and SDS-PAGE (B) of insulin extracted from polymeric gel during storage 
(lane 1: fresh insulin, lane 2-5: insulin extracted from polymeric gel depot stored at 37°C, and 
lane 6-9 insulin extracted from polymeric gel depot stored at 4°C at day 15, 30, 45 and 60) 
3.13.  In Vivo Absorption and Bioactivity of Insulin 
The optimized formulations containing chitosan-zinc-insulin complex were selected for 
in vivo studies since they demonstrated a low initial burst release and controlled the release of 
insulin for longer duration during in vitro analysis. The formulations were injectable through 25 
G needle, and formed gel depot quickly after incubation at body temperature. The 
pharmacokinetic profile of insulin released from the delivery systems and associated 
pharmacodynamic effects are presented in figures 58-59. Additionally, the serum insulin 
concentration and blood glucose levels of untreated (control), and STZ treated animals are also 
presented. The fasting blood glucose level of untreated animals remained in between 90-125 
mg/dl throughout the study duration; while STZ treated rats showed fluctuating blood glucose 
levels between 300-550 mg/dl. 
3.13.1.  Comparison among the delivery systems at 30 IU/kg insulin loading 
The release profile of insulin and blood glucose levels of the rats treated with different 
formulations at 30 IU/kg insulin loading is presented in figure 58 A and B, respectively. The 
animals treated with the delivery system containing insulin alone showed highest initial burst 
release (52.1±7.6 µU/ml) followed by a continuous release over the period of 42 days, and 
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subsequent rapid reduction in insulin levels. In case of formulation containing zinc-insulin, 
though the initial burst release was reduced significantly (p<0.05) as compared to the 
formulation containing insulin alone, after ~14 days, an appreciable decline in the insulin level 
was observed, and the levels dropped continuously in 21-42 days. The delivery system 
containing chitosan-zinc-insulin complex showed significantly lower (P<0.05) initial burst 
release of insulin (11.4±2.1 µU/ml) as compared to the formulations containing insulin alone and 
zinc-insulin loaded delivery systems. Also, significantly higher (P<0.05) serum insulin levels 
were maintained for ~63 days, and then declined gradually over the period of 91 days. AUC was 
used to determine the bioavailability of insulin released, and is presented in table 16.  
Insulin bioavailability was enhanced in case of chitosan-zinc-insulin complex loaded 
delivery system, indicated by increase in AUC by 1.5 and 1.85 fold as compared to the 
formulations containing zinc-insulin and insulin alone, respectively. The physiological effects of 
released insulin denoted by reduction in blood glucose levels are depicted in figure 58B. The 
fasting blood glucose levels in rats administered with any of the delivery systems were 
significantly lower (p<0.05) than the diabetic rats in STZ treated group. In case of delivery 
systems containing insulin alone, and zinc-insulin it was observed that the blood glucose levels 
dropped suddenly in response to the large amount of insulin released and remained low until 21 
days, and then returned to pretreatment levels (~400 mg/dl) quickly. While, chitosan-zinc-insulin 
complex helped to maintain the blood glucose levels in the range of 100-150 mg/dl until ~63 
days. The blood glucose levels were significantly low as compared to the delivery systems 
containing insulin alone or zinc-insulin until 63 days suggesting that insulin was released slowly 
from the chitosan-zinc-insulin complex. 
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Figure 58. Serum human insulin (A), and blood glucose levels (B) of rats treated with (▲) 
insulin alone, (■) zinc-insulin, (●) chitosan-zinc-insulin complex loaded thermosensitive 
polymeric delivery systems, (×) streptozotocin control, and (♦) untreated control; (insulin 
loading; 30 IU/kg) (n=6, mean ± SD, *: significantly different than insulin alone, and #: 
significantly different than zinc-insulin at P<0.05) 
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3.13.2. Comparison among the delivery systems at 45 IU/kg insulin loading 
The in vivo release profile of insulin released, and blood glucose levels of rats treated 
with the delivery system containing insulin alone, zinc-insulin, and chitosan-zinc-insulin 
complex at 45 IU/kg insulin loading are presented in figure 59 A and B, respectively. The serum 
insulin levels of animals treated with the delivery system containing chitosan-zinc-insulin 
complex were significantly different (P<0.05) as compared to that of insulin alone, and zinc-
insulin. Serum insulin levels were maintained above 40 µU/ml over 70 days before gradually 
returning to baseline levels. Increase in insulin AUC by 1.3 and 2 fold was noticed as compared 
to zinc-insulin, and insulin alone containing formulations.  
The pharmacodynamic response reflected the pharmacokinetic profile of released insulin 
in that reduction in blood glucose was observed until ~70 days, and as the insulin release was 
reduced, blood glucose levels increased and reached to the pretreatment levels. Animals treated 
with insulin alone or zinc-insulin containing delivery systems showed a sharp drop in insulin 
levels after ~10 and 16 days, respectively. In the case of formulations containing chitosan-zinc 
insulin complex, the fasting blood glucose levels remained significantly (P<0.05) low until ~70 
days as compared to insulin alone, or zinc-insulin containing formulations. The blood glucose 
levels were comparable to that of control (untreated group) up to 63 days, and then increased 
gradually. 
For comparing the insulin release and blood glucose levels, insulin solution (2 IU/Kg in 
PBS) was administered to the diabetic rats via SC route, and the blood glucose and serum insulin 
levels were measured at 0.5, 1, 2, 4, 6, 8, 12 and 24 h post-injection. Immediately after 
subcutaneous administration, serum insulin levels increased rapidly, and the data showed values 
of Cmax and Tmax of 55.75±6.4 µU/ml and 1 h, respectively (figure 60A). Corresponding sudden 
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decline in blood glucose levels was noticed, and reached to ~20% of the pre-administration 
levels within 1 h (figure 60B). Insulin levels reduced over the period of 12 h, and reached below 
the detection limit. Similarly, blood glucose reached to the pretreatment levels after 12 h. 
 
 
Figure 59. Serum human insulin (A) and blood glucose levels (B) of rats treated with (▲) insulin 
alone, (■) zinc-insulin, (●) chitosan-zinc-insulin complex loaded thermosensitive polymeric 
delivery systems, (×) streptozotocin control, and (♦) untreated control; (insulin loading; 45 
IU/kg) (n=6, mean ± SD, *: significantly different than insulin alone, and #: significantly 
different than zinc-insulin at P<0.05) 
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Table 16. In vivo pharmacokinetic parameters of insulin in rats 
Treatment groups Insulin 
dose 
(IU/kg) 
AUC(0-t)  
(µU.day/ml) 
Fold increase in 
AUC compared 
to insulin alone 
Fold increase in 
AUC compared 
to zinc-insulin 
Insulin alone 30 1481.36±105.6 --- --- 
Zinc-insulin 30 1886.68±92.2 1.27 --- 
Chitosan-zinc-insulin 30 2733.08±103.8 1.85 1.5 
Insulin alone 45 1686.79±93.8 --- --- 
Zinc-insulin 45 2073.58±110.1 1.23 --- 
Chitosan-zinc-insulin 45 3458.79±153.3 2.1 1.3 
(Mean ± SD, n=6, t: 90 days for polymeric delivery systems; Solution group (Insulin dispersed in 
PBS, injected via SC route), Cmax, Tmax, and AUC0-t for solution group: 55.75±6.4 µU/ml, 1 h, 
and 6.18±0.35 µU.day/ml, respectively) 
3.13.3.  Body weight determination 
Initially after STZ injection a marked reduction in the body weight of rats was observed 
in all treatment groups. The STZ treatment group showed continuous loss of body weight at the 
end of three months (figures 61, and 62). The rats treated with insulin formulations showed a 
gradual weight gain, and was significantly (P<0.05) higher than STZ treated animals. Though 
there was no significant difference observed in the body weights of rats in either of the treatment 
groups, the chitosan-zinc-insulin complex treated animals showed progressive weight gain and 
were comparable to that of non-diabetic control. 
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Figure 60. Serum insulin concentration (A), and blood glucose levels (B) of rats treated with 
insulin solution (2 IU/kg, in PBS pH 7.4 via subcutaneous route, (n=6, mean ± SD)) 
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Figure 61. Body weight profile of rats in (●) control (untreated) group, and treated with (■) 
streptozotocin (n=6, mean ± SD), (Inset shows the reduction in body weight after STZ treatment) 
3.13.4. Detection of anti-insulin (rH) antibodies 
The rat serum samples collected at 1, 2 and 3 month time points were screened for the 
presence of antibodies against insulin released from the delivery systems, and it was observed 
that no antibodies against human insulin (rH) were developed (figure 63). For comparison 
purposes, rat IgG were used as control. No antibodies were observed against released insulin 
initially or after 90 days of treatment and the antibody response was comparable to that of 
control (untreated) group. It indicated that the released insulin was non-immunogenic in nature. 
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Figure 62. Body weight profile of rats treated with (♦) insulin alone, (■) zinc-insulin, and (●) 
chitosan-zinc-insulin incorporated thermosensitive polymeric delivery systems  
(Insulin dose: A) 30 IU/kg, and B) 45 IU/kg, n=6, mean ± SD) 
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Figure 63. Detection of anti-insulin (rH) antibodies in rat serum treated with formulations at 
different insulin dosing 
3.14. Biocompatibility of the Delivery Systems 
The in vitro and in vivo biocompatibility studies of the delivery systems performed using 
an MTT assay, and skin histological analysis is discussed in following sections. 
3.14.1. In vitro biocompatibility of the delivery systems 
Figure 64 shows the cell viability quantitatively measured by an MTT assay for 
thermosensitive polymeric delivery system with and without chitosan incubated at 37 and 70°C, 
respectively for 10 days. It was observed that the HEK293 cells grew better in the extracts 
prepared from chitosan containing thermosensitive delivery systems than unmodified 
(thermosensitive polymer only), and PBS, or DMSO treated cells (Figure 65). Initially, at 24 h 
the cell viability was ~60-80% for the concentrated polymeric extracts (1:1 dilution with growth 
medium), while the extracts diluted to 1:16 ratio showed close to 100% cell growth. At 48 and 
72 h, no significant difference (p>0.05) in the cell viability was observed as compared to control 
(growth medium only), and instead the polymeric delivery system containing chitosan showed 
higher cell viability as compared to the cells treated with polymeric extracts without chitosan. 
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Figure 64. In vitro biocompatibility of the delivery systems containing chitosan + 
thermosensitive polymer extracts prepared by incubating the delivery systems for 10 days, 37°C 
(A), and 70°C (B), and thermosensitive polymer only at 37°C (C), and 70°C (D) 
 
 
 
Figure 65. In vitro biocompatibility of chitosan, DMSO, and PBS extracts prepared by 
incubating for 10 days at 37°C (A-C), and 70°C (D-F), determined by MTT cell viability assay  
(n=6, mean ± SD) 
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3.14.2. In vivo biocompatibility of the delivery systems 
Figures 66 and 67 represent the in vivo biocompatibility analysis of the polymeric 
delivery systems with and without chitosan. The rats were injected with the polymeric delivery 
systems containing chitosan, and the inflammatory response to the foreign material was 
observed, and compared to that of control (untreated), and is presented in figure 66. Histology of 
untreated skin (control group) is presented in figure 66A. The representative light microscopy 
images of skin following administration of chitosan containing thermosensitive polymeric 
delivery system at 1, 7, 30 and 90 days is shown in figure 66B-E. 
The severity of the response to the foreign material was observed by the presence of 
leukocytes and fibroblasts near the site of injection. The nuclei of the neutrophils or other 
inflammatory cells are stained purple after H & E staining, and thus can be easily identified from 
the surrounding connective tissue. Figures 66 B and C represent the clear incidence of acute 
inflammatory response to the polymeric delivery system containing chitosan, at day 1 and 7, 
respectively. Large neutrophil infiltration at the site of injection was observed initially. Chronic 
inflammatory response to the delivery system at day 30 is depicted in figure 66D. However, this 
response subsided considerably 30 days post-injection, indicated by the presence of few 
inflammatory cells, and the skin tissue surrounding the delivery system closely resembled to that 
of control at 90 days (figure 66E). 
Similar type of inflammatory behavior was observed in case of rats treated with only 
thermosensitive polymeric delivery system without chitosan as presented in figure 67 (A-D). 
Thus, it was noticed that the subcutaneous administration of polymeric delivery systems 
with/without chitosan showed an inflammatory response due to injection and continual presence 
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of polymeric gel in the body. But, at the end of the study no signs of chronic inflammation, or 
necrosis were observed. 
   
   
 
Figure 66. Light micrographs of rat skin histology after H and E staining: control (A); and 
subcutaneous skin tissue sampled after injecting the delivery systems containing chitosan + 
thermosensitive polymer at day 1 (B), day 7 (C), day 30 (D) and day 90 (E) 
 
A B 
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E 
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Figure 67. Light micrographs of rat skin histology after H and E staining: the subcutaneous skin 
tissue sampled after injecting the delivery system containing thermosensitive polymer only: 
day 1 (A), day 7 (B), day 30 (C), and day 90 (D) 
 
To determine the degree of collagen deposition at the tissue-delivery system interface, the 
skin samples were also stained with Gomori’s trichome stain which specifically stains collagen 
(figures 68A-C). The collagen density determined by ImageJ 1.45 software showed that the 
collagen deposition increased until 30 days (figure 68B), but was comparable to the control at the 
end of the study (90 days) (figure 68C). The skin histology of animals treated with 
thermosensitive polymer (without chitosan), is presented in supplementary information (figures 
69 A-B). The results indicate that the addition of chitosan did not change the biocompatible 
nature of the thermosensitive polymeric delivery system. 
B 
C D 
A 
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Figure 68. Light micrographs of rat skin histology after staining with Gomori’s trichrome stain: 
control (A); and skin subcutaneous tissue sampled after injecting the delivery systems containing 
chitosan + thermosensitive polymer at day 30 (B), and day 90 (C) 
 
     
Figure 69. Light micrographs of rat skin histology after staining with Gomori’s trichrome stain: 
skin subcutaneous tissue sampled after injecting the delivery system containing thermosensitive 
polymer: day 30 (A), and day 90 (B) 
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4. DISCUSSION 
4.1. Synthesis, Characterization of Triblock Copolymer and Factors Affecting Polymer 
Degradation 
The development of controlled delivery systems primarily focuses on the release of 
therapeutics at a constant rate in order to achieve and maintain the desired therapeutic level for 
prolonged period. The drug release from polymeric delivery system occurs via diffusion of 
incorporated molecule or degradation of polymer matrix or by combination of both (216). 
Typically the initial phase is diffusion-controlled while later stage is both diffusion and polymer 
degradation controlled (217). High water solubility and small size of incorporated drug, as well 
as highly porous microstructure, low degree of crosslinking and increased swelling of polymer 
are some factors which increase the diffusion of drug out from the polymer matrix. While the 
proportion of hydrophobic/hydrophilic components of polymer influence its degradation rate. 
Due to the high water content/retention, in situ gel forming delivery systems are considered ideal 
for entrapment of variety of macromolecules and extensively studied in biomedical field. The 
important characteristic of polymer hydrogels is their ability to absorb water, and it constitutes at 
least 10% of the total weight of a hydrogel (218). The water retention and swelling properties 
provide a suitable pathway for diffusion of incorporated molecules (219). It has been observed 
that the swelling of polymer hydrogel depends on the hydrophobic/hydrophilic content of the 
polymer. Higher degree of swelling was observed in case of PLA-PEO-PLA polymer gels with 
higher PEG content or lower LA/EG ratio (220). Water absorption and retention capacity of the 
degradable polymer, however, reduces eventually due to the loss of the polymer chains over the 
period of time. Similar findings have been reported in case of a thermosensitive polymer 
containing poly (N-(2-hydroxypropyl) methylacrylamide lactate (pHPMAm-lac), and PEG 
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blocks (30). The delivery systems containing copolymer (1500-1500-1500) and (1600-1500-
1600) exhibited a zero-order release kinetics for the incorporated model protein which is highly 
desired for controlled delivery systems (84). In our studies, the degradation profile of PLA-PEG-
PLA triblock copolymer was investigated in detail and the effect of various molecules on 
degradation behavior and in vitro release pattern was also evaluated. Two thermosensitive 
triblock copolymers with 1500-1500-1500 (copolymer A), and 1600-1500-1600 (copolymer B) 
chain lengths were synthesized by the ring opening polymerization of D, L lactide, catalyzed by 
stannous octoate, using polyethylene glycol (PEG 1500 Da) as an initiator. 
The proton and 13C NMR spectroscopy results confirmed the structure of the synthesized 
copolymers. Integrating the proton NMR signals helped in molecular weight determination. The 
chromatogram from GPC analysis showed unimodal distribution, and the polydispersity index 
indicated the narrow molecular weight distribution, showing the sufficient purity of the 
synthesized copolymers. The aqueous copolymeric solutions of PLA-PEG-PLA showed 
concentration dependent sol-gel transition in response to changes in temperature. The copolymer 
consists of both hydrophobic and hydrophilic residues and the gelation takes place due to the 
aggregation of micelles in response to temperature. Increasing polymer concentration causes 
increase in aggregation of micelles, leading to gelation at lower temperatures due to packing of 
aggregated micelles. Increasing hydrophobicity of the copolymer reduces its LCST and increases 
UCST (84), and therefore aqueous copolymer solutions containing higher number of PLA units, 
showed gelation at lower temperature and concentration. It indicated that polymer concentration 
in the delivery system is an important factor which alters its physical state. The aqueous 
solutions of both copolymers at a concentration of 30% and 40% w/w existed in sol state with 
sufficiently low viscosity at room temperature, and passed through 25 G needle easily.  
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The cryo-SEM images of the polymeric delivery system maintained at room temperature 
and body temperature showed a noticeable difference in their morphologies. The delivery system 
maintained at room temperature did not show any particular three dimensional surface 
characteristics, but the freshly cut surface of the delivery system maintained at body temperature 
showed presence of two distinct domains. The polymer-rich area (white area) was observed 
showing the presence of polymer network, and dark area was seen in which no structure was 
observed (water filled pores). The results suggested that the delivery system showed a distinct 
temperature dependent phase separation. 
The weight loss measurements during hydrolytic degradation of copolymers A and B 
showed that the copolymer with higher PLA chain length took more time to degrade than 
copolymer with smaller chains. It was also noted that increasing copolymer concentration in the 
delivery system (40%w/w) reduced the rate of degradation and was significantly (P<0.05) 
different from the delivery system containing 30% w/w copolymer. But, both the delivery 
systems showed similar degradation rate after ~50 days onwards. The results suggest that higher 
polymer concentration resulted in tighter connection between polymer chains which reduced the 
pore size of hydrogel matrix. This might have led to the formation of less water accessible pores 
during initial period of degradation, which could have decreased the water exposure, and chain 
mobility, and thereby degradation of copolymer B. The reduce speed of degradation could help 
in extending the overall release period of the incorporated molecules. As the polymer degraded, 
bigger pores were formed in the gel network resulting in absorption of more water.  
PLA-PEG-PLA copolymer contains two different sites where hydrolysis can takes place, 
namely, ester bonds within PEG segments, and another is in LA segments. During degradation of 
the ester bonds, PLA and PEG undergo hydrolysis randomly along the chain as well as by chain 
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unzipping process (cleavage of end unit of the chain). However, which end group of the PLA 
segment (carboxylic or hydroxyl end) degrades faster than internal bonds is still not well 
understood (221). The studies in case of similar polyester, PLGA, indicated that the degradation 
occurs by similar processes including i) random scission of chain, ii) chain unzipping process, 
and iii) complete solubilization of degradation products (222-224). The copolymer A and B 
containing delivery systems did not show any significant change in LA/EG ratio over the period 
of 45 days, and hence it was difficult to determine the specific degradation/hydrolysis sites. The 
results also indicated that increasing polymer concentration did not significantly affect the 
LA/EG ratio. A rapid loss of EG fraction, with a gradual and slow hydrolysis of LA segments 
was observed as the time proceeded. Random scission and hydrolysis of internal bonds in both 
PLA and PEG chains might have occurred leading to increased mobility and loss of PEG 
segments from the pores of the hydrogel. Thus, due to the loss of hydrophilic content, the 
polymer gel became more opaque in appearance. This preferential loss of PEG segments along 
with loss of molecular weight might have resulted in loss of overall strength of the gel over time 
(225). Our results were in agreement with the previous studies reporting that the preferential 
diffusion of a significant amount of hydrophilic PEG rich blocks from the thermosensitive PLA-
PEG-PLA copolymer based gel results in the formation of an opaque gel (226). 
GPC helped in determining the change in molecular weight of copolymer during 
hydrolytic degradation. The initial chromatogram for copolymer A showed unimodal distribution 
with a bell-shaped peak. This single peak was attributed to the similar molecular weight (MW) of 
the copolymer. But, as the degradation proceeded, a slight increase in RT, and a bimodal peak in 
GPC chromatogram suggested that the polymer might have degraded into smaller chains. This 
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point onwards, the bimodal distribution increased with reduction in MWs illustrated by increased 
RT.  
4.2. Effect of Drug Type on Polymer Degradation and In Vitro Release 
The factors affecting in vitro release of two model proteins including lysozyme and 
insulin from thermosensitive PLA-PEG-PLA polymer based delivery systems were investigated 
by Al-Tahami K (84). Increasing polymer concentration, molecular weight, and chain length of 
PLA residues reduced the release rate of proteins from the delivery systems. The polymeric 
delivery systems containing shorter PLA chains even at increasing polymer concentrations did 
not show any significant difference in the release profile of lysozyme. The result suggested that 
though increasing copolymer concentration often results in reduction of release rate, higher 
amount of short PLA chains did not improved the hydrophobicity of copolymer and hence did 
not alter the release profile (84). Similar type of behavior is reported in case of ketoprofen 
release from polymeric hydrogels (217). It suggests that the drug release from the delivery 
system also depends on some additional factors, such as size of hydrogel, pore size, polymer 
degradation, amount and nature of incorporated molecules, and interaction between incorporated 
molecule and hydrogel matrix.  
In our studies, the in vitro drug release behavior of three model drug molecules namely, 
insulin, BSA and risperidone from the PLA-PEG-PLA (copolymer A) was studied in detail. 
Since these three molecules differ in their solubility and hydrophobicity, their distribution in the 
copolymeric delivery system differs. PLA-PEG-PLA forms micelles in aqueous environment 
with hydrophilic PEG facing the aqueous phase forming ‘shell’ and hydrophobic PLA forms the 
‘core’ region. Due to the core-shell structure the partitioning of drug molecules depends on their 
hydrophobicity and results into different release profiles. Hydrophobic drug usually partitions 
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into micellar core and results in sustained release (217). Therefore, along with the polymer 
structure and concentration, the release profile also depends on the physical and chemical 
properties of the incorporated molecule.  
The size of protein is another key factor affecting its release from the porous hydrogel. 
Larger protein is supposed to be released slowly than smaller protein, because it takes more time 
for larger molecule to diffuse out through the narrow interconnected channels of the hydrogel 
matrix (227). BSA is an ellipsoid protein with ~66400 Da molecular weight, while insulin is a 
small protein (~6000 Da), and hence, BSA should be released slower than insulin; however, it 
was observed that the release of BSA was much faster than insulin (128,228). Water solubility is 
another feature which influences the release pattern and duration of various molecules. 
Molecules with high water solubility show immediate release from the hydrogel probably due to 
faster dissolution and diffusion from the delivery system. BSA has high water solubility 
(aqueous solubility: ~40 mg/ml) (228), while risperidone is a small hydrophobic molecule 
(molecular formula: C23H27FN4O2) with very low water solubility about 2.8 µg/ml (229). Insulin 
also has limited solubility at neutral pH (~0.1 mg/ml), and addition of zinc further reduces its 
solubility (2). Our studies indicated that BSA showed highest initial burst release and released 
over shorter duration, followed by insulin and risperidone. But, once polymer degradation 
became predominant, larger pores were formed in the hydrogel resulting in widening the 
channels leading to increased release irrespective of the size of the molecule. Still, the release 
rate for risperidone was much lower which was exclusively contributed to its high 
hydrophobicity. Sandor et al., (230) reported that the delivery systems containing larger proteins 
form larger pores on the surface which allows initial dissolution of protein aggregates present on 
the surface. The polymeric delivery system consisting of BSA (large hydrophilic protein, ~66400 
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Da) might have formed larger channels near the surface during initial release, which led to rapid 
penetration of water molecules inside the gel. Interconnecting channels formation and/solvation 
of protein in the previously formed channels within the polymer matrix along with the water 
penetration enhances polymer degradation (230). All these combined effects might have resulted 
in the faster release of BSA. Since the delivery systems containing a smaller protein (Insulin~ 
5808 Da), and a hydrophobic molecule (Risperidone, 410 Da) formed smaller channels in the gel 
matrix, they got entrapped in the polymer matrix resulting in low initial burst release and 
prolonged release duration. Though the delivery system containing small protein forms higher 
percentage of small pores, this type of structure entraps protein within the delivery system due to 
the collapsing of channels (230). Some additional factors, such as affinity of protein for polymer 
due to ionic and hydrophobic interactions, charge on protein at physiological pH, and polymer 
degradation/erosion can also play an important role in protein release from the polymeric 
delivery systems (231). 
The in vitro release studies demonstrated that the release of large hydrophilic protein 
from the delivery system led to increased water uptake resulting in faster degradation of polymer 
matrix. BSA containing delivery systems showed significantly (P<0.05) higher LA/EG ratio after 
30 days of degradation than that of initial, indicating preferential loss of hydrophilic PEG 
segments. The residual polymer appearance was visually compared and it was observed that the 
blank polymeric delivery system appeared more solid, while the drug loaded delivery systems 
appeared more porous. The rate of degradation of delivery system was also faster in case of BSA 
formulations than that of insulin and risperidone. The type of drug incorporated in the delivery 
system can alter the mechanism of polymer degradation (232). The effect of six different drugs 
on the release profile and degradation of polylactic-co-glycolic acid (PLGA) polymer pellets was 
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investigated, and it is reported that rate of polymer degradation and the drug release pattern were 
significantly different for those molecules, and the type of drug incorporated influences the 
mechanism of polymer degradation (232). Incorporation of a cationic copolymer, chitosan in the 
delivery system also affected the degradation rate of the delivery system. The results suggested 
that due to the excellent buffering ability of chitosan, it resisted the change in the pH of the 
release medium for longer duration and might have resulted in reduction in acid-catalyzed 
degradation of copolymer chains. 
The GPC results also indicated that BSA containing delivery system showed rapid 
reduction in in molecular weight of the copolymer, and at the end of 60 days most of the polymer 
was hydrolyzed into smaller segments indicated by corresponding increase in RT. At the end of 
90 days period no peak corresponding to original polymer was detected. SEM studies showed 
that the BSA containing delivery system appeared more porous, indicating that the polymer 
degradation took place faster in presence of large hydrophilic protein. A striking difference in the 
porous morphologies of the delivery systems was seen during release of risperidone, BSA or 
insulin. The results also suggested that the hydrophobic nature and solubility of the incorporated 
molecule considerably affected the porous structure of the hydrogel. BSA loaded delivery 
systems showed presence of large pores on the surface which suggested that BSA might have 
escaped easily from the gel creating bigger, open, water accessible pores as compared to 
risperidone and insulin. 
4.3. In Vitro Release of Insulin from Thermosensitive Polymeric Delivery Systems 
To achieve zero-order release kinetics from the delivery system capable of delivering a 
therapeutic agent regardless of its concentration over extended period is a challenging task. 
Usually a characteristic phenomenon of ‘burst release’ observed often shortens the lifetime of 
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delivery system. Also it is difficult to maintain the constant release rate as the drug in the 
delivery system depletes. Especially in case of insulin which has a narrow therapeutic window, 
high initial burst release is not favorable since it leads to high drug concentrations near or above 
toxic levels in vivo. The scope of our work was to determine the effect of various formulation 
factors on release profile of insulin from thermosensitive delivery system and, ultimately, 
optimize the delivery system which could deliver insulin at basal level over extended period with 
no or minimal initial burst. Since this was the most promising copolymer in terms of release 
period and rate as reported by Al-Tahami (84) it was further used to study the release profiles of 
various molecules. The thermosensitive PLA-PEG-PLA copolymer was used as the delivery 
system and was optimized to deliver insulin at basal level for three months in its 
conformationally and chemically stable and biologically active form. It has been demonstrated 
that increasing copolymer concentration in the delivery system from 30 to 40% w/w led to 
reduced initial burst and extended the release of insulin. The insulin loading also governed the 
overall release profile and affected the initial burst release (84). We observed in our initial 
studies that though higher copolymer concentration controlled the release for longer period, it did 
not significantly affect the initial burst release at higher insulin loading. The results indicated the 
importance of protein loading on the release profile. It was obvious to observe higher initial burst 
release with increasing insulin loading in the delivery system which is mainly attributed to the 
presence of higher amount of unassociated insulin on the surface of the delivery system. With 
increasing polymer concentration the secondary burst release of insulin was reduced showing 
that smaller pores/channels could have formed in the delivery system at higher polymer 
concentration. These smaller channels possibly occluded the pathway of entrapped insulin 
molecules and reduced their escape from the polymer matrix. There are number of reasons which 
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could affect the secondary burst release of insulin. All formulations showed secondary burst 
release which may be due to the degradation of polymer matrix, leading to increased size of the 
pores/channels formed or because of increased solubility of insulin inside the polymer matrix 
due to development of acidic conditions. In case of formulation containing insulin alone the 
faster release of insulin during initial phase could form larger pores and channels in the polymer 
matrix that are more release medium accessible. Therefore it would increase the diffusion of 
insulin from the delivery system release duration than expected (233).  
Almost all formulations showed slow and incomplete release of insulin at the end stage 
and a significant amount of insulin remained in the delivery system. As described earlier 
formation of acidic degradation products of PLA may be one of the reasons for incomplete 
release (234, 235). Other reason could be due to the irreversible aggregation, precipitation, 
and/or degradation of insulin in the formulation or during release that made it unavailable for 
release. Incomplete release may also be attributed to the protein adsorption onto the surface of 
degrading delivery system, or due to the ionic interactions between the protein and charged end 
groups in the polymer, which can lead to many problems related with protein instability (236). 
Sluzky et al., (237) have highlighted the importance of mechanical stress on insulin aggregation, 
and showed that agitation and hydrophobic surfaces lead to insulin aggregation in the 
formulation. Insulin fibril formation could be one of the reasons of its aggregation and 
precipitation. The main driving force of for fibril formation is the exposure of hydrophobic 
surfaces, and formation of β-sheets which stabilize the fibril structure. For the initiation of fibril 
formation and aggregation, the dissociation of insulin hexamers/dimers into monomers is 
necessary. When a large portion of insulin is in the form of hexamers or in oligomeric state, the 
effective surface available for unfolding of monomers and hydrophobic interaction is very low. 
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Zinc is a well-known divalent cation used to stabilize the insulin hexameric assembly, and can be 
used to reduce dissociation of insulin oligomers which in turn avoid the exposure of hydrophobic 
surfaces leading to inhibition of fibril formation/aggregation (238). In our body zinc ions also 
control the biosynthesis and storage of insulin in the crystal form in pancreatic beta cells, and 
help preventing its degradation within the storage vesicle.(239) Zinc has been used to control the 
insulin release from various formulations including polyanhydride, PLGA microspheres and 
ethylene-vinyl acetate copolymer matrix (2,3,240,241). Addition of zinc to insulin helped to 
reduce the initial burst release and controlled the release of insulin from the PLA-PEG-PLA 
copolymer based delivery system (84). Being small (Mw: 5808 Da) and high water solubility, 
monomeric insulin can easily diffuse through the pores/channels of the polymer matrix leading 
to high initial burst. Formation of zinc-insulin hexamer reduces its water solubility, increases its 
size and hence reduces its diffusion from the porous polymer matrix. Zinc imparts stability to 
insulin but as the amount of insulin depletes in the delivery system, zinc dissociates and diffuses 
out, leading to the dissociation of hexamers and dimers into monomers. Thus, in attempt to 
improve the release profile of insulin at higher loading and to improve its stability, zinc was 
added to the formulations (5:1 zinc ions: insulin hexamer). Our preliminary studies showed that 
addition of zinc (5:1 zinc: insulin hexamer) helped to control the release of insulin for longer 
duration from the thermosensitive polymeric delivery system as compared to insulin alone, and 
helped to decrease the initial burst release. But it did not significantly reduce the initial burst 
release as the insulin loading was increased. Additionally, the delivery system did not release the 
incorporated protein completely and about 20-25% of the total insulin loading remained in the 
delivery system at the end of release period. The incomplete release could be due to the highly 
compact nature of hexamers which might have precipitated and did not release out.  
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It is very important for a suitable controlled delivery system to be able to release protein 
in its conformationally and chemically stable and biologically active form, since protein can be 
easily destabilized during formulation processes. Structural deformation is one of the reasons for 
the loss of protein's activity and incomplete release. For proper biological response, the tertiary, 
secondary, as well as primary structure of the protein has to be maintained. Therefore, it is 
important to examine the stability of proteins released from the polymeric delivery systems. 
Hence the effect of zinc addition on stability of insulin at higher insulin loading was also 
evaluated. Our preliminary studies showed that the pH of the release medium dropped after 30 
days of in vitro release, and the internal pH within the hydrogel might be more acidic than the 
releasing medium. Insulin is a very fragile molecule and undergoes degradation or aggregation 
due to moisture and the acidic environment created by the degradation products of polymer 
during release. Various analytical techniques were utilized to evaluate the stability of the 
released insulin from the delivery systems containing zinc-insulin. CD studies provided valuable 
information about the secondary and tertiary structure of insulin released from the delivery 
systems. CD spectra of released insulin in far UV region showed the presence of two minima due 
to the major contribution of α helix, and indicated that the secondary structure of insulin was 
preserved. But after ~42 days, an increase in random coils and reduction in α-helix and β-sheets 
was observed indicating the loss of secondary structure of insulin released. This reduction can be 
explained on the basis of an additional time gap between the actual insulin release from the 
delivery system and the sampling period. Marked increase in tyrosyl signal was observed in all 
released samples of insulin initially in near UV-CD region, and this spectrum provided some 
helpful information about the aggregation state of insulin (tyrosyl signal intensity). The 
hexameric form of insulin shows highest negative intensity, while monomer intensity is least 
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negative in near UV region (242). Tyrosyl contributes about 50-85% of the near UV-CD signal 
and increased tyrosyl signal intensity indicates the presence of insulin hexamer/dimers. Along 
with tyrosine residues, disulfide bridges also contribute to the near UV-CD signal, but the exact 
contribution and the proportions are difficult to determine experimentally (242). Tyrosyl signal 
intensity reduced eventually and two months released samples showed marked decrease in the 
signal intensity as compared to fresh insulin indicating loss of its tertiary structure.  
Insulin is a small protein with molecular weight of 6 kDa, and has a tendency to self-
associate to form oligomers. The presence of higher ordered structures in native PAGE indicated 
that the released insulin was in the form of mixture containing monomers, dimers and hexamers. 
SDS-PAGE under non-reducing conditions was performed to dissociate non-covalent aggregates 
of insulin. Under non-reducing conditions a single band corresponding to native insulin was 
observed in SDS-PAGE experiments. These results helped to conclude that the higher ordered 
aggregates detected in native PAGE analysis were non-covalent and there was no aggregation of 
insulin during formulation and release. Similarly no additional bands below 6 kDa during native 
and SDS-PAGE indicated that insulin did not undergo degradation during formulation. As 
mentioned earlier, there are number of factors which could affect the chemical stability of insulin 
during release from the polymeric depots.  
Insulin is susceptible to several chemical modifications which could alter its primary 
structure and its biological activity. When the peptide/protein is encapsulated inside the poly 
(lactic-co-glycolic acid) (PLGA) copolymer matrix the most common reactions that can occur 
are, deamidation, acylation and peptide bond cleavage. The acylation products can be observed 
due to the reactions between polymer and peptide under neutral pH and low moisture content 
(243). The results of MALDI-TOF MS analysis showed that the primary structural integrity of 
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insulin was conserved in the released samples without any major degradation products till one 
month release period. A very small peak corresponding to a split product was observed which 
might be due to the double (+2) protonated insulin molecule. Some degradation products were 
detected in the released samples after two months which were difficult to identify. They could 
have formed due to the prolonged time gap between the actual release and sampling, or due to 
the acidic microenvironment due to polymer degradation. Another reason could be due to 
degradation of insulin in the delivery system. But a peak corresponding to intact insulin at ~5808 
Da indicated that the primary structure of insulin was conserved. The stability studies suggested 
that some degradation/aggregation products of inulin were formed during in vitro release even in 
presence of zinc indicating that zinc alone is not sufficient to stabilize insulin in the polymeric 
delivery system.  
To reduce the initial burst release from the delivery system, insulin should be made 
unavailable for immediate diffusion after placement of the delivery system in the release 
medium. Most importantly, the rate of insulin diffusion through the polymer matrix should be 
controlled. In order to reduce the initial diffusion of insulin monomers from the polymeric 
delivery system, chitosan-zinc-insulin complexes were prepared. The electrostatic interaction 
between chitosan and insulin is weak in nature, but can help to reduce the diffusion of protein 
from the polymeric hydrogel matrix by increasing its size. Since chitosan is also known to 
stabilize proteins, the complex will also help to stabilize insulin in the delivery system during 
release. It was observed that the complexes were formed at optimized pH conditions. The 
essential factors such as stability of insulin in presence of chitosan, complex formation and its 
dissociation were evaluated. It was noted that the chitosan-zinc-insulin complex formation took 
place in the pH range of 6.5-6.8. The entrapment efficiency of complex was found to be ~70-
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76%. Gel retardation assay confirmed that chitosan and insulin form stable complexes since most 
of the protein was retained in the gel well during native PAGE analysis. The results also showed 
that the complex formation between zinc-insulin and chitosan was influenced by the amount of 
chitosan present in the system. The complex formed was weak in nature and dissociated very 
easily in the presence of an anionic surfactant SDS, and released insulin preserved its structural 
integrity. Fluorescence, Circular Dichroism spectroscopy and Differential Scanning Calorimetry 
helped to determine the structural integrity of insulin in presence of chitosan during complex 
formation. The fluorescence property of the proteins can give some information regarding the 
molecular environment of the protein. The aromatic residues like tryptophan and tyrosine 
dominate the fluorescence property of a protein, and any change in this gives the information 
about their environment (244). Since insulin does not contain any tryptophan residues, the 
fluorescence signal is solely affected by the presence of tyrosine and phenylalanine residues on 
the surface which contribute towards oligomer formation. The interaction between chitosan and 
hemoglobin was studied by fluorescence spectroscopy. There was no shift in the intrinsic 
fluorescence property of hemoglobin after addition of chitosan. These results indicate the 
partially reversible nature of the interaction (244). Our studies also demonstrated that the 
fluorescence property of insulin (tyrosine/phenylalanine fluorescence) did not alter after addition 
of increasing chitosan amounts. It also supports our observation that the interaction between 
chitosan and insulin is very weak and does not change the tertiary structure of insulin. We 
observed a small change in the secondary structure of insulin which could be due to hydrophobic 
interactions or hydrogen bonding between chitosan and insulin at increasing chitosan amount. 
The results of CD analysis also confirmed that chitosan did not alter the secondary structure of 
insulin in the concentration range used in this study. DSC helped to determine the stability of 
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insulin in dilute solution by analyzing the changes in its midpoint of transition (Tm). The change 
in ∆H and Tm of a compound eventually reflects its ability to absorb heat in response to gradual 
increase in temperature. It has been reported that addition of divalent cations help to stabilize 
insulin by neutralizing the charges at the center of insulin hexamer and which increases its Tm 
(2,3,84). The effect of different ligands like phenol, m-cresol, resorcinol, at various zinc 
concentrations on the stability of insulin has also been evaluated by DSC, and it was observed 
that these compounds helped to stabilize zinc-insulin hexamers (245). Our results showed that 
addition of chitosan has further stabilized the zinc-insulin hexameric assembly as indicated by 
increased thermal stability (i.e., Tm and ∆H values) in comparison to the zinc-insulin. The 
increase in Tm compared to chitosan-free zinc-insulin was ~4.5°C. Increased hydrophobic 
interactions between hexamers and chitosan could be one of the reasons for increased 
stabilization of hexameric assembly. It was also noticed that increasing zinc: insulin hexamer 
ratio beyond 4:1 did not show any additional stabilizing effect determined by DSC. To determine 
the amount of insulin loading in the complex, the chitosan-zinc-insulin complexes were 
centrifuged and the supernatant was tested for free insulin. The insulin loading was found to be 
~75% of the total insulin used. After quantification the insulin loading in the delivery system was 
adjusted.  
Chitosan-zinc-insulin complexes were mixed with the thermosensitive polymer solution 
(30% w/w) and thermoreversible nature of the delivery system was checked. The incorporation 
of chitosan-zinc-insulin complex in the delivery system did not change its thermosensitive 
nature. After increasing insulin loading in the delivery system, a slight increase in the gelling 
time was observed, but all formulations were injectable at room temperature, and showed rapid 
conversion from sol to gel near body temperature. Initially the effect of chitosan addition on in 
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vitro release of insulin and zinc insulin was observed at low protein loading. Significant 
reduction in the initial burst release was observed after incorporating chitosan-zinc-insulin 
complex in the polymeric delivery system as compared to insulin alone or zinc-insulin. The 
coefficient of determination values showed best fit for zero order release with chitosan-zinc-
insulin complex. The results showed that by increasing the size of the insulin decreased its 
diffusion from the polymer matrix, and the release rate was more dependent on the dissociation 
of chitosan-zinc-insulin complex as well as the polymer degradation. Depending on these results 
the formulation parameters were optimized. It seems logical that adding surplus zinc ions to 
insulin increases stability of its hexameric structure and could help inhibiting fibril formation. 
But, studies have also shown that, the insulin formulations containing zinc ions > 4/hexamer are 
prone to hydrolytic cleavage at A8-A9 position (131). Though no specific split products 
corresponding to hydrolysis at A8-A9 were observed in MALDI-TOF mass analysis, some low 
molecular weight products were detected. These products might have formed due to hydrolysis 
or deamidation of insulin due to excess zinc ions present. Hence for our further studies zinc: 
insulin hexamer ratio of 4:1 was used. The concentration of the thermosensitive polymer selected 
was 30% w/w for our further experiments since the delivery system was easily injectable at this 
concentration even at higher insulin loading. The chitosan amount was varied and the effect of 
increasing chitosan amount on initial burst release as well as the release profile of zinc-insulin 
was determined. At the same time it was observed that formulations were injectable. The release 
profile of insulin from chitosan-zinc-insulin complex loaded thermosensitive delivery system at 
higher loading was studied. The stability of released insulin was determined by above mentioned 
analytical techniques. Formulation containing zinc-insulin showed significant reduction in the 
initial burst release as compared to the formulations without zinc and prolonged the release of 
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insulin up to 63 days. Even though zinc addition controlled the release initially in a better way as 
compared to the formulation without zinc, a high secondary burst was also observed. It was 
noted that addition of chitosan to insulin did not help to improve the initial burst as well as 
overall release duration. A high initial burst followed by a short-term release was observed, and 
only 65% of the total protein was released from the delivery system. Large amount of insulin 
remained inside the delivery system after two months of release from the formulations 
containing insulin alone, zinc-insulin and chitosan-insulin. Though we quantified the amount of 
insulin remaining in the delivery system, we did not find a simple mass balance between the 
amount of unreleased and released insulin. The sum of the released insulin amount and the 
insulin remaining in the delivery systems after completion of the release period was not equal to 
the amount of insulin incorporated in the delivery system. This difference (~8-13% of the total 
insulin amount incorporated in the delivery system) could be attributed to the 
degradation/precipitation or aggregation of insulin in the release medium after successful release. 
Delivery system containing chitosan-zinc-insulin complex showed significant reduction in the 
initial burst as well as showed almost complete release of insulin (~95%) within three months as 
described in results. This might be due to the ionic interactions present between chitosan and 
insulin which might have stabilized the insulin inside the delivery system, and during release. 
These ionic interactions, along with slow dissociation of insulin hexamers into 
dimers/monomers, may have contributed to the prolonged and complete release. Thus, use of 
zinc or chitosan alone was not sufficient to reduce the initial burst and to control the insulin 
release. Similarly, it was observed that at higher protein loading (formulation H: 45 mg insulin 
loading) chitosan-zinc-insulin complex containing delivery system performed better as compared 
to the formulations containing insulin alone or zinc-insulin. Increasing protein loading from 30 to 
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45 mg in the delivery system showed slight increase in initial burst release, but the overall 
release period was unaffected. A slight increase in initial burst release was seen due to increased 
insulin loading leading to the formation of more pores in the polymer matrix and thereby 
shortening the overall release period (26). Increasing chitosan amount in the delivery system led 
to a small reduction in the initial burst, but there was no significant difference in the release 
pattern observed. The formulations containing chitosan-zinc-insulin complex showed higher 
correlation (r2) for zero order release kinetics. The results indicate that the chitosan-zinc-insulin 
complex plays an important role in reducing the initial burst release of insulin as compared to the 
formulations containing insulin alone and zinc-insulin. But interestingly in our recent studies it 
was noticed that after increasing insulin loading to 60 mg in the delivery system, zinc-insulin 
containing formulation showed minimal initial burst release as compare to the formulations 
containing insulin alone as well as chitosan-zinc-insulin complex. 
Additionally, it was noted that the release of insulin was very slow until ~1 month 
followed by a sharp secondary burst release probably caused due to degradation of the delivery 
system resulting in release of precipitated/aggregated insulin. This secondary burst released most 
of the insulin in approximately 20 days, and then a plateau appeared. The results indicated that 
though zinc decreased initial burst by reducing solubility of insulin, it did not control the release 
which reduced the usefulness of the delivery system. In case of delivery system containing 
insulin alone, similar release pattern was observed but the majority of the insulin (~50%) was 
released in 30-35 days with overall release duration up to 60 days. As discussed earlier, acidic 
microenvironment within the delivery system during polymer degradation is one of the major 
factors of insulin instability. This acidic environment can be reduced by incorporating a basic 
excipient in the delivery system (246). Chitosan carries abundant amino groups on its surface 
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and gets ionized in acidic pH leading to swelling of the polymer network (247). This may reduce 
the exposure of protein to the damaging environment and results in increased stability. The effect 
of acidic microenvironment on the stability of insulin was also assessed. Insulin alone, zinc-
insulin and chitosan-zinc-insulin complexes, were incubated with the lactic acid which is the 
major end product during polymer degradation, and the thermostability of insulin was 
investigated using DSC. The DSC results showed that presence of lactic acid reduces the 
thermostability of insulin alone and zinc-insulin but did not significantly alter insulin structure in 
the form of chitosan-zinc-insulin complex. These results demonstrate the additional stabilizing 
effect of chitosan on insulin structure. Chitosan also possesses good buffering ability which 
might have resisted the major pH change in the microenvironment of the delivery system. 
Addition of chitosan to zinc-insulin shifted the best fit model from higuchi to zero order, which 
is an ideal model for the long-term controlled release. 
4.4. Stability of Released Insulin 
Stability of insulin released from the delivery systems during in vitro studies was studied 
using CD, DSC, PAGE/SDS-PAGE, HPLC and MALDI-TOF mass spectroscopy. As mentioned 
earlier, presence of moisture, agitation, and acidic pH influence insulin stability. The CD 
spectroscopy results showed attenuation in the CD signal intensities indicating loss of α helix 
and increase in random ordered structures. Insulin gets exposed to the harsh conditions like 
agitation, acidic polymer degradation products as well as aqueous environment once it is released 
from the delivery systems. This can lead to its degradation in the release media. Since aromatic 
residues play important role in insulin dimer, tetramer and hexamer formation their removal from 
insulin surface leads to loss or reduction in near UV-CD signal (248). All released samples of 
insulin showed reduction in the intensity of near as well as far UV spectra indicating reduction in 
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α helix and β sheets as well as tertiary structure of insulin during release. However, the presence 
of two minima in far UV region and minima at 278 nm due to tyrosyl residues in near UV-CD 
region indicated that the secondary and tertiary structure of insulin was relatively conserved 
during release. It has been established that zinc addition helped to preserve the secondary 
structure of insulin, and prevented its aggregation when exposed to harsh manufacturing 
conditions during microsphere preparation (2).  
Our DSC results also confirmed that the addition of chitosan to zinc-insulin complex 
stabilized the zinc-insulin hexamer and enhanced its stability during release. The DSC results 
also showed that chitosan-zinc-insulin complex released insulin in its native form upon dilution. 
In addition to secondary and tertiary structural changes, insulin aggregates can be formed due to 
exposure to various formulation conditions as well as during release. PAGE helped to determine 
the presence of aggregates while SDS-PAGE under non-reducing conditions helped to determine 
the nature of aggregates. PAGE results indicated the presence of dimers in the released samples 
but a single band corresponding to native insulin (6 kDa) in SDS-PAGE allowed us to conclude 
that the aggregates detected were non-covalent. The results also suggested that the primary 
structure of insulin was conserved throughout the release period as evidenced by the presence of 
monomers.  
Insulin is known to undergo many chemical modifications that limit its biological 
activity. It has been reported that the terminal amino acid residue of A chain (Asn 21), is prone to 
deamidation at acidic pH. Rate of deamidation at A21 decreases with increasing pH, and near 
neutral pH this reaction is slower and takes place exclusively at asparagine residue present in B 
chain (Asn B3) (128). The interactions between polymer and incorporated protein, as well as the 
acidic climate inside the matrix are known to accelerate the acid-catalyzed reactions of the 
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peptide bonds, which is one of the reasons of insulin instability and incomplete release 
(249,250). Hence it is critical for the delivery system to protect incorporated insulin in its intact 
form during release. HPLC and MALDI-TOF mass spectroscopy techniques helped to determine 
the presence and nature of chemical modifications that might have occurred in insulin during 
release. Our MALDI-TOF MS results showed that with increasing the time of incubation, insulin 
solution (control) showed large amount of degradation products and signal corresponding to 
intact insulin disappeared after 30 days of incubation. The results suggest that insulin gradually 
lost its structural stability in PBS at 37°C. Formulations containing insulin alone and zinc-insulin 
showed presence of deamidation and cyclic imide product formation after one month of release. 
Since cyclic imide is stable at acidic pH, increase in its signal intensity observed in two months 
released samples suggested the presence of acidic microenvironment due to 
degradation/hydrolysis of polymer (243). The delivery system containing insulin alone showed 
the presence of insulin dimer with a peak corresponding to 11685.47 m/z indicated that there is 
formation of covalent insulin dimers in the released sample. Polymeric formulation containing 
chitosan-zinc-insulin complex showed a major peak corresponding to intact insulin with a 
negligible peak at 5789 m/z. the results indicate that addition of chitosan to zinc-insulin (4 zinc 
ions/insulin hexamer) has helped to preserve its primary structure during entire release period. 
Addition of chitosan has also helped to reduce the acidic environment inside the polymeric 
hydrogel indicated by the presence of a very small peak corresponding to cyclic imide in two 
months released sample. The extent of degradation in the released insulin samples was also 
assessed using RP-HPLC. Chemically intact insulin showed a single peak at 9.8 min. In contrast 
to intact insulin, incubated insulin control showed an additional peak at 4.8 min indicating 
degradation of protein at day 15. The prolonged incubation time increased the appearance of 
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degradation peaks with concurrent reduction of peak at 9.3 min for intact insulin, and the peak 
disappeared after 30 days of incubation showed complete degradation of insulin. The HPLC 
chromatograms showed that primary structure of insulin did not change during release. HPLC 
chromatograms of insulin released from the delivery system showed presence of some 
degradation products, but still the major peak corresponding to native insulin provided the 
evidence that chemical integrity of insulin was retained. 
4.5. Stability of Insulin in the Delivery System During Release and Storage 
Although insulin was structurally stable during release, the information was insufficient 
to demonstrate the stability of insulin remaining in the delivery system during release. The 
microenvironment present in the delivery system plays an important role in maintaining the 
stability of protein. Tang and Singh, (4) reported that the presence of acidic environment caused 
due to hydrolysis of polymer backbone, and protein degradation products can affect the stability 
of protein inside the delivery system. As discussed earlier, protein can undergo deamidation, 
acylation, or peptide bond cleavage in the polymeric delivery systems. Increased cyclic imide 
product formation in case zinc-insulin containing delivery systems (formulation B) indicated 
increased hydrolysis and deamidation reactions occurred. The delivery system containing insulin 
is stored at 4°C, and also remains at body temperature for extended duration after administration. 
Therefore insulin should be stable for intended storage duration as well as in the gel depot during 
entire release period at body temperature. Therefore structural stability of insulin was evaluated 
at storage and body temperatures after extracting it from polymer matrix. The HPLC and 
MALDI-TOF MS analysis confirmed that the insulin extracted from gels showed major signal 
similar to intact insulin, indicating that no significant degradation occurred inside the gel depot 
during release as well as storage. Similarly, native PAGE results also showed that the insulin 
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extracted from the gels during release and storage at 37 and 4°C was chemically intact. Our 
results confirmed that addition of chitosan helped stabilizing insulin in the delivery system by 
shielding it from the acidic environment developed inside the delivery system due to polymer 
degradation over the period of time. 
The acidic byproducts formed during degradation of the triblock copolymer lead to 
decrease in pH of microenvironment in the gel matrix, which is the major cause of insulin 
instability. This acidic microclimate can be reduced by incorporating a basic excipient in the 
delivery system (246). Chitosan possesses abundant amino groups on its surface, and hence, acts 
as proton sponge (247,251). It also possesses good buffering ability which could resist the major 
pH change in the microenvironment of during degradation of polymer gel matrix. Our 
preliminary results indicated that the addition of chitosan to zinc-insulin could have reduced the 
exposure of protein to the damaging environment resulting from PLA degradation, leading to 
increased stability. Our studies also demonstrated that the presence of lactic acid residues 
reduced the thermostability of insulin alone and zinc-insulin, but did not significantly affect 
insulin in the form of chitosan-zinc-insulin complex determined by DSC. These results further 
confirmed the stabilizing effect of chitosan on insulin structure. 
4.6. In Vivo Absorption and Bioactivity of Insulin 
Our in vitro release studies, and stability studies indicated that the increased size (zinc-
insulin hexamer), and slow dissociation of zinc-insulin after complex formation with chitosan 
helped to reduce insulin diffusion from the thermosensitive polymer gel matrix, and prolonged 
the insulin release in vitro. This slow diffusion of insulin resulted in reduced initial burst release, 
and further the complex helped to stabilize insulin during release and storage, while providing 
controlled release over extended duration in vitro. Therefore, optimized delivery systems 
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containing chitosan-zinc-insulin complex were further evaluated for their ability to deliver 
insulin in vivo using streptozotocin (STZ) induced diabetic rat model. A single dose STZ 
induced diabetic rat model is widely accepted experimental model to study the effect of various 
controlled release insulin formulations. A single dose STZ (55 mg/kg) causes selective toxicity 
to pancreatic beta cells, and produces type 1 diabetes in the experimental animals (252). STZ 
action is manifested via alkylation of DNA, which in turn causes drastic reduction in insulin 
level affecting overall glucose metabolism in the body, and thereby producing hyperglycemia. 
The blood glucose levels of rats after STZ treatment increased rapidly, and were hyperglycemic 
after 5-7 days. As expected, SC injection of insulin solution demonstrated the shortest duration 
of action and the blood glucose levels reverted to the pretreatment levels within 12 h post 
treatment. The factors which alter the insulin absorption after subcutaneous administration are its 
molecular weight, and association state at the administration site (253). The results showed that 
after SC administration of insulin solution, insulin being in its monomeric form was absorbed 
quickly leading to a spike in insulin levels. The polymeric delivery system containing insulin 
alone also demonstrated a rapid increase in serum insulin concentration, indicating an initial 
burst release due to the quick escape of unassociated surface-localized insulin monomers after 
injection. These surface localized insulin monomers being smaller in size might have escaped 
easily by diffusion, resulting in a spike in insulin levels. Additionally, the delivery system 
showed a short-term release of insulin which could be due to the aggregation or degradation of 
insulin in the delivery system. These results were also supported by the reduction in 
pharmacodynamic response of insulin. Addition of zinc to insulin reduced the initial burst due to 
the increased size and reduced solubility of insulin. It also helped in relatively sustaining the 
release of insulin for longer duration as compared to insulin alone. Zinc is known to exhibit 
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fibrillation inhibitory effect on insulin, and stabilizes hexameric assembly (35). Although zinc-
insulin hexamer formation helped to reduce the initial burst release of insulin and prolonged the 
release duration, there was no appreciable improvement in the bioavailability as compared to the 
formulations containing insulin alone. The delivery systems containing chitosan-zinc-insulin 
complex showed marked reduction in the initial burst release, indicated by a gradual and slow 
rise in serum insulin levels. This might be due to the enlarged size (zinc-insulin hexamer), and 
the complex formation with chitosan by electrostatic interactions which might have helped in 
reducing insulin diffusion from the polymer gel matrix.  
The initial burst release of insulin is the major cause of hypoglycemia and is a critical 
aspect which needs to be addressed during the development of controlled delivery systems. The 
balance between glucose production and its utilization gets altered due to the large variation in 
plasma insulin levels after its administration (254). Reduction in peak/trough ratio of insulin (i.e. 
lowering the variability) is highly desirable to lower/prevent the occurrence of hypoglycemia-
associated complications (155). Formulations containing chitosan-zinc-insulin showed a gradual 
increase in serum insulin with very low peak-free levels after administration, and additionally the 
release was continuous for ~70 days. These formulations also showed increase in AUC by 1.2-2 
fold as compared to zinc-insulin and insulin alone containing formulations, respectively. This 
could be due to the slow dissociation of large chitosan-zinc-insulin complexes, into insulin 
oligomers and finally to zinc-free insulin monomers. The chitosan-zinc-insulin complex loaded 
thermosensitive polymeric delivery system released small amount of insulin over prolonged 
period of time leading to higher absorption rates. It has been well documented that the absorption 
rate of insulin via subcutaneous route is a complex phenomenon, and is inversely related to its 
concentration (255). Thus, the slow dissociation of insulin from the chitosan-zinc-insulin 
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complex might have reduced its degradation by the proteases present at the injection site, and 
thereby improved its absorption (35). Since chitosan is known to stabilize proteins (168,172-
174), the complex formation might have offered additional stabilizing effect which protected 
insulin after administration. These results also confirmed our earlier findings showing that 
chitosan-zinc-insulin containing thermosensitive polymeric delivery system maintained at body 
temperature preserved the structural integrity of incorporated insulin for prolonged period (256).  
The pharmacodynamic effect of insulin released from different delivery systems was 
evaluated by the regulation of blood glucose levels. The high initial burst release of insulin 
observed after administration of formulations containing inulin alone caused rapid reduction in 
blood glucose levels below the normal levels, and suggested that the delivery system containing 
insulin alone would not be a good choice, since it may lead to a hypoglycemic shock. Zinc-
insulin containing formulations did not show a sharp drop in blood glucose, indicating reduction 
in initial burst release due to formation of zinc-insulin hexamers (increased size, and reduced 
solubility), but lowered the blood glucose levels for slightly longer duration as compared to 
insulin alone. The results suggest that the incorporated insulin might have precipitated/degraded 
in the delivery system, and failed to elicit the biological response. Chitosan-zinc-insulin 
containing formulations (insulin loading: 30 and 45 IU/kg) showed gradual and sustained 
reduction in blood glucose over the period of 7 days, without any sign of hypoglycemia. This is 
considered as the most important and desirable property of insulin containing controlled delivery 
systems. The delivery systems containing chitosan-zinc-insulin complexes helped maintaining 
the blood glucose levels below 200 mg/dl, for prolonged duration as compared to insulin alone or 
zinc-insulin containing delivery systems. Additionally, the blood glucose levels were comparable 
to that of control (untreated rats) for considerably longer duration and then increased gradually. 
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The results also showed that there was no significant difference (P>0.05) in blood glucose levels 
in two consecutive time points until 56-63 days, which can be interpreted as the 
pharmacodynamic manifestation of the continuous release of insulin at a steady rate. This data 
also demonstrates that the biological activity of insulin released from chitosan-zinc-insulin 
complex was preserved during fabrication and maintained during the entire release duration. All 
the delivery systems released insulin for relatively shorter period in vivo as compared to in vitro 
release. It has been well documented and also observed in our earlier studies that the in vivo 
release duration of insulin was shorter as compared to that of observed during in vitro release, 
which could be as a result of faster degradation of the delivery system in vivo than in vitro 
(35,257). But, as far as the biological activity of released insulin is concerned, chitosan-zinc-
insulin complex containing delivery systems showed better glycemic control over longer 
duration as compared to the delivery system containing insulin alone or zinc-insulin. 
Some of the macro and micro vascular complications due to diabetes include stroke, 
neuropathy, amputations, retinopathy, and renal failure, leading to increased disability, reduced 
life expectancy, and huge health costs (258). The animals in the streptozotocin treatment group 
developed not only diabetes as indicated by increased fasting blood glucose values, but also 
showed signs of cataract which is one of the earlier complications of diabetes mellitus. Similarly, 
the animals treated with the delivery systems containing insulin alone also showed signs of 
cataract by the end of study indicating that the delivery system did not release insulin sufficient 
enough to alleviate the diabetic complications. No signs of retinopathy were observed in rats 
treated with zinc-insulin or chitosan-zinc-insulin containing formulations indicated that the 
released insulin helped in preventing the onset of diabetes related microvascular complications. 
It has been reported that STZ induced diabetes causes reduction in body weight due to the 
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loss/degradation of structural proteins, which mainly contribute to the body weight (259). Thus, 
after STZ treatment, a significant and drastic weight loss was observed in all groups. A gradual 
improvement in body weight was noticed after administering the rats with insulin formulations, 
while the rats in STZ treatment group showed continuous weight loss. This increase in body 
weight may be due to the prolonged release and in turn effect of insulin from the delivery 
system. 
Proteins undergo physical degradation like unfolding, misfolding, aggregation, or 
chemical degradation such as oxidation, deamidation, isomerization, that can result in an 
immune response (260). Protein aggregation in the commercially available preparations has 
reported to be a key factor underlying the unwanted immune responses of therapeutic proteins. 
Insulin aggregates are known to invoke antibody formation (261), and hence insulin aggregation 
inside the delivery system could alter its release, stability, activity, safety and overall duration of 
action after administration. Fineberg et al. (262), have reported that the formulation is one of the 
crucial factors that alter the immunogenic potential of insulin. Soluble forms of insulin are 
known to be less allergenic than intermediate or long-acting insulin preparations. The acidic 
preparations of insulin are reported to be more immunogenic than neutral formulations. Our 
ELISA results indicated that no immune response against human insulin observed in all 
treatment groups, which signified that the released insulin was non-immunogenic in nature. 
4.7. Biocompatibility of the Delivery Systems 
Biocompatibility is an array of complex characteristics and indicates the level of 
interaction between the implanted delivery system and the host tissue. It is difficult to determine 
the biocompatibility of a material by a single method, and always require complex set of in vitro 
and in vivo methods. In our earlier studies we have already demonstrated the biodegradable and 
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biocompatible nature of the thermosensitive polymeric delivery system (PLA-PEG-PLA, Mw: 
4500 Da) in vitro (35). Chitosan, another polymer used in this study is a linear polysaccharide 
composed of β-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine units distributed 
randomly. Chitosan is eliminated from the body by renal clearance, and the degree of acetylation 
as well as its molecular weight affects the degradation rate. High molecular weight chitosan 
undergoes degradation by chitinases in the body leading to the formation of smaller chains 
(263,264).  It is reported as a biocompatible and biodegradable positively charged polymer with 
minimum immunogenic potential and also possesses low cytotoxic potential (166). Zinc also gets 
eliminated from body via renal clearance (265). It is important to consider the potential 
cytotoxicity of the thermosensitive polymer (PLA-PEG-PLA) with or without chitosan, and its 
residual degradation products. An indirect cytotoxicity method was used, where the cells were 
exposed to the polymer extracts prepared at 37 and 70°C which simulated the long-term effects 
of the injected depot forming delivery system (65,266). Prior to the treatment, the extracts were 
neutralized to disregard the effect of pH, and to emphasize on the effect of polymer degradation 
products on cell viability. Thus, the results showed the effect of concentration of polymer and its 
degradation products only on the cell viability. Growth medium without polymer addition served 
as negative control and used to determine the percent cell viability. Our in vitro cytotoxicity 
study results indicated that the addition of chitosan did not change the biocompatible nature of 
the delivery system containing thermosensitive polymer. The polymer extracts of 
thermosensitive copolymer containing chitosan prepared at 70°C showed higher cell viability in 
comparison to extract prepared at 37°C. Chitosan has been found to exhibit good 
biocompatibility and extremely low cell toxicity (166). Chitosan accelerates cell proliferation, 
and also possesses wound healing property (267). Since greater amount of chitosan would be 
156 
 
extracted in its low molecular weight soluble form at 70°C, which has led to lesser cell toxicity 
than the extract prepared at 37°C. In an effort to determine the biocompatible nature of the 
delivery system in vivo, the subcutaneous tissue surrounding the depot was excised and observed 
for inflammatory reactions. Tissue healing process is usually initiated through cascade of 
inflammatory stages including acute inflammation, chronic inflammation, and granular tissue 
formation at the injection site (61,268). During in vivo biocompatibility evaluation, it was 
noticed that the subcutaneous administration of polymeric systems with/without chitosan showed 
an inflammatory response due to injection and continual presence of polymeric gel in the body. 
But, at the end of the study no signs of chronic inflammation, or necrosis were observed. Thus, 
as expected the inflammatory response to the developed delivery systems was short-lived, and 
the delivery systems were biocompatible.  
The extent of fibrosis, organization of collagen fibers and collagen density around the 
depot are also important in determining the biocompatible nature of the depot forming systems. 
Gomori’s trichrome stain was used to determine the nature and presence of collagen deposition 
at the subcutaneous tissue-delivery system interface. Though frequent removal and replacement 
of the release medium during in vitro release reduces the acidic environment with subsequent 
reduction in protein degradation, it is difficult to predict whether it reflects in vivo conditions 
(269). It has been reported that the fibrous capsule formation around the delivery system possibly 
retards the effective elimination of the polymer degradation products out of the site (269). This 
leads to increased acidic microenvironment near injection site, and in turn reduces the stability of 
encapsulated protein. It has been reported that usually the collagen fibers are arranged randomly 
without a specific organization with a sparse density, but in response to injury due to implanted 
material, collagen become well-defined and increased collagen deposition is usually observed 
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near the site of implantation (270). In our experiments, it was noted that the collagen deposition 
at the site of injection was a short-term response. Increased collagen deposition was observed 
initially, but the its density reduced eventually and the skin tissue observed at the end of the 
study period showed absence of residual scar tissue indicated the biocompatible nature of the 
delivery system. Since no scar tissue/fibrous capsule were observed near the gel depot, it allowed 
us to conclude that polymer degradation products are removed continuously after degradation 
from the injection site. 
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5. SUMMARY, CONCLUSION AND FUTURE DIRECTIONS 
Smart polymers have revolutionized the field of polymeric drug delivery to achieve 
sustained and/or targeted delivery of numerous therapeutic agents. These polymers are becoming 
progressively relevant in the field of protein and peptide delivery, as researchers are learning the 
ways to take advantage of their interesting properties and control them. Thermosensitive 
polymers, a class of smart polymers which exhibit temperature-dependent reversible sol/gel 
transitions, have been studied and used extensively in past decade for drug delivery due to their 
unique and fascinating properties (14). 
In our studies, PLA-PEG-PLA thermosensitive copolymers were synthesized and were 
used to deliver various drug molecules in vitro and in vivo. This research consisted of two parts; 
the first part deals with the degradation behavior of copolymers in response to changes in 
formulation parameters. PLA-PEG-PLA triblock copolymers with chain lengths 1500-1500-
1500, and 1600-1500-1600 were synthesized and characterized for their structure, molecular 
weight, and polydispersity index, and phase transition behavior. The proton and 13C NMR 
spectra confirmed the structure of the synthesized copolymers, while integrating the proton NMR 
signals helped in molecular weight determination. The GPC analysis indicated the narrow 
molecular weight distribution, showing the sufficient purity of the synthesized copolymers. The 
polymeric delivery systems showed temperature dependent sol-gel transition, and can exist in 
solution form outside the body (room temperature). The injectability is an essential property for 
the proposed controlled delivery systems. The delivery systems were freely injectable and 
formed semisolid depots at body temperature within seconds upon injection.  
The hydrolytic degradation behavior of copolymer, and release profile of incorporated 
agents were investigated in detail. The PLA-PEG-PLA triblock polymer preferentially degraded 
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by the hydrolysis, and the concentration as well as PLA chain length affected its degradation. 
Increasing the copolymer concentration, and PLA chain length significantly (P<0.05) reduced 
hydrolytic degradation of polymer. NMR analysis also showed an increase in LA/EG ratio as the 
degradation proceeded. 
The release profile of three different molecules BSA, insulin and risperidone from the 
thermosensitive delivery systems was evaluated. BSA showed higher initial burst release 
(13.54±0.89%), followed by insulin (7.32±3.1%), and risperidone (2.13±0.047%). BSA was 
released rapidly and the release period lasted for ~42 days, including a fast release phase for 7 
days, followed by a slow release; while insulin and risperidone were released in a controlled 
manner for ~70-80 days. The GPC analysis of polymer residuals showed increased degradation 
rate in the presence of BSA as compared to polymer alone, insulin or risperidone. The size of 
pores formed in the delivery system as determined by SEM was dependent on the type of drug 
incorporated. BSA containing hydrogel showed significantly (p<0.05) larger pores than insulin 
or risperidone loaded hydrogels at day 30, but pore size increased and was comparable 
irrespective of drug type at day 60. The results suggested that not only polymer structure and 
concentration, but the drug properties are also important while designing the delivery systems. 
BSA being a large hydrophilic protein showed higher initial burst release, followed by insulin 
and risperidone. BSA could have formed larger channels near the surface during initial release 
phase, which led to rapid penetration of water molecules inside the gel matrix. This channel 
formation, and/solvation of protein in the previously formed channels and water penetration 
enhanced the polymer degradation. All these combined effects could have resulted in the faster 
release of BSA. Therefore, it is essential to consider the hydrophobicity, solubility, and size of 
the incorporated drugs while formulating a delivery system. SEM studies also showed a striking 
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difference in the porous morphologies of the delivery systems containing risperidone, BSA or 
insulin. BSA containing delivery system showed was more porous and therefore BSA might 
have escaped easily from the gel creating even bigger, open, water accessible pores as compared 
to risperidone and insulin. 
It was also noted that the presence of a cationic polymer, chitosan also modulated the 
polymer degradation behavior. The thermosensitive polymer based delivery system in presence 
and absence of a cationic polymer showed a marked difference in pH of the release medium. In 
case of thermosensitive polymer, the pH of the release medium dropped rapidly after and 
reached to ~4.5 at the end of the study. While, the delivery system containing chitosan resisted 
the change in pH for longer duration and then pH reduced gradually. However, the pH of the 
release medium still remained higher as compared to the delivery system without chitosan. Due 
to the excellent buffering ability of chitosan it has resisted the change in the pH of the release 
medium for longer duration leading to reduction in acid-catalyzed degradation of copolymer 
chains. 
The second part of this research involved development of an injectable, biodegradable 
polymeric controlled delivery system to deliver insulin at basal level for prolonged period after a 
single injection. Proteins represent a vast majority of the biologics, which face issues like short 
half-life, delicate structure and the physical/chemical instabilities. These problems, combined 
with their delivery issues, necessitate the need of frequent injections to obtain the desired 
therapeutic effect. Insulin is one of such proteins requiring frequent injections for treatment of 
the patients with diabetes. The chronic insulin administration leads to numerous complications 
and the pain from multiple daily injections adversely affects the quality of life of patients. 
Controlled delivery of insulin can be helpful to address the difficulties associated with the 
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traditional administration methods. The choice of delivery system reflects the clinical outcome of 
the insulin delivered, and involves simultaneous consideration of number of interdependent 
factors. Some of important factors include stability, release rate, release duration, and biological 
activity of incorporated insulin, as well as biocompatibility and biodegradability of the delivery 
system. 
Since PLA-PEG-PLA triblock copolymer with 1500-1500-1500 chain length was the 
most promising copolymer in terms of release rate and duration, it was used in our experiments.  
Polymer concentration, insulin loading, chitosan and zinc addition were shown to affect 
the insulin release in vitro. Addition of zinc to insulin helped to reduce its solubility, increased its 
size so that its diffusion thorough the polymeric delivery system is reduced. Formulations 
containing zinc-insulin significantly (P<0.05) reduced the burst release and prolonged the release 
as compared to insulin alone. With increasing insulin loading in the delivery system from 60 to 
100 mg increased the initial burst release but did not alter duration of release. Insulin released 
from zinc-insulin and insulin alone containing delivery systems showed partial loss of secondary 
structure over the release duration. MALDI-TOF MS analysis showed presence of degradation 
products during release. The presence of additional free zinc ions (>4) in insulin preparations 
increased its hydrolytic degradation. Hence, there should be an optimum balance between zinc 
and insulin amount, and zinc alone is not sufficient to stabilize insulin in the delivery system. 
Also, increasing zinc:insulin hexamer ratio beyond 4:1 did not show any additional stabilizing 
effect during our preliminary studies, and hence was used in our further experiments. 
A new approach of incorporating insulin in the form of chitosan-zinc-insulin complex 
was utilized to reduce the initial burst release of insulin from the polymeric delivery systems. A 
controlled delivery system for insulin based on the chitosan-zinc-insulin complex incorporated in 
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PLA-PEG-PLA thermosensitive polymer was successfully developed. The chitosan-zinc-insulin 
complex is weak in nature and easily dissociates in presence of an anionic surfactant. Addition of 
chitosan did not alter the structural integrity of insulin determined by UV, fluorescence and CD 
spectroscopy, and has helped stabilizing the zinc-insulin hexameric assembly. The delivery 
systems prepared after incorporation of chitosan-zinc-insulin complexes in aqueous copolymer 
solutions (30%w/w) were easily injectable, and were able to form gel at body temperature. 
Formulations containing chitosan-zinc-insulin (30 to 60 mg) released insulin continuously over 
84 to 90 days with a significant (P<0.05) reduction in the initial burst release and minimal 
secondary burst while the formulations containing insulin, zinc-insulin, and chitosan-insulin 
exhibited high  initial burst (7 to 14%) accompanied by a large secondary burst and incomplete 
release.  
CD and DSC studies indicated that the released insulin was stable. MALDI-TOF MS 
analysis showed that the chemical integrity of insulin released and extracted from gel was 
conserved after two months of release. Native and SDS-PAGE showed that the insulin 
aggregates observed were non-covalent nature. HPLC analysis showed that after two months, 
released and extracted insulin was comparable to native insulin. Thus, our results indicated that 
chitosan-zinc-insulin complex formation improved the stability of the insulin inside the delivery 
system and protected it from aggregation during the entire release and storage period determined 
by PAGE, HPLC, and MALDI-TOF MS.  
The ability of the delivery system to provide basal level of insulin for three months after a 
single subcutaneous injection was investigated in vivo using streptozotocin-induced diabetic rat 
model. In vivo studies indicated chitosan-zinc-insulin complex containing delivery systems 
controlled the release of insulin over 70 days, necessary to maintain the basal insulin levels. The 
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complex formation significantly (P<0.05) reduced the initial burst release of insulin from the 
polymeric delivery system in comparison to zinc-insulin or insulin alone. The released insulin 
was in its monomeric and biologically active form which was absorbed in the body as evident by 
reduced blood glucose levels. The blood glucose levels were comparable to that of control 
(untreated group), and were significantly (P<0.05) lower than untreated diabetic rats. No 
significant difference (P>0.05) in blood glucose levels in two consecutive time points until 56-63 
days was observed, which is an indicator of pharmacodynamic manifestation of continuous 
release of insulin at steady rate. The delivery systems also showed increase in bioavailability of 
insulin as compared to zinc-insulin and insulin alone. The formulations containing insulin did not 
provoke any immunogenic response, and helped reduce the diabetic complications.  
The biocompatibility of the delivery system containing thermosensitive polymer 
incorporated chitosan was tested in vitro and in vivo. The in vitro cytotoxicity study results 
showed that the addition of chitosan did not change the biocompatible nature of the 
thermosensitive polymeric delivery system. The results were confirmed by histological 
examination of skin tissue samples removed at specific time points from injection sites of rats 
determined by light microscopy. Though a typical inflammatory reaction was observed at the 
injection site initially, the skin tissue showed no signs of chronic inflammation, fibrous capsule 
formation, or necrosis, and was highly comparable to control skin samples after 90 days. The 
results suggest that the polymeric delivery system containing chitosan was biodegradable and 
biocompatible in vivo. This signifies that the chitosan-zinc-insulin complex incorporated in the 
thermosensitive polymeric delivery system can be used as an alternative to the conventional 
daily multiple dose basal insulin therapy. 
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Gomori’s trichrome stain was used to determine the nature and presence of collagen 
deposition at the subcutaneous tissue-delivery system interface. It was observed that increased 
collagen deposition at the site of injection was a short-term response, and the collagen density 
reduced eventually at the end of the study and showed no presence of any residual scar tissue 
indicating the biocompatible nature of the delivery system. The results also helped to conclude 
that the polymer degradation products are removed continuously after degradation at the 
injection site.  
In conclusion, our in vivo studies indicated chitosan-zinc-insulin complex containing 
delivery systems controlled the release of insulin for prolonged period, necessary to maintain the 
basal insulin levels. The formulations containing insulin did not provoke any immunogenic 
response, and helped to reduce the diabetic complications. The polymeric delivery system 
containing chitosan was biodegradable and biocompatible in vivo. This signifies that the 
chitosan-zinc-insulin complex incorporated in the thermosensitive polymeric delivery system can 
be used as an alternative to the conventional daily multiple dose basal insulin therapy. 
5.1. Future Directions 
The choice of polymer reflects the clinical outcome of the therapeutics, and hence 
simultaneous consideration of number of interdependent factors is important while developing a 
delivery system. This study was confined to the PLA-PEG-PLA copolymer based in situ gel 
forming delivery system with limited PLA and PEG content. There are number of biodegradable 
polymers which can be used with different hydrophobic/hydrophilic content, and can be 
optimized for the delivery of various small as well as large molecules. The polymers include 
PCL-PEG-PCL (59), poly(beta-amino ester) (PAE) pentablock copolymer PAE-PCL-PEG-PCL-
PAE (59), mPEG-PLGA-mPEG (4), thermosensitive hydrogel/collagen/chondroitin sulphate 
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(CS) (271), cationic Poly(organophosphazenes) (272), cyclotriphosphazenes (273), and 
hyaluronic acid/Pluronic F127 (274) to name a few. 
Polyelectrolyte complex formation between charged polymers and peptides and proteins 
has been the focus of applied research, and there are various research directions which could be 
pursued based on our work. In most of the cases during polyelectrolyte complex formation, the 
structural integrity of incorporated molecule is preserved, and hence numbers of studies have 
been carried out in order to make use of this unique physicochemical property for drug delivery 
purposes. The factors influencing polyelectrolyte complex formation include overall charge on 
the molecules, concentration, as well as temperature, pH, ionic strength of the medium, and 
presence of salts. Though we have used some of the methods for characterizing the complex 
formation, it should be investigated in detail using other instrumental techniques such as light 
scattering, Infrared Spectroscopy (IR), and Isothermal Scanning Calorimetry (ITC). The weight 
ratio of polymer: protein is an important factor determining the complex formation, and hence 
needs to be optimized further. 
Various chemical alterations in the thermosensitive polymer backbone itself which could 
potentially interact with different charged molecules could be another approach in modifying the 
release pattern from the delivery system. Additionally, the effect of natural/synthetic polymers or 
stabilizing agents (sugars, polyols), which are able to form complexes with various therapeutic 
agents could help modifying the release rate and duration of incorporated molecules. A 
combination of delivery systems can be an another approach where encapsulated 
proteins/peptides in the form of microspheres or nanoparticles can be incorporated into the in situ 
gel forming delivery system so as to control the release rate. Various therapeutic proteins or 
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peptides such as erythropoietin, growth hormone, calcitonin, bone morphogenetic protein-2 
(rhBMP-2) can be ideal candidates for such a type of delivery system.  
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